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1. SUMMARIES 
1.1 English summary 
Endothelial dysfunction is an independent risk factor for cardiovascular complications associated 
with aging and diabetes. Transglutaminase 2 (TG2) is a ubiquitously expressed enzyme with 
calcium-dependent transamidase activity; it is overactive in aging and diabetes and has been linked 
with fibrotic processes in the cardiovascular and renal systems (e.g. stiffening, calcification) as 
well as with endothelial dysfunction in diabetes and inward remodeling in hypertension. These 
effects have been ascribed to the open TG2 conformation. On the other hand, the closed 
conformation of TG2 has GTP-binding activity, acting as a G protein in transmembrane signaling, 
opening potassium channels in vascular smooth muscle cells (VSMCs) and participating in cell 
survival. This led to the hypothesis that induction of the closed conformation by pharmacological 
means would present blood-pressure lowering effects and prevent endothelial dysfunction. 
Native electrophoresis in purified human TG2 revealed that the reversible inhibitor LDN 27219 
was able to induce the closed conformation of the enzyme in vitro.  LDN 27219 concentration-
dependently relaxed small arteries from rats and humans, mounted in isometric myographs. This 
direct vasorelaxant effect was endothelium and nitric oxide (NO) dependent. Additionally, 
incubation with LDN 27219 potentiated acetylcholine-induced relaxation and hyperpolarization 
by increasing sensitivity to NO through the opening of large conductance calcium-activated 
potassium channels (KCa1.1). Voltage clamp recordings in freshly isolated VSMCs confirmed that 
LDN 27219 increased KCa1.1 currents similarly to GTP. Small mesenteric arteries from older rats 
presented higher levels of transamidase activity and were more sensitive to the potentiation of 
acetylcholine relaxation by LDN 27219 compared to arteries from younger animals. Accordingly, 
infusion of LDN 27219 decreased blood pressure more effectively in 35-week than in 12-week-
old anesthetized rats. Contrarily, induction of the open conformation of TG2 with irreversible 
inhibitors such as VA5 and Z-DON had no effect on vascular tone or blood pressure, but reduced 
acetylcholine vasorelaxation, potassium currents in isolated VSMCs, and prevented the 
potentiating effect of LDN 27219 on acetylcholine relaxation. These results suggest that arteries 
from aging animals present higher amount of TG2 in its open conformation and that 
pharmacological modulation of TG2 to the closed state could potentially restore age-related 
changes in endothelial function. 
The age-dependent vasoprotective effects of the closed TG2 conformation induced by LDN 27219 
were also found in small mesenteric arteries from normoglycemic db/+ mice. Additionally, LDN 
27219 was shown to partially reverse endothelial dysfunction in arteries from diabetic db/db mice 
ex vivo. Therefore, the effect of three-week treatment with LDN 27219 on the development of 
endothelial dysfunction in arteries from db/db mice was explored. Long-term treatment with LDN 
27219 was more effective in treatment of endothelial dysfunction in small arteries than treatment 
with an angiotensin II type 1 receptor (AT1) antagonist (candesartan), without affecting blood 
pressure. This effect seemed to be independent from the arterial sensitivity to NO, suggesting that 
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other mechanisms related to endothelial cell survival could play a role in the prevention of 
endothelial dysfunction by TG2 modulation in the long term. 
Finally, with the perspective of future application of TG2 modulators to prevent renovascular 
complications in aging and diabetes, we studied the functional expression of calcium-activated 
potassium channels in the intrarenal vascular endothelium and their role in the endothelium-
derived hyperpolarization. Through voltage clamp studies in isolated endothelial cells and 
immunohistochemistry, endothelial expression of KCa1.1, intermediate and small conductance 
calcium-activated potassium channels (KCa3.1 and KCa2.3, respectively) was revealed. Isometric 
tension recordings on rat intrarenal arteries showed that endothelial KCa1.1 and KCa3.1 channels 
play a major role in the acetylcholine-induced vasorelaxation of preglomerular vasculature, 
suggesting that KCa1.1 channel modulation by TG2 could be a potential strategy to improve 
preglomerular vascular function. 
In summary, the findings of the present thesis suggest that TG2 conformation plays an important 
role in the endothelial function of small arteries, mainly through opening of KCa1.1 channels and 
increasing endothelial cell survival. Therefore, modulation of TG2 to its closed conformation 
could be a potential strategy to treat endothelial dysfunction in situations where TG2 is overactive, 













1.2 Dansk resumé 
Endothelcelle dysfunktion er en selvstændig risikofaktor for kardiovaskulære komplikationer ved 
aldring og diabetes. Transglutaminase 2 (TG2) er et udbredt enzym med calcium-afhængigt 
transamidase aktivitet. Enzymet er over-aktiv hos ældre personer samt personer med diabetes, og 
er set i sammenhæng med fibrotiske processer i det kardiovaskulære system og nyrerne (f.eks. øget 
stivhed og forkalkning) såvel som ved endothelcelle dysfunktion ved diabetes og forhøjet blodtryk. 
Disse effekter er blevet tillagt den åbne konformation af TG2. Den lukkede protein konformation 
af TG2 har GTP-bindende aktivitet og fungerer som G-protein i transmembran-signalering, 
hvorved der åbnes kaliumkanaler i vaskulære glatte muskelceller (SMCs), og TG2 bevirker også 
øget celleoverlevelse. Dette har ledt til hypotesen, at induktion af den lukkede konformation vha. 
farmakologiske metoder vil resultere i blodtryksnedsættende effekter og forebygge endothelcelle 
dysfunktion. 
Nativ electroforese af isoleret human TG2 viste at den reversible hæmmer LDN 27219 var i stand 
til at fremkalde den lukkede konformation af enzymet in vitro. LDN27219 afslappede 
koncentrations-afhængigt små modstandskar fra rotter og mennesker. Den direkte vasodilaterende 
effekt var endothelcelle-afhængig og medieret af nitrogenmonoxid (NO). LDN27219 potenserede 
også acetylkolin-fremkaldt vasodilatation og hyperpolarisering ved at øge følsomheden for NO 
gennem åbningen af calcium-aktiverede kaliumkanaler med stor konduktans (KCa1.1). Patch clamp 
studier af isolerede vaskulære glatte muskelceller (VSMCs) bekræftede at LDN 27219 øgede 
KCa1.1-konduktivitet på samme måde som GTP. Små mesenteriekar fra aldrende rotter udviste 
højere niveauer af transamidase-aktivitet og var mere følsomme overfor LDN27219 potentiering 
af acetylkolin-afslapning sammenlignet med arterier fra yngre dyr. Infusion af LDN 27219 
formindskede blodtrykket mere effektivt hos 35 uger gamle bedøvede rotter end hos 12 uger gamle 
rotter. Derimod havde induktion af den åbne konformation af TG2 med irreversible hæmmere 
såsom VA5 og Z-DON enten ingen effekt på vaskulær tonus eller på blodtryk, men reducerede 
acetylkolin vasodilatation, kalium-strøm i isolerede VSMCs, og hæmmede den potentierende 
effekt af LDN 27219. Disse resultater tyder på, at arterier fra aldrende dyr har et højere indhold af 
den åbne konformation af TG2, og at farmakologisk modulation af TG2 til den lukkede 
konformation potentielt kan hæmme aldersrelaterede ændringer i endothelcelle-funktion. 
De aldersafhængige karbeskyttende effekter af den lukkede TG2-konformation fremkaldt af LDN 
27219 blev også fundet i små tarmarterier fra normoglykæmiske db/+ mus. Herudover hæmmede 
LDN 27219 også endothelcelle dysfunktion i arterier fra diabetiske db/db mus ex vivo. Derfor 
undersøgte vi også effekten af tre-ugers behandling med LDN 27219 på endothelcelle dysfunktion 
i arterier fra db/db mus. Langsigtet behandling med LDN 27219 viste sig at være mere effektiv i 
at forebygge endothelcelle dysfunktion i små arterier end behandling med en angiotensin II type 1 
receptor (AT1) antagonist (candesartan), uden at påvirke blodtrykket. Denne effekt ved lang tids 
behandling med et stof som fremkalder den lukkede konformation af TG2 synes at være uafhængig 
af den arterielle følsomhed overfor NO, hvilket tyder på at andre mekanismer relateret til 
endothelcelle overlevelse kan spille en rolle i forebyggelsen af endothelcelle dysfunktion. 
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Med henblik på fremtidig anvendelse af TG2-modulatorer til at forebygge renovaskulære 
komplikationer hos ældre patienter samt patienter med diabetes undersøgte vi den funktionelle 
ekspression af calcium-aktiverede kaliumkanaler i det intrarenale vaskulære endothelium og deres 
rolle i den endothel-afhængige hyperpolarisering. Ved patch clamp studier af isolerede 
endothelceller og immunohistokemi påvistes ekspression i endothelceller af KCa1.1, samt 
mellemstore og små ledende calcium-aktiverede kaliumkanaler med lille og mellemstor 
konduktans (hhv. KCa2.3 og KCa3.1). Funktionelle isometriske målinger i rotters intrearenale 
arterier viste at endothelcelle KCa1.1- og KCa3.1-kanaler spiller en stor rolle i acetylkolin-fremkaldt 
vasodilatation af den præglomerulare vaskulatur, hvilket tyder på at KCa1.1-kanalmodulation af 
TG2 kunne være en potentiel strategi til at forbedre præglomerular vaskulær funktion. 
Sammenfattende tyder resultaterne i denne afhandling på at TG2-konformation spiller en vigtig 
rolle i endothelcelle-funktionen i små arterier, hovedsageligt igennem åbningen af KCa1.1-kanaler 
og øget overlevelse af endothelcellerne. Derfor kan modulation af TG2 til dets lukkede 
konformation være en potentiel strategi til at behandle endothelcelle dysfunktion i situationer hvor 

















1.3 Resumen en español 
La disfunción endotelial es un factor de riesgo independiente para las complicaciones 
cardiovasculares asociadas con el envejecimiento y la diabetes. La transglutaminasa 2 (TG2) es 
una enzima expresada virtualmente en todos los tejidos y que presenta actividad transamidasa 
dependiente de calcio; esta actividad está incrementada en el envejecimiento y la diabetes, 
habiendo sido relacionada con procesos fibróticos en los sistemas cardiovascular y renal (p. ej. 
rigidez, calcificación, etc), así como con disfunción endotelial en diabetes y remodelado vascular 
interno en hipertensión. Todos estos efectos han sido atribuidos a la conformación abierta de la 
TG2. Por otro lado, en su conformación cerrada, la TG2 puede unirse con GTP, actuando como 
proteína G en la señalización transmembrana, abriendo canales de potasio en células musculares 
lisas vasculares (VSMCs) y promocionando la supervivencia celular. Lo anteriormente expuesto 
condujo a la hipótesis de que la estabilización de la conformación cerrada por medios 
farmacológicos podría reducir la presión sanguínea y prevenir la disfunción endotelial. 
La electroforesis nativa de TG2 humana reveló que el inhibidor reversible LDN 27219 es capaz 
de inducir la conformación cerrada de la enzima in vitro. El LDN 27219 produjo relajación en 
arterias pequeñas de ratas y humanos montadas en miógrafos isométricos. Este efecto vasorelajante 
directo resultó ser dependiente del óxido nítrico (NO). Además, la incubación con LDN 27219 
aumentó la sensibilidad del músculo liso arterial al NO por medio de la apertura de canales de 
potasio activados por calcio de alta conductancia (KCa1.1), potenciando de esa manera la 
hiperpolarización y vasorelajación inducida por acetilcolina. Registros de patch-clamp con fijación 
de voltaje en VSMCs aisladas confirmaron que el LDN 27219 incrementa la corriente a través de 
canales KCa1.1 de manera similar al GTP. Las arterias mesentéricas pequeñas de animales de 
mayor edad presentaron niveles más elevados de actividad transamidasa y fueron más sensibles a 
la potenciación causada por el LDN 27219 comparadas con las arterias de animales más jóvenes. 
Consecuentemente, la infusión de LDN 27219 causó una disminución de la presión arterial más 
pronunciada en animales de 35 semanas que en animales de 12 semanas de edad. Por el contrario, 
la inducción de la conformación abierta de la TG2 por inhibidores irreversibles como VA5 y Z-
DON no alteraron la tensión vascular ex vivo ni la presión arterial in vivo, aunque redujeron la 
vasorelajación inducida por acetilcolina en arterias y las corrientes de potasio en VSMCs aisladas, 
previniendo los efectos del LDN 27219 ex vivo. Estos resultados sugieren que las arterias de 
animales de mayor edad presentan mayores cantidades de TG2 en su conformación abierta y que 
la promoción de la conformación cerrada podría restaurar los cambios en la función endotelial 
causados por la edad. 
Estos efectos vasoprotectores dependientes de la edad y provocados por la conformación cerrada 
de la TG2 inducida por LDN 27219 fueron observados también en arterias de ratones db/+ 
normoglicémicos. Además, LDN 27219 fue capaz de revertir parcialmente la disfunción endotelial 
en arterias de ratones db/db diabéticos ex vivo. Basándonos en estos resultados, estudiamos los 
efectos del tratamiento con LDN 27219 durante tres semanas en el desarrollo de la disfunción 
endotelial en arterias de ratones db/db. El tratamiento con LDN 27219 a largo plazo demostró ser 
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más efectivo que el tratamiento con candesartan, un antagonista de los receptores tipo 1 de 
angiotensina II, en la prevención de la disfunción endotelial en arterias pequeñas sin afectar a la 
presión arterial. Este efecto resultó ser independiente de la sensibilidad arterial al NO, sugiriendo 
que otros mecanismos relacionados con la supervivencia de las células endoteliales podrían tener 
un papel en la prevención de la disfunción endotelial modulada por la TG2 a largo plazo. 
Finalmente, con la perspectiva de aplicar moduladores de la TG2 en el futuro para prevenir 
complicaciones renovasculares durante el envejecimiento y la diabetes, estudiamos la expresión 
funcional de canales de potasio activados por calcio en el endotelio de arterias intrarenales y su 
papel en la hiperpolarización derivada del endotelio. Utilizando registros de patch clamp en células 
endoteliales aisladas e inmunohistoquímica, encontramos la expresión de canales KCa1.1 y de 
canales de potasio activados por calcio de intermedia y pequeña conductancias (KCa3.1 y KCa2.3 
respectivamente) en el endotelio de arterias intrarenales. Registros de tensión isométrica revelaron 
que los canales KCa1.1 y KCa3.1 tienen un papel esencial en la vasorelajación inducida por 
acetilcolina en la circulación preglomerular, sugiriendo que la modulación de canales KCa1.1 por 
la TG2 podría ser una estrategia potencial para mejorar la función vascular preglomerular. 
En resumen, los hallazgos de la presente tesis sugieren que la conformación de la TG2 juega un 
papel importante en la función endotelial de las arterias pequeñas, principalmente por medio de la 
apertura de canales KCa1.1 y del aumento de la supervivencia de las células endoteliales. Por ello, 
la modulación de TG2 a su conformación cerrada constituye una estrategia prometedora para el 
tratamiento de la disfunción endotelial en estados que cursan con sobreactivación de la TG2, como 












The endothelium regulates vascular tone in response to hemodynamic and chemical signals, and 
endothelial dysfunction is an independent predictor of complications in cardiovascular disease and 
one of the contributors to the increased cardiovascular risk associated with aging and diabetes 
(1,2). Therefore, further understanding and new approaches to maintain endothelial cell function 
throughout aging and altered metabolic states are required to prevent development of vascular 
complications in the elderly and in diabetic population.  
Transglutaminase 2 (TG2) is a ubiquitously expressed member of the enzyme family of 
transglutaminases (TG1-7 and Factor XIIIa).  In the presence of calcium, TG2 acquires an open 
conformation that has transamidase activity, which catalyzes the covalent crosslinking of structural 
proteins (3). The open conformation of TG2 is thought to be mainly active extracellularly and 
during local increments of intracellular calcium. On the other hand, the closed conformation of 
TG2 that is mainly present intracellularly has GTP-binding activity and acts as a G protein (Ghα), 
linking several receptors with their signaling cascades (4).  
In the vasculature, TG2 is highly expressed in both the endothelium and the vascular smooth 
muscle cell (VSMC) layer (5). The transamidase activity of TG2 has been linked with an inward 
remodeling in hypertension (6–8). Reduced nitric oxide (NO) production leads to externalization 
and increased TG2 transamidase activity (9,10). This increased transglutaminase activity has been 
linked to vascular stiffness in aging (9–11). High glucose concentrations increase intracellular 
calcium and reactive oxygen species (ROS) production leading to upregulation of TG2 
transamidase activity in endothelial cells. Inhibition of transamidase activity prevented 
hyperglycemia-induced endothelial cell apoptosis and endothelial leakage in diabetes (12–14). 
Besides the detrimental effect of the open conformation promoting vessel stiffness and endothelial 
dysfunction, our group and others have recently described that TG2 plays a role in the regulation 
of vascular tone in conductance and resistance arteries (11,15). Additionally, TG2 is recognized 
as an important target in renal fibrosis and diabetic nephropathy, due to the profibrotic effects of 
its transamidase activity (16,17). 
TG2 was recently discovered to play a role in cell survival and cancer malignancy (18). Therefore, 
there has been an increasing interest in developing new TG2 irreversible inhibitors that lock the 
enzyme into its open conformation, inhibiting at the same time the transamidase and GTP binding 
activities (19–22). On the other hand, there are some reversible TG2 inhibitors, as LDN 27219 
(23,24), that seems to be able to stabilize the enzyme in its closed conformation. However the 
available evidence comes only from “in silico” docking simulations (25). Although we have found 
a vasorelaxant effect of some TG2 inhibitors in resistance arteries through the opening of 
potassium channels (15), the role played by the different conformations of TG2 in the regulation 
of vascular tone remains unexplored.  
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The main objectives of this thesis are to explore the effects on vascular tone of conformational 
modulation of TG2 using pharmacological tools. Moreover, we assessed whether the promotion 
of the closed conformation of TG2 improves endothelial function in aging and diabetes by opening 
of potassium channels. A future perspective is that TG2 modulators can be used to treat 
renovascular complications in diabetes. Therefore, we explored the identity of the potassium 
channels involved in pre-glomerular endothelium-dependent vasorelaxation in the kidney. 
3. BACKGROUND  
3.1 The vascular endothelium 
The architecture of the arterial wall can be divided in three layers: the outer tunica adventitia, 
which contains the extracellular matrix (ECM), progenitor cells, and fibroblasts; the middle tunica 
media is formed by VSMCs, whose contraction level determines the diameter of the vascular 
lumen; and the inner tunica intima, formed by the endothelium. The endothelium is the cellular 
monolayer in the interface between the bloodstream and the vascular wall, acting both as a sensor 
of hemodynamic and metabolic changes, and as an endocrine organ to maintain homeostasis. The 
most basic function of the endothelium is acting as a semipermeable barrier, controlling the 
diffusion or active transport of molecules from the blood by different mechanisms (26). Still, it 
also regulates other processes such as thrombosis, inflammation, generation of new vessels 
(angiogenesis), and vascular tone (27).  
The vascular endothelium can regulate the tone of the underlying VSMCs layer by the release of 
different vasoactive substances in response to hemodynamic changes and chemical signals. The 
most well-known of these factors is NO, which is synthetized by endothelial NO synthase (eNOS). 
The synthesis of NO is constitutive in endothelial cells, and might be enhanced by different 
compounds such as acetylcholine (ACh).  NO diffuses to the VSMCs, where it stimulates soluble 
guanylate cyclase. The events result in an increased formation of cyclic GMP (cGMP), followed 
by downstream activations of several pathways leading to vasodilatation. These pathways include 
the opening of large-conductance calcium-activated potassium channels (KCa1.1), which lead to 
hyperpolarization of VSMCs and subsequent relaxation (28–30). Endothelial cells also release 
prostacyclin, which is synthesized by cyclooxygenases (COX) and relaxes the underlying VSMCs 
through the increase of cyclic AMP (cAMP) by adenylate cyclase activation. Besides these well 
identified vasodilatory factors, there is the so-called endothelium-derived hyperpolarization 
(EDH), which is responsible for the remaining endothelium-dependent vasodilatation in conditions 
of eNOS and COX inhibition. EDH seem particularly important in small arteries and arterioles 
(31,32). The identity of the factors mediating EDH has been a subject for debate, seeming to be 
dependent on the context and vascular bed, but several candidates such as epoxyeicosatrienoic 
acids, C-natriuretic peptide, H2O2, potassium ions, and direct electrical coupling through 
myoendothelial gap junctions are currently thought to be of physiological importance (33–36). 
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The direct spread of hyperpolarization from the endothelium to the VSMCs through 
myoendothelial gap junctions requires the activation of calcium-activated potassium channels in 
the endothelium (37). Based on their conductance, these channels can be divided in small, 
intermediate, and large-conductance calcium-activated potassium-channels (KCa2.3, KCa3.1 and 
KCa1.1, respectively). The opening of KCa2.3 and KCa3.1 channels is voltage-independent and 
requires binding of calcium to calmodulin, which is bound to their intracellular terminus. As these 
channels are present in the vascular endothelium, they are recognized as the main participants 
responsible for the EDH response (38). On the other hand, KCa1.1 channels opening is triggered 
by both voltage and calcium, and additionally can be further regulated by associated β-subunits 
(39). Due to these characteristics and to its expression in the VSMCs of virtually all vascular beds, 
KCa1.1 channels have been suggested to act as an important negative feedback to limit the 
magnitude of depolarization and contraction in the VSMCs (40,41). As previously mentioned, 
KCa1.1 channels also plays a role in the NO-dependent vasodilation mechanism (29,30). Although 
the expression of KCa1.1 is considered to be limited to the VSMCs in physiological conditions, the 
channel has also been detected in the endothelium of large porcine renal arteries (42) and murine 
preglomerular arterioles (43). These findings suggest that KCa1.1 channels may play a role in the 
EDH response of the renal circulation. 
In addition to these vasodilatatory substances, the endothelium is also able to release 
vasoconstrictors such as endothelin-1 and prostanoids like thromboxane A2 in different situations 
(44). An adequate balance between endothelium-dependent vasodilation and vasoconstriction is 
essential for maintaining homeostasis, and the loss of this balance in favor of vasoconstriction is 
characteristic of endothelial dysfunction. 
The assessment of endothelial function in the patient is complicated, and the golden standards are 
the intra-arterial infusion of endothelium-dependent vasodilators in the forearm or coronary 
circulation, followed by evaluation of the effects by gauge-strain plethysmography or doppler 
tipped guidewire respectively. These methods are invasive and time-consuming, limiting their use 
in a clinical setting. Therefore less invasive measurements of flow-mediated vasodilation in the 
brachial artery using ultrasound, finger plethysmography and peripheral arterial tonometry have 
also been used (45). Although there are several circulating markers used to measure endothelial 
function such as E-selectin, plasminogen activator inhibitor-1 or Von Willebrand factor (VWF), 
these factors do not reflect the production of NO and should only be used as complementary 
methods (46). In research animals, the most direct way to assess endothelial function is ex vivo 
examination of vessel reactivity to endothelium-dependent vasodilators. 
3.2 Endothelial dysfunction 
Endothelial dysfunction is characterized by a shift in the actions of the endothelium toward 
increased vascular permeability and proinflammatory state, reduced vasodilation, and 
prothrombosis. Cardiovascular risk factors such as smoking, aging, obesity, insulin resistance, and 
elevated blood pressure can result in increased oxidative stress and reduced NO bioavailability. 
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Under physiological circumstances and laminar shear stress, eNOS produces NO that maintains 
the quiescent state of the endothelium by different mechanisms. Still, when uncoupled due to 
excessive oxidative stress, eNOS participates in the generation of ROS, prolonging the damage 
and maintaining a proinflammatory environment (28,46). Endothelial dysfunction leads to 
atherosclerosis, connects multiple risk factors with end-organ damage, and therefore is an 
independent predictor of cardiovascular events (47,48). 
3.2.1 Endothelial dysfunction in aging 
Advanced age reduces endothelium-dependent vasodilations in both animals and humans (1). 
Reduction of both NO bioavailability and endothelium-derived hyperpolarizing factors participate 
in the reduced vasodilation associated with aging (1,28,49). Several reasons have been proposed 
to explain this reduced NO production, including; increased activity of arginase competing with 
eNOS for arginine (50), augmented ROS production (51,52), and reduced expression and activity 
of eNOS, resulting from induction of nuclear factor kappa beta (NF-κB) (53) or reduced 
bioavailability of tetrahydrobiopterin (BH4), a co-factor required for eNOS activity (54). Finally, 
endothelial cells undergoing senescence present reduced eNOS activity, suggesting that the 
process of telomere shortening itself could play a role in the onset of endothelial dysfunction (1). 
In addition, VSMCs present reduced expression of soluble guanylate cyclase with aging (55). 
Increased endothelium‐dependent contractions caused by prostaglandins seem to be an important 
part of endothelial dysfunction during aging (28). 
3.2.2 Endothelial dysfunction in diabetes 
Type 2 diabetes is commonly associated with other risk factors such as hypertension, obesity, and 
dyslipidemia, which can induce damage of the endothelium. Additionally, insulin resistance and 
chronic exposure to hyperglycemia seem to be independent factors leading to endothelial cell 
apoptosis and reduced NO bioavailability.  In physiological circumstances, insulin stimulates NO 
production by eNOS phosphorylation. Still, inflammatory cytokines such as tumor necrosis factor-
α (TNF-α) can inhibit insulin signaling, reducing eNOS phosphorylation and contributing to 
insulin resistance (56). The relationship between inflammation and insulin seems bidirectional. 
Thus, the excess of insulin during hyperinsulinemia leads to the activation of transcription factors 
such as NF-κB. This results in increased inflammation and monocyte cell adhesion to endothelial 
cells (57). Hyperglycemia produces metabolic changes in endothelial cells through different 
mechanisms that lead to increased ROS generation and formation of advanced glycation end-
products (AGE), which are protein modifications with deleterious effects in endothelial cells such 
as NO quenching and inflammation (58). One of these modifications, O-linked β-N-
acetylglucosamination (O-GlcNAcylation), has been shown to be of particular importance in the 
development of cardiovascular complications in diabetes (59,60). Besides reduced endothelium-
dependent vasodilation, these processes also increase endothelium-dependent contractions, both 
through COX overexpression (61) and increased production of endothelin-1 (62,63). Endothelial 
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dysfunction in diabetes leads to macrovascular and microvascular complications such as 
atherosclerosis, nephropathy, and retinopathy (64). 
3.2.3 Endothelial dysfunction in hypertension 
Hypertension is thought to have mainly renal and central origins (65). Endothelial dysfunction 
seems to be, in most cases, a consequence of chronically elevated blood pressure rather than a 
cause in hypertension (66). However, reduction of endothelium-derived vasodilation and NO 
bioavailability might aggravate the increase in blood pressure and reduce adequate organ 
perfusion, resulting in end-organ damage and complications (66). A lot of the mechanisms through 
which endothelial function is impaired in hypertension are shared with the previously described 
pathophysiological states, including increased arginase activity, reduced levels of BH4, and mainly 
increased ROS generation and inflammation levels (1,28). In arteries from some hypertensive 
animal models, a reduced expression of soluble guanylate cyclase has been found in addition to 
reduced eNOS expression, which not only suggests a reduced NO production but also decreased 
NO sensitivity at the VSMC level (67). Endothelium-derived contractile factors are also increased 
in hypertension of both humans and experimental animal models, particularly vasocontracting 
prostaglandins play an important role in essential hypertension patients (68). Meanwhile, 
endothelin-1 seems to play a significant role in hypertension related to kidney disease (69) and 
pre-eclampsia (70). 
3.2.4 Endothelial dysfunction in kidney disease 
Chronic kidney disease (CKD) results in progressive loss of kidney function and is accompanied 
by an increased risk of cardiovascular disease, which is a leading cause of mortality in CKD 
patients (71). Systemic endothelial dysfunction is observed at every stage of CKD, including in 
children (72), and worsens with the progression of the disease and improves following kidney 
transplantation (73,74). This evidences that the accumulation of uremic toxins, a consequence of 
decreased renal clearance, induce endothelial dysfunction as in independent factor (75,76), playing 
a role in the increased incidence of cardiovascular death among CKD patients. 
Endothelial dysfunction in the renal circulation mediates, at least partially, the onset of the most 
common forms of CKD. In diabetic nephropathy, hyperglycemia induces renal endothelial 
dysfunction through the mechanisms described above. In brief, these involve endothelial cell 
apoptosis (77), increased permeability through overactive Vascular Endothelial Growth Factor 
(VEGF) signaling (78), and glomerular efferent arteriole contraction (79), hence participating in 
the damage to the glomeruli and reducing kidney function. Moreover, increased ROS generation 
aggravated by endothelial dysfunction upregulates profibrotic signals such as TGFβ1 in the late 
stages of the disease, inducing fibrosis (80). Another common form of CKD is the typical 
presentation of hypertension-induced kidney injury, called arteriolar nephrosclerosis, in which 
renal pathophysiology endothelial dysfunction is suspected to play an important role (81). 
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Regulation of vascular tone in the kidney is crucial for its proper function, controlling the 
glomerular filtration rate and the renal blood flow (82,83). EDH-type relaxation has been shown 
to be of particular importance for the control of the preglomerular circulation, and therefore, the 
correct identification of the calcium-activated potassium channels involved in this response in the 
kidney is key to developing potential renoprotective therapies. 
3.2.5 Therapeutic approaches to improve endothelial function 
Some of the therapies used in the clinic to address cardiovascular risk factors have shown to 
improve endothelial function until a certain extent, most likely through limiting the damage to the 
endothelium. Normalization of blood glucose by antidiabetic treatment (insulin, metformin, etc.) 
have been shown to produce a small improvement in endothelial function (84–86). However, their 
effects are limited since the damage in the endothelium seems to be persistent for a long time even 
after blood glucose-lowering (87,88). New generation antidiabetic drugs such as glucagon-like 
peptide 1 receptor and sodium-glucose cotransporter 2 inhibitors have demonstrated an additional 
vaso- and renoprotective effect compared to traditional blood glucose-lowering strategies, most 
likely through their capacity to directly improve endothelial function (89,90). Similarly, limited 
are the effects on endothelial function of statins and other cholesterol-lowering therapies, as shown 
by different meta-analyses (91). Antihypertensive treatment with β-blockers or calcium channel 
antagonists has also shown contradicting efficacy improving endothelial function, particularly in 
the peripheral vasculature. However, newer β-blockers (e.g., carvedilol) seem to be superior due 
to an apparent antioxidant effect, also shared by calcium channel antagonists (92). Despite the 
inhibition of the renin-angiotensin-aldosterone system being considered a cornerstone in the 
treatment of renal complications in hypertensive or diabetic patients due to its blood pressure-
lowering and antiinflammatory effects (81), therapy with angiotensin-converting-enzyme, 
angiotensin II type 1 receptor (AT1), or renin inhibitors have also shown only limited and context-
specific improvement of systemic endothelial function (92). 
In conclusion, new approaches are needed to improve endothelial function and lower the risk of 
cardiovascular complications in aging and diabetic patients. Some new experimental strategies 
target different pathways, such as endothelial cell senescence in aging (1),  AGE generation and 
its signaling in diabetic patients or the inflammatory component through interleukin inhibition 
(93). Antioxidant treatments were considered a promising direction to take, but the role of ROS in 
endothelial dysfunction has demonstrated to be more complicated than initially thought, having 
protective roles in certain circumstances. Hence, most clinical trials have shown little to no benefit 
of antioxidant therapy in cardiovascular protection (94). Treatments modulating the opening of 
potassium channels in the vasculature are also considered a potential path to directly improve 
endothelium-dependent vasodilation (38), an approach that could be particularly useful in 
peripheral and intrarenal arteries, where the EDH-type vasodilation seems to be prevalent (32). 
Moreover, opening of potassium channels could indirectly lead to an increased release of NO (95). 
However, drugs directly modulating potassium channels can present undesired effects in cardiac 
conduction and in the central nervous system (96). 
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3.3 TG2: activities, cellular location and regulation 
The enzyme family of transglutaminases is composed of transglutaminases 1-7, coagulation factor 
XIIIa and the catalytically inactive erythrocyte membrane protein band 4.2. All the members of 
the family except band 4.2 have calcium-dependent transamidase activity. TG2, also known as 
tissue transglutaminase, is the most widely expressed member of this family and probably the best 
characterized, being virtually present in most tissue and cell types (3). TG2 is composed of four 
structural domains: 1) an NH2-terminal β-sandwich (aminoacids 1-140), 2) the catalytic core 
(aminoacids 141-453) which contains the catalytic triad for transamidase activity (Cys277, His335, 
and Asp358) and the calcium-binding sites (aminoacids 430-453), 3) a β-barrel (aminoacids 479-
586) that contains the specific GTP/GDP binding site not present in most of the other 
transglutaminases, and 4) a second COOH-terminal β-barrel (aminoacids 587-687) (97,98). The 
position of these domains can vary depending on the binding of different effectors, being this 
related to its functions and resulting in the two most common conformational states of TG2: the 
open and the closed conformations. Essential for this conformational change is the regulatory loop 
between the catalytic core and the first β-barrel (aminoacids 454-478), which acts as a joint across 
which the conformation varies (97). Truncated forms of TG2 with shorter COOH-terminus are 
also found in some cells, such as leukocytes, VSMCs, and endothelial cells (99). These shorter 
variants of TG2 usually have impaired GTP binding although their relevance in physiology or 
pathophysiology is yet to be explored. 
 
Figure 1. Scheme of the structural domains of the TG2 protein and their function. The NH2-terminal β-
sandwich domain contains a binding site for fibronectin and is responsible for promoting cell-matrix 
interactions. In its calcium-induced open conformation, the catalytic core domain of TG2 is responsible for 
transamidase activity. The β-barrel 1 domain contains a GTP/GDP/ATP-binding site. These nucleotides 
promote the close conformation of the enzyme that plays an important role in transmembrane signaling. 
The COOH-terminal β-barrel 2 domain can activate phospholipase C when the enzyme is in the closed 
conformation. 
In the calcium-bound open conformation, the TG2 catalytic triad is exposed and the enzyme has 
the classical transamidase activity, which results in rapid deamidation of glutamine residues of 
proteins, polyamine incorporation and ϵ-(γ-glutamyl)lysine isopeptide bond formation between 
substrate proteins (protein crosslinking). In contrast, when GTP, GDP, or ATP are present, TG2 
acquires a closed conformation in which the catalytic triad is inaccessible, therefore lacking 
transamidase activity (100). In its closed conformation TG2 has been reported to have GTPase and 
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ATPase activity (101) which allows it to act as a G protein (Ghα) in transmembrane signaling 
mediating phospholipase C δ1 (PLCδ1) activation (102). Only two other members of the 
transglutaminase family of enzymes, TG3 and TG5, are inhibited by GTP, although they do not 
seem to have hydrolytic activity (103,104). 
In addition to the mutually exclusive transamidase/GTPase activities, several other activities of 
TG2 have been described. Through in vitro experiments, it has been reported that TG2 has protein 
kinase activity, being dependent on its closed conformation/ATP binding activity and inhibited by 
calcium. Still, it is unclear whether this activity plays a role in physiology or pathophysiology in 
vivo (98). TG2 has also been shown to directly interact with several proteins as an 
adhesion/scaffold protein in a way that is variably dependent on its conformation, with some 
interactions being favored by the closed (105) and others by the open conformation (106,107). 
TG2 also has protein disulfide isomerase (PDI) activity independently of calcium and nucleotides 
(108), therefore the role of TG2 conformation in this activity, if any, remains unknown. 
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Figure 2. Schematic representation of conformation-dependent TG2 activities and TG2 activities in which 
the effect of enzyme conformation, if any, is not known. 
TG2 is present in several subcellular compartments as well as extracellularly, and its functions are 
going to be dependent on its location and microenvironment. The extracellular space is 
characterized by low concentrations of nucleotides and high calcium concentration, therefore when 
localized in the ECM, TG2 is believed to be mainly in its open conformation. Through its 
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transamidase activity, extracellular TG2 is known to enhance ECM stability by crosslinking 
fibronectin and collagen fibrils (109,110). Moreover, TG2 participates in post-translational 
modification of other extracellular proteins usually leading to their stabilization in the cell 
membrane, such as Transforming Growth Factor β1 (TGFβ1) binding protein (111), VEGF A 
(112) and AT1 receptors (113). Despite higher concentrations of calcium outside of the cell, TG2 
transamidase activity is not continuously active and requires a reductive environment, being 
inhibited by oxidation (8). Another regulating factor of extracellular transamidase activity is NO, 
which causes S-nitrosylation of TG2 and inhibits its activity (114). Overactivation of extracellular 
transglutaminase activity during tissue damage or due to decreased NO bioavailability leads to 
ECM deposition, playing a role in the onset of fibrotic lesions and increasing cardiovascular 
stiffness (9,115,116). Besides its transamidase-dependent functions, TG2 also acts as a scaffolding 
protein in the extracellular surface of the cell membrane, interacting with integrins, fibronectin, 
and syndecan-4, and promotes cell adhesion, migration, and cell survival (3). Although these 
particular interactions seem favored by the closed conformation (105), other instances in which 
TG2 acts as a scaffold protein in the cell membrane depend on the open conformation, like in its 
interaction with endostatin (106). The mechanisms through which TG2 is externalized are unclear 
and seem highly context-specific, including passive release through cell damage (117,118), 
microvesicle shedding (8,119,120), endosomes (120,121) and rapid externalization through pores 
formed after P2X7 receptor activation in macrophages (122). In the vasculature, S-nitrosylation of 
TG2 by NO, not only inhibits the transamidase activity but it also reduces TG2 externalization 
(10).  
Most of TG2 is located intracellularly in the cytosol. Due to the low concentration of calcium and 
high concentration of nucleotides inside of the cell, intracellular TG2 is thought to be mainly in its 
closed conformation, and measurements of TG2 conformation in cells seems to support this idea 
(123). TG2 has been shown to act as a G protein, coupled with α1B and α1D adrenoceptors, 
thromboxane A2, oxytocin, and follicle-stimulating hormone receptors, linking their stimulation 
with PLCδ1 activation by direct interaction with GTP-bound TG2 (124,125). Via its GTPase 
activity, TG2 also regulates other pathways participating in the activation of extracellular signal-
regulated kinases 1 and 2 (ERK1/2) in cardiomyocytes (126) and inhibiting adenylate cyclase 
activity in vascular endothelial cells and fibroblasts (127). GTP-bound TG2 has also been shown 
to positively modulate KCa1.1 channels in the vascular smooth muscle (128). In general, the 
GTPase activity of intracellular TG2 has been linked with cell survival and protection (18). 
Intracellular TG2 can acquire an open conformation, activating its transamidase activity during 
cellular stress, and it is involved in some mechanisms of NF-κB activation and other processes 
related to inflammation (129,130). Local increases in calcium concentration have also been shown 
to activate TG2 transamidase activity (8). These local activations could explain the role of TG2 in 
monoaminylation of cytoplasmic proteins, which seem to be important in modulation of the 
cytoskeleton and vesicular trafficking, particularly in the vasculature (131–133). The scaffolding 
activity of TG2, which is independent of its transamidase and GTPase activities, has also been 
shown to play a role intracellularly activating NF-κB (134).  
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Besides located intracellularly in the cytosol, TG2 also appears associated with the mitochondrial 
membrane, inner mitochondrial space, and occasionally to the mitochondrial matrix and inner 
mitochondrial membrane. However, the mechanisms involved in TG2 mitochondrial trafficking 
are entirely unknown. Mitochondrial TG2 can activate cell apoptosis through its transamidase 
activity, and its PDI activity is essential for correct disulfide bond formation in complexes I, II, 
IV, and V of the electron transport chain (135,136). TG2 is also present in the cell nucleus 
associated with chromatin, where it has been shown to regulate gene expression through 
transcription factor and histone transamidation (frequently in processes linked with apoptosis, e.g., 
hepatic alcohol-induced cell death). Independently of its transamidase activity, TG2 scaffolding 
capability allows it to act as a transcriptional coactivator (typically in processes related with 
cytoprotection, e.g., reducing neuronal death during ischemia by interacting with hypoxia-induced 
factor 1 (HIF-1) signaling) (137). As previously mentioned, TG2 kinase activity might be involved 
in the phosphorylation of p53, histones H1 and H3, and retinoblastoma protein, but the relevance 
of this activity in vivo is unclear (98). 
 
Figure 3. Schematic representation of different cellular functions of TG2 depending on its activity, 
conformation and location. TF = Transcriptional factor. 
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TG2 gene expression is increased during tissue remodeling, endoplasmic reticulum stress, 
inflammation, viral infection, cancer and apoptosis, and it is mediated by interleukins 1 and 6,  
TNF-α, epidermal growth factor, retinoic acid, HIF-1, NF-κB and TGFβ1 (18). With these two last 
factors, a positive-feedback loop exists as TG2 plays an essential role in their activation. The 
transcriptional regulation of TG2 suggests its importance as a marker of cellular stress.  
3.4 TG2 in the vascular system health and disease 
Although TG2 is the most widely expressed member of the transglutaminase family of enzymes 
in the vascular wall, including endothelial and VSMCs, some other transglutaminases have been 
found in the vasculature of rodents, such as TG1 and TG4 in rat aortae and vena cava (138). In rat 
small mesenteric arteries, PCR studies showed a weak band for TG1 mRNA besides a marked 
expression of TG2, however TG1 protein expression was not detected by immunoblotting (15). 
Another important transglutaminase in the cardiovascular system is Factor XIIIa, which is 
primarily present in bone marrow-derived cells such as platelets, monocytes, and macrophages 
(139). 
3.4.1 S-nitrosylation of TG2 in age-related vascular stiffness 
As previously mentioned, NO regulates both the activity and the cell location of TG2 in the 
vascular system via S-nitrosylation of the protein (10). In cultured human aortic endothelial cells 
(HAECs), the release of NO by S-nitrosoglutathione reduced the amount of TG2 in the surface of 
the cell membrane. At the same time, treatment with the NO synthase (NOS) inhibitor L-NG-
nitroarginine methyl ester (L-NAME) increased it. Aortic rings from aging rats and humans have 
higher levels of transamidase activity compared to aortae from younger individuals, this difference 
being abolished by the ex vivo treatment with L-NAME. This was correlated with decreased TG2 
S-nitrosylation, a higher amount of ECM crosslinks and increased stiffness in arteries from older 
individuals, while the expression of TG2 remained unchanged (9).  
Additionally, in vivo treatment with L-NAME increased transamidase activity in aortae from wild 
type, but not from TG2 knockout mice (9). The role of NO in regulating TG2 location was also 
confirmed in fibroblasts in addition to endothelial cells (10), and the role TG2 in increased vascular 
stiffness due to decreased NO was also confirmed using eNOS knockout mice (116). These results 
suggest that decreased NO bioavailability due to aging increases TG2 externalization. Increased 
externalization and reduced S-nitrosylation of TG2 lead to elevated transamidase activity in the 
vasculature, resulting in increased ECM crosslinking and central vascular stiffness. Moreover, 
recent studies suggest that a similar process could be involved in ventricular stiffness associated 
with aging (140).  
3.4.2 Role of TG2 in endothelial dysfunction in diabetes 
The role of TG2 in glucose metabolism is a controversial topic. TG2 knockout mice have been 
reported to have glucose intolerance and impairment of insulin secretion (141), although later 
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studies from other groups have not been able to replicate these observations in TG2 knockout mice 
from a different background (142), pointing at the background as the reason for the altered glucose 
metabolism in the previous studies instead of the ablation of TG2. On the other hand, three 
different missense mutations in the TG2 gene have been identified in three families with early-
onset diabetes mellitus, while being absent in 600 normoglycemic controls (141). Even though 
these mutations were not fully penetrant and did not appear to be the only cause of diabetes in 
these families, when the mutant proteins were overexpressed in a rat insulinoma cell line, this 
resulted in decreased insulin secretion in vitro compared to cells overexpressing wild type TG2 
(143). The mutations were identified to alter both the transamidase and the GTP binding activities 
of TG2, suggesting that both activities could participate in different steps of insulin secretion, 
although more research is needed to identify the mechanisms involved and their actual relevance 
in the onset of diabetes (143).  
The transamidase activity of TG2 has been shown to mediate endothelial cell death in response to 
increased extracellular concentrations of glucose in human umbilical vein endothelial cells 
(HUVECs) (12). Later studies also showed that TG2 transamidase activity was involved in VEGF-
induced vascular leakage, and that silencing of the TG2 gene or TG2 inhibition by cystamine was 
able to prevent it in the retina of streptozotocin-induced diabetic mice (13). Moreover, the same 
group suggested that a ‘vicious cycle’ between ROS and TG2 was responsible for the sustained 
endothelial cells damage present even after blood glucose normalization with insulin in aortae 
from streptozotocin-induced diabetic mice. Aortic endothelial cells from wild type diabetic mice, 
but not the ones from TG2 knockout or cystamine-treated diabetic mice, had increased 
transamidase activity, oxidative stress, expression of inflammatory adhesion molecules, and 
apoptosis even after blood glucose normalization with insulin (14). These results suggest that the 
transamidase activity of TG2 plays a harmful role in endothelial dysfunction in diabetes. 
A very recent study found that TG2, most likely through its transamidase activity, increased the 
transcription of glucose transporters GLUT-1 and GLUT-3 in fibroblasts during infection with 
intracellular bacteria Chlamydia trachomatis, increasing glucose import. Moreover, the study 
found a correlation between TG2 transamidase activity and O-GlcNAcylation of proteins, 
suggesting that TG2 might be an important player in glucose-derived metabolic pathways in cells 
(144). Considering the potential contribution of increased and sustained O-GlcNAcylation of 
proteins to vascular dysfunction in diabetes (60), this could be another possible mechanism to 
explain the role of TG2 in diabetic-related endothelial dysfunction. 
3.4.3 TG2 in hypertension and regulation of vascular tone 
Sustained vasoconstriction and reduced blood flow lead to inward eutrophic remodeling in 
resistance arteries, resulting in the reduced arterial lumen (145). Although this mechanism is 
adaptive and directed to maintain sufficient organ irrigation, it can result in end-organ damage in 
the end (146). Through its transamidase activity, TG2 has been shown to regulate inward 
remodeling in resistance arteries (6). In TG2 knockout mice, inward remodeling of small 
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mesenteric arteries in response to reduced blood flow was delayed compared with wild type mice, 
although the transamidase activity of Factor XIIIa from macrophages was able to compensate with 
time (7). In phenylephrine (Phe)-treated rats, in vivo treatment with cystamine reduced small artery 
inward remodeling without affecting blood pressure, as well as reduced small artery outward 
remodeling in Phe and amlodipine-treated rats (147). It should be noted that cystamine is an 
unspecific inhibitor with several effects other than transglutaminase inhibition (148), and these 
results should be interpreted with caution. 
The contribution of TG2 during arterial remodeling in hypertension seems to be different in 
large/conductance arteries, where the expression and transamidase activity of TG2 have been 
shown to decrease in proliferating aortic VSMCs (149) and aortic VSMCs of hypertensive rat 
models (150), which would correspond with a proliferative VSMCs phenotype. Moreover, aortic 
VSMCs from TG2 knockout mice had increased proliferation rates compared with VSMCs from 
wild type mice (151). These studies suggest that the expression of TG2 is linked with a contractile 
VSMC phenotype. However, through specific signaling pathways during stress or growth, 
extracellular TG2 can promote VSMC proliferation and dedifferentiation through its transamidase 
activity. For example, aortic VSMCs from TG2 knockout mice had reduced proliferation in 
response to the activation of the platelet-derived growth factor receptor /Akt1 pathway, compared 
with VSMCs from wild type mice (152).  
Moreover, TG2 knockout mice also presented attenuated vessel occlusion in a carotid artery 
ligation model of neointima formation (152). Another example of a potential mechanism through 
which TG2 could promote VSMC dedifferentiation is the established link between TG2 and 
serotonin signaling. In aortic VSMCs, TG2 catalyzes serotonylation of Ras homolog family 
member A (RhoA), which increases its activation and degradation, leading to increased Akt1 
activity and most likely playing a role in the inhibition of vascular contraction after long-term 
stimulation with serotonin (131). Increased serotonylation of RhoA in pulmonary arteries from 
hypoxic rats suggest that this mechanism might be relevant in arterial remodeling during 
pulmonary hypertension (131). In short, the role of TG2 in vascular remodeling is complex and 
seems to depend on the specific pathophysiological context and level of the vasculature. 
Aside from its role in arterial remodeling, TG2 can contribute to hypertension participating in other 
mechanisms. Isopeptide modification of AT1 receptors by TG2 has been shown to stabilize the 
receptor preventing its ubiquitination-dependent degradation in a mouse model of preeclampsia 
(113). This mechanism was also observed in an experimental mouse model of inflammation-
induced hypertension (153), where TG2 was shown to be upregulated by interleukin 6 and HIF-1. 
In this model, transamidase activity was required for the production of agonistic autoantibodies 
against AT1 receptors, highlighting the potential role of TG2 in inflammation-induced 
hypertension (154).   
TG2 has been suggested to participate in the regulation of vascular tone through different 
mechanisms. TG2 transamidase activity has been suggested to participate in the modification of 
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α-actin in the vascular smooth muscle, catalyzing the incorporation of serotonin (132) and 
noradrenaline (NA) (155). The relevance of these processes in VSMC contraction is unclear and 
has only been inferred through the inhibitory effects of high concentrations of cystamine on 
serotonin and NA-induced contraction in myograph-mounted arteries. Cystamine is an unspecific 
transglutaminase inhibitor and such high concentrations are likely to have several pharmacological 
effects. Therefore these results should be interpreted with caution. Nevertheless, vasorelaxant 
effects of cystamine in small mesenteric arteries have been shown to be at least partially dependent 
on TG2 inhibition and linked to the opening of voltage-gated potassium channels in the smooth 
muscle (15). Inside-out patch-clamp recordings revealed that the GTP binding activity of TG2 is 
involved in the opening of KCa1.1 channels in the vascular smooth muscle of rabbit mesenteric 
arteries (128), which could be related with a potential role of the closed conformation of TG2 in 
vasorelaxation. This potential role is supported by the observation of increased vasoconstriction to 
Phe of aortic rings from TG2 knockout mice when compared to aortic rings from wild type mice. 
These differences were abolished when the endothelium was removed, suggesting the involvement 
of endothelial pathways that would fit with downstream activation of KCa1.1 channels in the 
smooth muscle. However, surprisingly no difference was found in endothelial function between 
aortae from TG2 knockout and wild type mice (151). These results point out to a role of TG2 in 
the regulation of vascular tone, although more research is needed to uncover the relevant 
mechanisms and relevance of the different conformational states of TG2.  
3.4.4 Role of TG2 in atherosclerosis 
The role of TG2 in inflammation and ECM deposition has led to hypothesize about its role in 
atherosclerotic plaque formation and stability. However its contribution to the phenomenon is still 
a controversial topic. In human atherosclerotic coronary arteries TG2 is overexpressed in the 
neointimal tissue and vascular wall, and co-localizes with COX-2 and NF-κB (156). Theoretically 
TG2 could participate in the initial formation of the atherosclerotic plaque through its 
proinflammatory activities in the vascular wall. However, using a mice model of atherosclerosis 
with TG2 knockout macrophages resulted in larger atherosclerotic lesions in the aortic valve, due 
to reduced phagocytic capacity of macrophages lacking TG2 and subsequent accumulation of 
necrotic cells (157). These findings suggest a protective role of TG2 in macrophages.  
Concerning the role of TG2 in atherosclerotic plaque composition, reduced collagen content and 
increased inflammation were observed in the atherosclerotic lesions of an apolipoprotein E (apoE) 
and TG2 double knockout model, indicating decreased plaque stability (158). Contrarily, in a 
similar double knockout model from a different research group, no alterations in the composition 
of the plaques compared with mice expressing TG2 were found (159). In a mouse model of 
oscillatory flow in which a tapered perivascular cast was placed around the carotid artery, the 
arteries from TG2 knockout mice presented significantly fewer monocytes adhered to the 
endothelium compared to the arteries from wild type mice. However, atherosclerotic lesions were 
absent in both types of mice. This supports the idea that TG2 might be important in the initial 
phases of plaque formation. However, when the tapered perivascular cast model was applied to 
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apoE knockout mice, treatment with a transglutaminase inhibitor increased the size of the lesion 
in addition to reducing the macrophage number and fat content, but only in the lesions distal to the 
cast, which were exposed to oscillatory shear stress (160). It should be noted that the inhibitor used 
in these experiments, L682777, is a potent non-selective transglutaminase inhibitor which also 
inhibit factor XIIIa (161). Factor XIIIa has been shown to play an important role in the onset of 
atherosclerosis (162). Therefore it cannot be ruled out whether the observed effects of L68277 
might be due to the inhibition of factor XIIIa as well. Vascular calcification is a frequent 
phenomenon in atherosclerotic lesions and a complication of long-term administration of vitamin 
K antagonist, warfarin. Genetic ablation of TG2 has been shown to reduce calcium content in 
warfarin-treated mice (163), supporting the importance of TG2 in this process.  
3.4.5 TG2 in angiogenesis 
TG2 has been reported to present both pro- and antiangiogenic effects. Autoantibodies targeting 
TG2 in celiac disease are known to interrupt different steps of angiogenesis. However, a recent 
study shows that activation of Ras homolog family member B (RhoB) is associated with these 
effects (164), suggesting that the antiangiogenic effect might be due to overactivation of TG2 
transamidase activity by those autoantibodies instead of due to its inhibition. Celiac autoantibodies 
have been shown to increase TG2 and RhoA activation previously, leading to vascular 
permeability (165) and supporting this hypothesis. Also supporting the role of excessive TG2 
transamidase activity in antiangiogenesis, the addition of exogenous TG2 increased fibrosis by 
ECM crosslinking, which led to reduced angiogenesis and tumor growth in experiments by 
different groups (107,166). TG2 has been shown to inhibit angiogenesis through other mechanisms 
such as activation of TGFβ1 in cultured endothelial cells (167). Contrarily, in the context of wound 
healing, TG2 had tissue stabilizing and proangiogenic effects in the skin (168). Moreover, in 
hypoxic conditions, which stimulates angiogenesis, TG2 colocalized with the antiangiogenic agent 
endostatin in the ECM surrounding HUVECs, suggesting a potential proangiogenic role of TG2 
during hypoxia by interfering with endostatin signaling (106). However, the interaction between 
TG2 and endostatin has been linked with antiangiogenic effects and vascular rarefaction in murine 
age-related kidney fibrosis (107), suggesting that the effects of this interaction in angiogenesis are 
complex and context-specific. The interaction of TG2 with endostatin is dependent on calcium and 
therefore occurs with the open conformation of the enzyme (106). TG2 inhibition or knockdown 
inhibited angiogenesis, reducing matrix-bound VEGF A in HUVECs, supporting a positive role 
of TG2 in VEGF-mediated angiogenesis which was dependent on its transamidase activity (112). 
On the other hand, TG2 has also been suggested to participate at different levels of VEGF-
signaling exerting negative regulation of angiogenesis; for example, extracellular TG2 seems to 
interact with VEGF receptor 2 and promotes its trafficking to the nucleus upon its activation, 
limiting its effects. Therefore, inhibition by cystamine enhanced VEGF-induced migration of 
cultured cells (169). More recently, TG2 was shown to bind to heparan sulfate proteoglycans, 
interfering with their binding to VEGF165 and inhibiting early stages of angiogenesis. This resulted 
in transiently enhanced retina vessel formation and increased vascularization of VEGF165-
33
containing matrigel implants in TG2 knockout mice (170). As previously mentioned, the 
interaction of TG2 with heparan sulfate seems to be favored by the closed conformation of the 
enzyme (105). In VSMCs, the role of TG2 in motility is equally variable. In murine aortic VSMCs, 
genetic ablation of TG2 diminished cell migration (151), while in other experiments 
overexpression of TG2 has been reported to inhibit human aortic VSMC migration by participating 
in α1B-adrenoceptor signaling as a G protein (171), although a negative influence in motility due 
to increased transamidase activity cannot be completely ruled out. 
Thus, the role of TG2 in angiogenesis is complex and seems dependent on the signaling pathway, 
subcellular location, and stage of the process. 
3.5 Role of TG2 in the dysfunctional kidney 
Fibrotic remodeling is the main pathophysiologic process associated with progression to end-stage 
renal disease in CKD (172). As previously mentioned, TG2 increases ECM rigidity by fibril 
crosslinking (109,110) but also participates in ECM deposition by TGFβ1 activation (115). Both 
the transamidase and the scaffolding activities of TG2 are important in this process (173,174) and 
have demonstrated to be relevant in renal scarring and fibrosis (175,176). In a 5/6-nephrectomy 
experimental rat model for CKD, treatment with two active-site directed inhibitors of TG2 
(NTU281 and NTU283) reduced the development of glomerulosclerosis and tubulointerstitial 
fibrosis, preventing a decline in kidney function. The TG2 inhibitor NTU281 had low cell 
membrane permeability, while NTU283 was membrane permeable. Treatment with either of the 
inhibitors reduced accumulation of collagen. Still, it did not mitigate TGFβ1 activation in diseased 
kidneys, suggesting that the beneficial effects were due to the inhibition of direct crosslinking by 
the extracellular TG2 transamidase activity, rather than by reducing its impact in TGFβ1 signaling 
(16). The less permeable inhibitor NTU281, was also used in a diabetic nephropathy model of 
uninephrectomized streptozotocin-induced diabetic rats, where it effectively reduced renal 
tubulointerstitial scarring, collagen deposition and number of myofibroblasts, reversing the 
increased serum creatinine and albuminuria in diabetic animals (17). The reduction in the number 
of myofibroblasts suggests that TG2 might play a role in myofibroblast transformation, which 
could be related with TGFβ1 signaling. TG2 has also been suggested to be important in 
myofibroblast transformation during liver fibrosis (177). However, it should be noted that both 
NTU281 and NTU283 are unspecific transglutaminase inhibitors, affecting Factor XIIIa, TG1 and 
TG3 equally. Although only Factor XIIIa has been found to be linked with early stages of fibrosis, 
it cannot be ruled out that the inhibition of other transglutaminases besides TG2 play a role in the 
effects of NTU281 and NTU283. 
Microvascular rarefaction and endothelial dysfunction are important hallmarks in the development 
of nephrosclerosis, particularly during aging (172). Overexpression and overactivation of TG2 has 
been shown in the kidneys of aging mice, in parallel with increased crosslinking of ECM and 
fibrosis and exogenous addition of TG2 reduced angiogenesis. Delivery of endostatin combined 
with folic acid-induced nephropathy, upregulated TG2. Additionally, subcapsular injection of TG2 
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and/or endostatin induced kidney fibrosis in young mice, and also increased the proportion of 
senescent cells. Moreover, the interaction of endostatin with TG2 stabilizing its open conformation 
was confirmed (107). These results suggest that both endostatin and TG2, besides their role in 
fibrosis, might be geronic proteins acting synergistically, and hence play a role in the onset of age-
derived kidney fibrosis and vascular rarefaction. The interaction between the open conformation 
of TG2 and endostatin has been previously shown (106), and this study suggests that this 
interaction might stabilize the open conformation of TG2 and lead to overactivation of the enzyme.  
In summary, TG2 plays a role in kidney fibrosis and its overactivation most likely contributes to 
vascular rarefaction of the fibrotic kidney. Achievement of vasoprotection and inhibition of TG2 
could be a promising strategy to prevent the development of CKD. 
3.6 Pharmacological modulation of TG2 
Due to the involvement of TG2 in different pathologies such as celiac disease, neurodegenerative 
diseases and, as discussed above, fibrotic diseases, a considerable effort has been made in the 
medicinal chemistry field to develop TG2 inhibitors (178). The recently discovered role of the 
closed conformation of TG2 in cell survival and cancer has increased the interest particularly in 
inhibitors able to modulate its conformation (19,179).  
3.6.1 Competitive amines, classic unspecific inhibitors 
The first TG2 inhibitors used were amines, such as derivatives of cadaverine or putrescine. They 
are transglutaminase substrates that act as competitive inhibitors preventing the formation of 
naturally occurring crosslinks (180). Some of these inhibitors are used for probing 
transglutaminase activity, like 5-(biotinamido)pentylamine (BPA), which can be detected with 
high specificity by streptavidin (181). Cystamine has been one of the most widely used inhibitors 
from this family, and besides its inhibitory mechanism as competitive amine, it presents an 
irreversible mechanism of inhibition that has been recently described.  Cystamine has been shown 
to promote the irreversible formation of a disulfide bond between Cys370 and Cys371 TG2 
residues that abolish its transamidase activity (182). When administered in vivo, cystamine is 
rapidly reduced in plasma and cytosol to cysteamine, which seems only to inhibit TG2 by the 
reversible competitive mechanism (183). Therefore, it has been hypothesized that the inhibition of 
intracellular TG2 transamidase activity might be due to cysteamine and not to cystamine.  
All competitive amines are general inhibitors for transglutaminases, with low specificity for the 
different isozymes, and high doses are needed to observe an inhibitory effect. The effect of these 
inhibitors in the conformation of TG2 as well as in its other effects besides the transamidase 
activity, if any, is unknown. In addition, cystamine has been shown to present several other off-
target effects like caspase-3 inhibition (148). For these reasons, competitive amines are being 
abandoned as inhibitors in the investigation of TG2, and this has forced the development of more 
specific modulators. 
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3.6.2 Irreversible inhibitors that lock the open conformation of TG2 
Several families of compounds targeted at the active site of TG2 have been developed in the last 
years. Bromodihydroisoxazole (DHI) derivatives, such as ERW1041E, have been used in vivo in 
different animal disease models, such as a mice model for inflammation-related hypertension 
(153), cardiac fibrosis (184) and pulmonary hypertension (185), with apparently low toxicity and 
successfully inhibiting transglutaminase activity and its consequences. These inhibitors have been 
proposed as probes of the open conformation of TG2. However, it is unclear if they can induce the 
open conformation themselves, reducing their usefulness to study conformation in a 
physiologically relevant way (186). The main limitations of this family of compounds are their 
moderate potency and low selectivity for TG2 when compared to other isozymes like TG1, TG3, 
and factor XIIIa (187). Sulfonium and imidazolium inhibitors like the previously mentioned NTU 
281-283 and L682777, respectively, have also been used in vivo in animal models of kidney 
disease (16,17) and atherosclerosis (160), with apparently low toxicity, but presenting selectivity 
issues with other transglutaminases, particularly with factor XIIIa. 
Michael acceptor inhibitors are α, β-unsaturated carbonyl compounds that participate in an 
addition reaction with thiolated nucleophiles, efficiently inhibiting many enzymes whose active 
site contains cysteine. Acrylamide inhibitors like NC9, VA4 and VA5 are part of this group and 
have demonstrated to be potent irreversible TG2 inhibitors. These inhibitors bind to the active site 
of TG2 and have been shown to lock the enzyme in its open conformation, preventing the 
conformational change to the GTP-bound form, both in the isolated enzyme (21) and in cells 
expressing a labeled TG2 for Förster resonance energy transfer (FRET) studies (19), showing also 
to be membrane permeable, reaching cytosolic TG2. Due to their ability to also inhibit the GTPase 
activity of TG2, these compounds have been shown to reduce cancer stem cell survival (19). The 
fluorescence of some of these compounds have allowed for their use as probes for TG2, although 
they seem to also inhibit factor XIIIa (188). 
Another widely used group of active-site targeted inhibitors are the peptidomimetic compounds 
from the ‘DON’ (6-diazo-5-oxo-L-norleucine) family, which replaced the Michael acceptor 
warhead by a ‘DON’ group, resulting in an increased potency and selectivity for TG2 compared 
to other transglutaminases. Boc-DON and Z-DON developed by the company Zedira (Darmstadt, 
Germany) are the most widely used compounds from this family, being non-membrane-permeable 
and membrane-permeable, respectively (189). Although these compounds are selective for TG2, 
they also inhibit TG1, TG3 and TG6 at working concentrations (189). Moreover, a crystal structure 
for Z-DON bound TG2 has been obtained, demonstrating that the compound is also able to lock 
the enzyme in its open conformation (22). Another inhibitor from this family, ZED1277, 
developed by Zedira and in Phase IIb clinical trials for celiac disease, is the only small molecule 
inhibitor of TG2 that has reached the clinical phase. 
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3.6.3 Reversible inhibitors that stabilize the closed conformation of TG2 
The first used molecules from this class were nonhydrolyzable GTP analogues, such as GTPγS 
and GMP-PCP, due to their presumed ability to bind to the GTP-binding pocket of TG2. These 
analogues have been used as research tools in vitro to investigate TG2 GTPase activity (128), but 
their potential interaction with other GTPases make them not suitable for research in vivo. 
More recently, acylhydrazide inhibitors were developed and were shown to be reversible allosteric 
inhibitors of TG2 (23), with slow-binding kinetics and variable mechanism of inhibition depending 
on the TG2 substrate (24), by binding to a GTP-related pocket. The parent compound of this 
family, LDN 27219, was shown to be non-competitive when the substrates were large proteins 
such as N-methylcasein and RN-Boc-Lys-NH-CH2-CH2-NH-dansyl. At the same time, it 
displayed a competitive mechanism with simpler tetrapeptides (24), suggesting that LDN 27219 
was able to bind to different conformational states of TG2. Moreover, the first assays showed that 
LDN 27219 was able to reduce TG2 transamidase activity inhibition by GTP. Therefore it was 
initially hypothesized that it could compete with GTP binding. Still, later experiments directly 
measuring GTP binding revealed that other compounds from the acylhydrazide family did not 
interfere with TG2 GTP-binding activity (189). These results suggest that LDN 27219 does not 
bind directly to the GTP pocket of TG2, but to a related site that is able to stabilize the closed 
conformation of the enzyme, mimicking the inhibitory effect of GTP but without directly 
competing with its binding. This idea is supported by in silico simulations suggesting that LDN 
27219 binds to a site near to the GTP-binding pocket and stabilizes the closed conformation. LDN 
27219 docking seems to interfere with the regulatory loop between the catalytic core and the first 
β-barrel (aminoacids 454-478), which, as previously mentioned, is essential for conformational 
change (25). Although this conformational effect has not been observed experimentally, the 
selectivity profile of acylhydrazide inhibitors also supports this idea (189), as these compounds 
are highly selective for TG2 and TG3, the only transglutaminases together with TG5 that are 
regulated by GTP binding. The selectivity for TG5 of these compounds has not been tested so far. 
Cinnamoyl inhibitors are a group of reversible TG2 inhibitors that have been shown to inhibit 
transamidase activity in a competitive manner to the donor substrate, CP4d being the most potent 
of this family (190). Photo labeling studies revealed that these inhibitors bind to the acyl-donor 
substrate-binding pocket of the active site (191). Still, despite this, FRET assays in living cells 
suggested that CP4d favors the closed conformation of the enzyme (19,123). The effect of these 
compounds in the GTPase activity of TG2, if any, is not known. 
3.6.4 Other mechanisms of TG2 inhibition with unknown conformational effects 
Acylideneoxoindol inhibitors are potent, non-competitive, and reversible TG2 inhibitors, which in 
recent studies have been found to bind to a low-affinity calcium-binding site on the catalytic core 
of TG2 (192). Surprisingly, these compounds were transamidase activity inhibitors only at 
saturating concentrations of calcium, while they activated TG2 transamidase activity at lower, but 
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physiologically relevant, calcium concentrations (192). This dual agonistic/antagonistic action 
highlights the complex regulation of TG2 and offers an interesting tool for its study.  
Quinoxaline and thieno[3,4-b]-pyrazine inhibitors were discovered using cancer cell proliferation 
inhibition assays. One of these molecules, GK921, has been shown to bind to the NH3-terminus of 
TG2 without interacting with the active site, but somehow inactivating the enzyme and inhibiting 
its interaction with p53, which results in apoptosis in renal cell carcinoma (193). The mechanism 
of inhibition of these compounds is not known. However, it has led to the generation of interesting 
hypothesis like the existence of functional TG2 dimers that might play a physiological role, and 
whose formation seems to be inhibited by these compounds (193).   
To target the essential role of TG2 GTPase activity in epithelial-to-mesenchymal transition, which 
facilitates cancer migration in adults as well as participating in the onset of pulmonary fibrosis 
(194), the design of inhibitors that bind to the GTP binding pocket, based on their in silico docking 
score, has been patented. Despite being an exciting approach to TG2 inhibition, the compounds 
have been neither synthesized nor tested in vitro yet (20). 
Another potential strategy to selectively inhibit TG2 is the use of antibodies or peptides. The 
advantage of this approach is that inhibitors can be targeted at particular interactions of TG2 with 
other molecules, affecting its scaffolding activity. For example, peptides and antibodies against 
the heparan-sulfate binding site to reduce cell adhesion and migration (105), and peptides to 
interfere with polymerization of IκB by TG2 and avoid the activation of the NF-κB pathway, have 
been patented (20). Antibodies targeting the catalytic site of TG2 to reduce transamidase activity 
and ECM deposition have also been developed, Zampilimab (UCB7858) by UCB Pharma being 
the most successful example, which is being tested in phase I/II clinical trials for chronic allograft 
injury after kidney transplant. The effect of peptides and antibodies in TG2 conformation is 
variable depending on the epitopes that they recognize. Recent studies have shown that 
autoantibodies from celiac disease patients were able to stabilize different conformations of TG2 
(195), activating or inhibiting its transamidase activity accordingly (196). The main limitation of 
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4. HYPOTHESIS AND AIMS 
The hypothesis of the present thesis is that activation of potassium channels and improved 
endothelium-dependent vasorelaxation by TG2 conformational modulation will prevent vascular 
dysfunction in aging and diabetes. 
The following specific aims were addressed: 
1- To assess whether conformational modulation of TG2 by inhibitors stabilizing the closed 
or the open conformation will affect potassium channel gating in the vascular wall, 
improving endothelium-dependent vasorelaxation and lowering blood pressure at different 
ages. 
2- To investigate whether in vivo treatment with TG2 inhibitors will prevent vascular 
dysfunction in diabetic mice. 
3- To characterize the potassium channels involved in the EDH-induced vasorelaxation in the 

















5. MATERIALS AND METHODS  
5.1 Animal welfare and ethical statements 
All animal protocols and care used in this study were approved by the Danish Animal Experiments 
Inspectorate (permissions 2014-15-2934-0159 and 2019-15-0201-0009) or by the Institutional 
Animal Care and Use Committee at Complutense University (Madrid, Spain), and were conducted 
in accordance to the Danish Animal Law which conforms to the European Union Guidelines for 
the Care and the Use of Laboratory Animals (European Union Directive 2010/63/EU). The animals 
were housed in the animal facility of the university and in cages (Universal Euro II or III type 
Long) with standard wood bedding and space for two rats or 4-6 mice. They were maintained on 
standard chow and water ‘ad libitum’, at a temperature of 22-23°C and with a 12 h cycle of light 
and dark. 
The study using human arterial tissue was approved by the Regional Ethics Committee, Central 
Denmark (permission 1-10-72-120-17) and conducted following the principles of the Helsinki 
Declaration II for medical research. All participants gave informed consent before participation. 
5.2 Animal models, study design and tissue preparation 
For the experiments in connection with the first aim, Male Wistar Hannover rats at 6-7, 12-14, and 
35-40 weeks of age were used. The rats used for the ex vivo experiments were randomly selected 
and euthanized by stunning, decapitation and exsanguination. The intestines were immediately 
extracted and placed in 4ºC physiological saline solution (PSS), see ‘Drug preparation and 
solutions’ for composition. Secondary to tertiary branches of the mesenteric artery were isolated. 
For in vivo blood pressure recordings, animals at 12-14 or 35-40 weeks of age were anesthetized 
with 35 mg/kg of S-ketamine and 50 mg/kg of pentobarbital sodium administered intraperitoneally 
(IP) after 8 h fasting and euthanized by pentobarbital overdose at the end of the experiment.  
Male Wistar Kyoto rats at 16–18 weeks of age were used for the experiments in connection with 
the third aim. These rats were decapitated with a guillotine and the kidneys were extracted and 
placed in 4ºC PSS. First- to third-order branches of the main renal artery, intrarenal arteries, which 
included the segmental and interlobar arteries, were dissected. 
Obese and diabetic db/db mice with a mutation in the leptin receptor and their lean normoglycemic 
heterozygous db/+ were used as a diabetes model in the experiments related to the second aim. For 
the ex vivo studies on the acute effects of LDN 27219 in isolated arteries, 16-17-week-old diabetic 
db/db male mice (C57BLKS/J-Leprdb/Leprdb) and 16-17, 24-25 and 39-40-week-old 
normoglycemic db/+ (C57BLKS/J-Leprdb/+) were used. Prior to euthanasia by cervical 
dislocation, body weight was registered and blood glucose levels were measured with a Contour 
Blood Glucose Monitoring System (Bayer, Denmark, Copenhagen S) using tail artery blood 
samples. The mesenteric bed was then immediately extracted and placed in PSS, and mesenteric 
arteries were dissected as previously described. For the long-term treatment study, 7-8-week-old 
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db/db male mice (C57BL/6J-Leprdb/ Leprdb) were randomly allocated into three groups: 1) 
treatment with IP injections of LDN 27219 (8 mg/kg/12h) and vehicle drinking water [LDN 27219 
treatment group] (n=12), or 2) treatment with IP injections of vehicle (each 12 h) and candesartan 
cilexetil (3 mg/kg/24h) in the drinking water [candesartan treatment group] (n=12), or 3) treatment 
with IP injections of vehicle (each 12 h) and vehicle drinking water [vehicle treatment group] 
(n=12). Age- and sex-matched db/+ mice (C57BL/6J-Leprdb/+) were included as healthy controls, 
receiving the same treatment as the vehicle treatment group. Using a non-compartmental model, 
pharmacokinetic studies of a single 2 mg/kg IP dose of LDN 27219 in living C57BL/6 mice (n=3) 
showed the half-life of the compound to be 4.94 ± 1.37 (SD) h, being the bioavailability 64.5%. 
For drug preparation and vehicle composition, see ‘Drug preparation and solutions’. Body weight 
and blood sugar were measured weekly, and food and water consumptions for each cage were 
registered each 3-4 days, coinciding with change of cages and renewing of water and chow. In half 
of the animals, blood pressure was also measured weekly using tail-cuff plethysmography (CODA 
System, Kent Scientific). After three weeks of treatment, mice were euthanized by cervical 
dislocation and the descending thoracic aortae and small mesenteric arteries were isolated as 
described above for ex vivo examination of endothelial function. The primary endpoint of the long-
term study was the treatment of endothelial dysfunction in the peripheral circulation, being 
secondary endpoints: endothelial dysfunction in large arteries, blood pressure, and the arterial 
sensitivity to NO and vasoconstrictors. 
Human subcutaneous arteries were dissected from fat biopsies of the gluteal region from both male 
and female patients (30-70 years of age) with or without essential hypertension. A list of patient 
characteristics can be seen in Table 2.  
Table 2: Data from human donors of fat biopsies 




Hypertension Female 43 4 
Hypertension Female 67 3 
Hypertension Female 47 2 
Healthy 
Control Male 62 none 
Healthy 
Control Male 43 none 
Healthy 
Control Male 39 none 
Healthy 
Control Male 33 none 
Healthy 
Control Female 35 none 
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5.3 Isometric tension recordings in isolated arteries ex vivo 
Small mesenteric arteries from rats (internal diameters 200-300 μm) and mice (internal diameter 
150-250 μm), rat interlobar arteries (internal diameters 200-300 μm), mice aortic rings (internal 
diameter >800 μm) and human subcutaneous arteries (internal diameters of 300-400 μm) were cut 
in segments of approximately 2 mm and mounted in microvascular myographs (Danish 
Myotechnology, Aarhus, Denmark) using two 25, 40 or 100 μm steel wires, depending on the 
vessel diameter. PSS solution in the myograph bath was maintained at 37ºC and continuously 
gassed with 5% CO2,-75% N2-20% O2 to maintain pH (7.4). Small arteries were then normalized 
to 0.9 times the estimated internal diameter at 100 mmHg of transmural pressure since it has been 
determined as optimal for force development in most small arteries (197). Aortic rings were 
stretched to a final force of 5.5 mN (passive tension of 1.38 mN/mm) in 1 mN increments and 
allowed to equilibrate for at least 30 min. The vessel viability was tested at the beginning of each 
experiment by measuring the vasoconstrictor responses to a solution with high potassium 
concentration (KPSS), equivalent to PSS except that NaCl was exchanged for KCl on an equimolar 
basis. The endothelium was removed in a subset of small arteries by rubbing the lumen with a 
human scalp hair. The presence or absence of endothelium was checked by addition of ACh (10-5 
mol/L) after pre-constriction with NA (10-7-5x10-6 mol/L), arteries with less than 75% of 
relaxation were discarded except for arteries whose endothelium had been removed and for those 
from aged or diabetic animals, in which some degree of endothelial dysfunction was expected. 
Mesenteric arteries from rats were pre-contracted with the thromboxane analogue, U46619 (4.10-
7 mol/L) and concentration-response curves (CRCs) for TG2 specific inhibitors, LDN 27219 (10-
8-10-5 mol/L) and Z-DON (10-10-3x10-5 mol/L) were constructed. To study the role of the 
endothelial pathways in LDN 27219 relaxation, CRCs in rat mesenteric arteries were constructed 
for it in presence of a NOS inhibitor, Nω-Nitro-L-arginine (L-NOARG) (10-4 mol/L), and in 
arteries without endothelium. Mesenteric arteries from mice and human subcutaneous arteries 
were pre-contracted with U46619 (3x10-7 - 3x10-8 mol/L), and CRCs for LDN 27219 (10-8-10-4 
mol/L) were constructed. To discard an effect by the solvent (Dimethyl sulfoxide = DMSO), 
control CRCs in which only the vehicle was added were performed in every experiment. 
Endothelial function of the arteries was assessed by pre-contracting the arteries to approximately 
90% of their contraction to KPSS with Phe (usually 3x10-6 – 10-5 mol/L for mesenteric arteries 
and 10-7 mol/L for aortae) and constructing CRCs for ACh (10-8 - 3x10-5 mol/L). Endothelium-
independent vasorelaxation was investigated by constructing CRCs for the NO donor sodium 
nitroprusside (SNP) (10-8 - 3x10-5 mol/L in mesenteric arteries and 10-9-3x10-5 for aortae) in Phe-
contracted arteries. To study the acute effect of LDN 27219 on endothelial function and on 
endothelium-independent vasorelaxation, ACh and SNP CRCs were constructed after 25 min 
incubation with either vehicle or LDN 27219 (10-6 - 3x10-6 mol/L). To study the effect of other 
TG2 inhibitors that lock the enzyme in its open conformation (21,22), CRCs for ACh and SNP 
were constructed in rat mesenteric arteries after 1h incubation with either Z-DON (4x10-5 mol/L), 
Boc-DON (10-5 mol/L), VA5 (10-5 mol/L) or vehicle. Differences in incubation time account for 
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the different membrane permeability of the compounds.  
To investigate which endothelial pathways are involved in LDN 27219 potentiation of ACh-
induced vasorelaxation, CRCs for ACh in absence and presence of LDN 27219 were repeated in 
arteries from rats after incubation with blockers of KCa2 and KCa3.1 channels, UCL 1684 (10-6 
mol/L) and TRAM-34 (10-6 mol/L) respectively, L-NOARG (10-4 mol/L), KCa1.1 channel blocker 
iberiotoxin (IbTx) (10-7 mol/L) and guanylate cyclase inhibitor ODQ (3x10-6 mol/L). 
To assess the EDH component in interlobar arteries, CRCs for ACh were performed in the presence 
of L-NOARG (10-4 mol/L) and COX inhibitor indomethacin (10-6 mol/L). Then the role of 
calcium-activated potassium channels in the EDH-mediated relaxation was assessed in the absence 
and presence of the IbTx (10-7 mol/L), TRAM-34 (10-6 mol/L), and UCL 1684 (10-6 mol/L). To 
confirm the functional expression of KCa1.1 channels on the endothelium of interlobar arteries, 
CRCs for KCa1.1 channel opener NS110216 (10-8 - 10-4 mol/L) (198) were constructed on Phe-
contracted (10-6 mol/L) arteries with and without endothelium, in the absence and presence of IbTx 
(10-7 mol/L). Functional expression of KCa2.3 channels was studied performing CRCs for the 
KCa3.1 and KCa2 channel opener SKA-31 (10-8 - 10-4 mol/L) (199) in the presence of TRAM-34 
(10-6 mol/L) alone or in combination with UCL 1684 (10-6 mol/L). 
Vessel reactivity to vasoconstrictors was also examined in the long-term treatment study with 
db/db mice constructing CRCs for NA (10-8-10-5 mol/L in mesenteric arteries and 10-9-10-7 mol/L 
in aortae).  
5.4 Electrophysiological recordings ex vivo 
5.4.1 Resting membrane potential (Em) measurements in myograph-mounted arteries  
Small mesenteric arteries from Wistar Hannover rats were mounted and normalized in a myograph 
as previously described (200). An Ag/AgCl electrode in the myograph bath was used as reference 
electrode and KCl-filled glass microelectrodes (40-100 MΩ of resistance) were used to obtain 
intracellular recordings of resting membrane potential. Input resistance was assessed by observing 
the change in potential caused by applying current pulses of 1 nA; the electrode resistance was 
compensated using the amplifier (Intro-710, WPI) before penetrating inside the smooth muscle 
cell.  PSS solution in the myograph chamber was maintained at 37ºC and under light bubbling with 
95% O2 - 5% CO2 through the protocol. 
The effect of 25 min incubation with LDN 27219 (10-6 mol/L) in Em and in ACh- (10-8-10-5 mol/L) 
induced hyperpolarization was studied in absence and presence of IbTx (10-7 mol/L). To minimize 
the effect of endothelial potassium channels the protocol was repeated in the presence of TRAM-
34 (10-6 mol/L) and UCL 1684 (10-6 mol/L).  
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5.4.2 Whole cell voltage clamp studies 
For isolation of VSMCs, rat mesenteric arteries were dissected, opened longitudinally and stored 
in 4 ºC dissociation solution (for composition, see ‘Drug preparation and solutions’). Arteries were 
then equilibrated during 10 min in a dissociation solution with bovine serum albumin (BSA)  (1 
mg/mL) at 37ºC and then exposed to the same solution supplemented with papain (0.5 mg/mL; 
Worthington Biochemical Corp., Lakewood, NJ, USA) and dithiothreitol (DTT) (1 mg/mL) at 
37ºC for 8 min. Arteries were then washed in 4 ºC dissociation solution and moved to dissociation 
solution containing BSA (1 mg/mL) and collagenase (0.7 mg/mL type F and 0.4 mg/mL type H; 
Worthington Biochemical Corp.) at 37°C for 3 min. After washing in 4 ºC dissociation solution, 
isolated VSMCs were obtained by gentle trituration of the digested arteries with a fire-polished 
glass pipette into the VSMC extracellular solution (for composition, see ‘Drug preparation and 
solutions’). 
To isolate rat intrarenal artery endothelial cells (RIAECs), intrarenal arteries were cut open 
longitudinally and incubated in trypsin/EDTA (0.25%/0.02%) in phosphate buffer saline (PBS) 
without Ca2+/Mg2+ (Biochrom KG, Berlin, Germany) for 30 min at 37º C. Subsequently, arteries 
were washed in 4 ºC dissociation solution and moved to EC extracellular solution (for composition, 
see ‘Drug preparation and solutions’), and RIAECs were scraped and aspirated from the luminal 
side using a pipette tip. 
Isolated cells were seeded in micro-dishes (ibid GmbH, Martinsried, Germany) and maintained at 
4º C until used for electrophysiological recordings within 6 h after the isolation procedure. During 
the recordings cells were continuously perfused (0.5 ml/min) at room temperature (21–25ºC) with 
their respective extracellular solutions. 
Patch pipettes were made of borosilicate glass capillaries (World Precision Instruments, FL, USA) 
fabricated using a dual-stage puller PP-830 (Narishige, Tokyo, Japan), the tips were fire polished 
using a microforge MF-830  (Narishige, Tokyo, Japan) and presented resistances of 4-7 MΩ. For 
the composition of patch pipette solutions, see ‘Drug preparation and solutions.’ To study the 
effect of intracellular GTP in LDN 27219 activity over potassium currents, VSMCs patch pipette 
solution containing 5x10-3 mol/L Na2GTP was used in some experiments. 
Membrane currents were recorded under the whole-cell configuration of the patch-clamp 
technique using an Axon Multiclamp 700A amplifier (Axon Instruments, Molecular Devices, CA, 
USA). Current recordings were digitized on line at 10 kHz and low pass filtered at 2 kHz using a 
Digidata 1440 A (Axon Instruments). To acquire and store data, pClamp 10 software was used. 
Em was recorded in some cells under gap-free conditions (I=0 pA) before starting voltage-clamp 
recordings. Current-voltage relations were determined using voltage ramps (-100 to 160 mV, 600 
msec for VSMCs and -100 to 120 mV, 500 msec for RIAECs) and a holding potential (Vh) of -65 
mV for VSMCs and -50 mV for RIAECs under the voltage-clamp configuration. 
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Drugs used in patch-clamp studies were dissolved in the extracellular solution at the desired 
concentration and applied to the recording micro-dish via a gravity-fed U-tube microperfusion 
system connected to a vacuum pump that allowed us to exchange the extracellular media. 
In VSMCs amplitudes of potassium currents were measured in control conditions and 12 min after 
the addition of LDN 27219 (3x10-5 mol/L) to the extracellular solution. To address which subtype 
of potassium channels were involved in LDN 27219 effect, the protocol was repeated in the 
presence of IbTx (10-7 mol/L), and of the voltage-gated potassium channel 7 (Kv7) blocker XE991 
(10-5 mol/L) was added. To study how conformational modulation of TG2 affected LDN 27219 
activity over potassium channels, the initial protocol was repeated after one h incubation with VA5 
(5x10-5 mol/L) or with Na2GTP (5x10-3 mol/L) present in the intracellular solution. 
In RIAECs, potassium currents were recorded under control conditions, after the addition of ACh 
(10-6 mol/L) and to study the calcium-activated potassium channels involved in response to ACh, 
IbTx (10-7 mol/L), TRAM-34 (10-6 mol/L) and UCL 1684 (10-6 mol/L) were cumulatively added 
to the extracellular solution. 
5.5 Immunohistochemistry 
Samples from freshly isolated RIAECs were seeded on positively charged surface microscope 
slides and fixed in 4% paraformaldehyde in 0.1 mol/L sodium phosphate buffer (PB), 
cryoprotected in 30% sucrose in PB and stored at -20°C. Isolated RIAECs were preincubated in 
2% BSA in PB containing 0.1% Triton-X-100 for one h. Then, cells were incubated with either a 
rabbit anti KCa2.3 channel antibody (Alomone Labs, Jerusalem, Israel) diluted at 1:100, a rabbit 
anti-KCa3.1 channel antibody diluted at 1:100 or a goat anti-KCa1.1 channel alpha subunit antibody 
(Alomone Labs, Jerusalem, Israel) diluted at 1:100 for 48 h. 
Endothelial cells were visualized for positive immunostaining for mouse anti VWF (Thermo 
Fisher Scientific, USA, 1:50 dilution). They were then washed and reacted with the second 
antibodies for 2h at room temperature. Secondary antibodies used were Alexa Fluor 594 (red) goat 
anti-rabbit (Invitrogen, Life Technologies S.A., Madrid, Spain, 1:200 dilution) and Alexa Fluor 
488 (green) goat-antimouse (Invitrogen, 1:200 dilution). The slides were covered with a specific 
mounting medium with 4′,6-diamidino-2-phenylindole (DAPI) (Molecular Probes, Eugene, USA), 
which stains all cell nuclei.  
Tissue samples from the kidney containing renal artery were fixed in 4 % paraformaldehyde in 0.1 
mol/L PB, pH 7.4, for 2 to 4 h at 4º C, and subsequently placed in 30 % sucrose in 0.1 mol/L PB 
for cryoprotection. The tissue was embedded and frozen in OCT compound (Tissue-Tek®. Sakura 
Finetek, Europe B.V.), and stored at -80°C. Transversal sections 5 µm thick were obtained by 
means of a cryostat and preincubated in 10% normal goat serum in PB containing 5% BSA and 
0.3% Triton-X-100 for 2-3 h. Then, sections were incubated with rabbit anti-KCa3.1, rabbit anti-
KCa2.3, rabbit anti-KCa1.1 and rabbit anti-sloβ1 (Alomone labs, Jerusalem, Israel) at a final 
concentration of 1:100 and a mouse anti-eNOS (Abcam, Cambridge, UK) at 1:400 during 48 h, 
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washed and reacted with the second antibody for 3 h at room temperature, Alexa Fluor 594 goat-
anti-rabbit and Alexa Fluor 488 goat-anti-mouse (1:200 dilution) (Abcam). The slides were 
covered with a specific mounting medium containing DAPI. No immunoreactivity could be 
detected in sections incubated in the absence of the primary antisera. 
5.6 Blood Pressure measurements 
5.6.1 Direct mean arterial pressure (MAP) measurements in anesthetized animals  
Wistar Hannover rats (12-14 and 35-40 weeks old) were anesthetized with s-ketamine (35 mg/kg) 
and pentobarbital (50 mg/kg) administered IP, and placed in a heated blanket to maintain body 
temperature at 37ºC, which was continuously monitored. Adequate depth of anesthesia was 
checked periodically by the absence of the toe pinch withdrawal effect, and 1/3 of the initial dose 
of anesthetics was administered IP when needed (usually each 1.5 h). For electrocardiographic 
recordings, ECG hypodermic needles were placed in the Einthoven’s bipolar lead II configuration, 
which were recorded by an animal bio-amplifier (AD Instruments). A solid-state catheter (model 
no. SPR-1000 Millar Inc, Houston, USA) was introduced into the carotid artery to measure MAP. 
Electrocardiographic and MAP data were continuously recorded on a computerized data 
acquisition system (PowerLab, ADInstruments) and ECG signals were low-pass filtered by using 
the standard filter file for ECG recordings. The ADInstruments software automatically obtained 
different electrocardiographical values.   
The rats were infused through a catheter placed into the jugular vein for 3 min with either three 
doses of LDN 27219 (0.1; 1 and 2 mg/kg) or the corresponding doses of the vehicle (polyethylene 
glycol 400 = PEG-400), using a syringe infusion pump system (Harvard Apparatus Model 55-
2219) and leaving a rest period of 10 min between doses. To study the effect of TG2 inhibitors 
that lock the open conformation of the enzyme, the animals in the vehicle group were infused with 
a single dose of VA5 (1 mg/kg) for 3 min at the end of the protocol. 
5.6.2 Indirect MAP measurements in conscious animals with non-invasive methods 
During the long-term treatment study, the blood pressure of diabetic db/db and healthy db/+ mice 
was recorded once a week using tail-cuff plethysmography with volume pressure recording 
(CODA System, Kent Scientific). To reduce the effects of the stress induced by this technique, as 
well as the variations due to the circadian rhythm, animals were trained during one week before 
the beginning of the study, animals were placed in the holders at least 10 min before the 
measurements, and the measurements were always carried out at similar times of the day. The 
temperature of the animals was continuously monitored and maintained at 37 ºC during the 
measurements. Measurements were repeated 20 times per animal, and results were averaged, 
excluding outliers (> 2 Standard Deviations (SD)). 
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5.7 Transglutaminase activity measurements 
5.7.1 Transglutaminase activity in vitro 
Liver samples from Wistar Hannover rats, snap-frozen with liquid nitrogen until the assay was 
performed, were thawed and homogenized in RIPA lysis buffer (for composition, see ‘Drug 
preparation and solutions’) with Halt Protease and Phosphatase Inhibitor Cocktail (ThermoFisher 
Scientifics, Massachusetts, USA). Livers were left 30 min on ice before sonicating for 45 seconds 
and then centrifuged at 13000 rpm for 10 min at 4 ºC. The supernatant was collected, and the 
protein concentration was measured by a modified Lowry method. Samples were prepared to 
achieve a concentration of 8 µg/µL using the diluent buffer of the Specific Tissue 
Transglutaminase Colorimetric Microassay Kit TG2-CovtTest (Zedira, Darmstadt, Germany). 
This commercially available test is based on the incorporation of a biotinylated preferred TG2 
substrate (Biotin-pepT26) as amine-acceptor into a spermine coated strip as amine-donor. After 
dilution, 25 µL the of sample were incubated with 25 µl of different concentrations of the inhibitors 
LDN 27219 (10-7 – 10-4 mol/L) or VA5 (10-7 – 10-5 mol/L), or the vehicle for 20 min on ice. Then, 
the microtiter strips coated with spermine were washed, and 50 µL of study sample or 50 µL of 
the standard were added along with 10 µL of diluent buffer and 50 µL of ice-cold assay-mixture 
(Biotin-pepT26 / CaCl2, 20% DTT). The plate was then incubated for 30 min at 37 ºC, and after 
pertinent washes with wash buffer and 0.1 mol/L NaOH incubated again with horseradish 
peroxidase (HRP) streptavidin (1:2000 dilution in wash buffer) for 15 min at 37 ºC. Later, HRP 
substrate was added for 5 min at room temperature, and subsequently, the reaction was stopped 
with a blocking reagent. The final optical density was read at 450 nm and data was quantitatively 
evaluated with the standard curve. Duplicates from each sample or standard were performed, and 
the average value was calculated in all the study samples. 
5.7.2 Transglutaminase activity ex vivo 
To measure transamidase activity ex vivo, a dot blot assay based on the incorporation of the 
transglutaminase substrate BPA to structural proteins was used. Small mesenteric arteries from 
rats of the different age groups were dissected and immediately incubated in PSS containing BPA     
(10-4 mol/L) and an increased concentration of Ca2+ (2.5x10-3 mol/L) at 37oC for four h. During 
incubation, PSS was continuously bubbled with 5% CO2,-75% N2-20% O2 to maintain pH (7.4). 
Then, unreacted BPA was washed by rinsing the arteries with PBS before tissue homogenization 
and protein extraction in RIPA lysis buffer with Halt Protease and Phosphatase Inhibitor Cocktail 
(ThermoFisher Scientifics, Massachusetts, USA). The amount of extracted protein was quantified 
by a modified Lowry method, and 10 μg of total proteins were loaded onto a nitrocellulose 
membrane using the BioRad Dot Blot apparatus. The membrane was blocked in 5% BSA for 2 h 
and then incubated with HRP-conjugated streptavidin (Amersham Bioscience; dilution 1:10000 in 
0.5% BSA) for two h to detect BPA incorporation.  The membrane was then washed in TBS-T, 
removed from the dot blot apparatus, and developed using an ECL-Plus kit (General Electric (GE) 
Health care, Copenhagen, Denmark). The images were captured by a luminescence camera using 
48
a PXi 4 Touch image analysis system (Syngene). After development, membranes were rinsed in 
water and stained with amido black (0.1% (w/v) in 10% acetic acid) for total protein staining. Blots 
were quantified using GeneTools 4 software (Syngene) and normalized to the total amount of 
protein.  
Additionally, small mesenteric arteries from rats at 12-14 weeks of age were used for the inhibition 
assay ex vivo. Arteries were incubated in PSS containing BPA and Ca2+ as previously described 
but in the presence of either vehicle, LDN 27219 (10-6 mol/L), Z-DON (4x10-5 mol/L) or DTT (10-
3 mol/L), which has been demonstrated to increase TG2 transamidase activity. Two replicates for 
each treatment and animal were added in one blot, and the average activity in control conditions 
was set to 100%. 
5.8 Molecular biology 
5.8.1 Native polyacrylamide gel electrophoresis (PAGE) 
To study the conformational shift of the enzyme, purified and functional human TG2 (2.5x10-6 
mol/L) protein produced in insect cells (Zedira. Darmstadt, Germany) was incubated for 30 min at 
room temperature in preincubation buffer (for composition, see ‘Drug preparation and solutions’) 
with or without Na2GTP (10-3 mol/L) or LDN 27219 (10-3 mol/L ) before adding Native Sample 
Buffer for Protein Gels (Bio-Rad) or in preincubation buffer with Z-DON (2x10-4 mol/L) 30 min 
prior addition of CaCl2 (5x10-3 mol/L) for 20 min. Native sample buffer was added (dilution 1:2), 
and 1.5 μg of protein was loaded onto a 4–20% Criterion™ TGX Stain-Free™ gel (Bio-Rad) using 
Tris-glycine (Bio-Rad) as the running buffer. Electrophoresis was applied at 125 V and 4 ºC for 
75 min. The bands were visualized using stain-free technology by exposing the gels to UV light 
and capturing the image using a PXi 4 Touch image analysis system (Syngene). Band intensity 
analysis was carried out using GeneTools 4 software (Syngene). 
5.8.2 Sodium dodecyl sulfate-PAGE (SDS-PAGE) 
Small mesenteric arteries from rats of different ages were snap-frozen with liquid nitrogen and 
kept at -80°C until homogenization. The tissue was homogenized and centrifuged in a lysis buffer 
(for composition, see ‘Drug preparation and solutions’) with Halt Protease and Phosphatase 
Inhibitor Cocktail (ThermoFisher Scientifics, Massachusetts, USA). The amount of protein 
extracted was quantified by a modified Lowry method, and samples were diluted in Laemmli 
Sample Buffer (Bio-rad) containing DTT to a final concentration of 1 g/L of total protein. After 
boiling (99°C for 5 min), the samples were left to refrigerate, and 10 μg of protein were loaded 
onto 4–20% Criterion™ TGX Stain-Free™ gels (Bio-Rad), using XT MOPS (Bio-Rad) as the 
running buffer.  
125 V  were applied for one h before being transfer to a polyvinylidene fluoride (PVDF) membrane 
by applying 100 V for one h at 4°C using Tris-glycine (Bio-Rad) (20% ethanol) as the transfer 
buffer. After the transfer, total protein was visualized using stain-free technology by exposing the 
membranes to UV light, and the images were captured using a PXi 4 Touch image analysis system 
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(Syngene). The membranes were washed twice for 15 min in PBS-T and TBS-T (for composition, 
see ‘Drug preparation and solutions’) for one h and then blocked in 0.3% I-block™ (Applied 
Biosystems) for 2–4 h before being incubated overnight at 4°C with the primary antibody. Anti-
TG2 antibody (ab421, Abcam) at a dilution of 1:200, anti-KCa1.1 alpha antibody (APC-107, 
Alomone labs) at a dilution of 1:100, and anti-KCa1.1 beta 1 antibody (ab3587, Abcam) at a dilution 
of 1:250 were used as primary antibodies in TBS-T with 0.3 % I-block™ (Applied Biosystems). 
The membrane was then washed in TBS-T and incubated for 2 h in the secondary antibody, Goat 
anti-Rabbit IgG (G-21234, Invitrogen). The membrane was developed using an ECL-Plus kit 
(General Electric (GE) Health care, Copenhagen, Denmark) and the images were captured by a 
luminescence camera using a PXi 4 Touch image analysis system (Syngene). Blots were quantified 
using GeneTools 4 software (Syngene) 
5.9 Drug preparation and solutions 
Unless indicated otherwise, all substances used in this study were dissolved in distilled water. For 
ex vivo experiments, U46619 was dissolved in ethanol and Boc-DON, LDN 27219, ODQ, TRAM-
34, UCL 1684, XE991, and Z-DON were dissolved in DMSO and stored at -20ºC. Further dilution 
of the above-mentioned compounds were made in distilled water. The DMSO concentration in the 
bath were kept below 0.01% and did not affect vessel contractility. For in vivo experiments, LDN 
27219 and VA5 were dissolved in PEG-400. 
For the long-term in vivo treatment, stocks of 20 mg/mL of LDN 27219 dissolved in PEG-400 
(100%) were stored at -20ºC until administration. LDN 27219 stock solutions were diluted in 
saline solution containing sulfobutylether-β-cyclodextrin (SBE-b-CD) to improve solubility (9 
mg/mL NaCl; 15 % (w/v) SBE-b-CD) immediately before injection, resulting in a clear solution 
with a final concentration of 2.00 mg/mL of LDN 27219 in 10% PEG-400 / 90% (15% (w/v) SBE-
b-CD in saline solution). For the treatment on the drinking water, stocks solutions of 1 mg/ml of 
Candesartan cilexetil was dissolved in a vehicle of PEG-400 (10% v/v), ethanol (5% v/v), 
Kolliphor® EL (2% v/v), and tap water (83% v/v) and the pH was adjusted to 9.0 with 0.5 mol/L 
Na2CO3, before dilution to the final concentration in tap water. Final concentrations needed to 
achieve the desired doses of candesartan cilexetil per day in the drinking water were determined 
by measuring water consumption every 3-4 days. 
5.9.1 List of used solutions and compositions 
- Physiological saline solution (PSS), composition (mmol/L): 119 NaCl, 4.7 KCl, 1.18 KH2PO4, 
1.17 MgSO4, 1.5 CaCl2, 24.9 NaHCO3, 0.026 EDTA and 5.5 glucose, pH= 7.4 
- High potassium PSS (KPSS), composition (mmol/L): 123.7 KCl, 1.18 KH2PO4, 1.17 MgSO4, 
1.5 CaCl2, 24.9 NaHCO3, 0.026 EDTA and 5.5 glucose, pH= 7.4 
- Dissociation solution, composition (mmol/L): 119 NaCl, 4.7 KCl, 1.18 KH2PO4, 1.17 MgSO4, 
24.9 NaHCO3, 0.027 EDTA, and 11 glucose, pH= 7.4 
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- VSMCs Extracellular Patch-Clamp solution, composition (mmol/L): 130 NaCl, 5 KCl, 1.2 
MgCl2, 1.5 CaCl2, 10 glucose and 10 HEPES, adjusted to pH 7.3 with NaOH 
- VSMCs patch pipette (intracellular) solution, composition (mmol/L): 130 KCl, 1.2 MgCl2, 0.1 
EGTA and 10 HEPES, adjusted to pH 7.2 with KOH 
- Endothelial Cells Extracellular Patch-Clamp solution, composition (mmol/L): 140 NaCl, 5 KCl, 
1 MgSO4, 1 CaCl2, 10 glucose and 10 HEPES, adjusted to pH 7.4 with NaOH 
- Endothelial Cells patch pipette (intracellular) solution, composition (mmol/L): 140 KCl, 1 
MgCl2, 2 EGTA, 1.71 CaCl2 and 5 HEPES, adjusted to pH 7.2 with KOH 
- RIPA lysis buffer, composition (mmol/L): 0.5 tris/HCL, 10 EDTA, 1.5 NaCl, 2.5 % deoxycholic 
acid, 10 % NP-40, pH= 7.4 
- Native PAGE preincubation buffer, composition (mmol/L): 75 imidazole, 0.5 EDTA, 5 DTT, 
pH= 7.2, 10% DMSO 
- SDS-PAGE Lysis buffer, composition (mmol/L):  20 tris/HCL, 5 EGTA, 150 NaCl, 20 
glycorophosphate, 10 NaF, 1 % triton X-1000, 0.1 % (v/v) Tween® 20, pH= 7.5 
- PBS-T, composition (mmol/L): 150 NaCl, 50 NaH2PO4, 0.05 % (v/v) Tween® 20 
- TBS-T, composition (mmol/L): 10 tris base,100 NaCl, 1 EDTA, 0.1 % (w/v) Tween® 20 
5.10 Randomization, blinding and statistical analysis 
All randomization in this study was performed using a random number generator. Group sizes for 
the in vivo studies were calculated with an expected effect size based on the in vitro results, desired 
power of 95% and an alfa of 0.05. For the long term study, the researcher injecting the animals, 
changing the drinking water bottles, performing the myograph experiments and analyzing the data 
was blinded to the treatment the animals were receiving. The vials containing stock solutions of 
either vehicle or treatment were coded by a colleague and dissolved to their working concentrations 
immediately before application, being indistinguishable from each other. 
Data are expressed as means ± SEM, being “n” the number of animals studied in each group. The 
normality of the data was verified examining their quantile-quantile (Q-Q) plots against the normal 
distribution. Native-PAGE results were analyzed by paired two-tailed Student´s t-test. CRCs and 
I-V relationships were analyzed by two-way ANOVA, in order to assess the potency of the 
agonists, their pD2 values (-logEC50) were calculated by a variable slope model of non-linear 
regression (GraphPad Prism 7.02) and, if the two-way ANOVA analysis was significant, compared 
by an F test. One-way ANOVA was used for multiple testing followed by Dunnett’s multiple 
comparison post hoc analysis against a control group when there was only one independent 
variable of interest. Values of P < 0.05 were considered significant. 
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6. SUMMARY OF RESULTS 
A more detailed description of the results can be found in the manuscripts. 
6.1 Role of TG2 conformation in age-dependent changes of endothelial function 
Changes in TG2 conformation were examined using native-PAGE. Confirming the results of 
previous in silico studies (25), in vitro incubation of purified and functional human TG2 with the 
reversible inhibitor LDN 27219 increased the relative abundance of the closed conformation 
compared to vehicle, while incubation with Na2GTP forced it into its closed conformation, and the 
irreversible inhibitor Z-DON in the presence of calcium forced it open (Figure 4A).  Measurements 
of BPA incorporation ex vivo revealed that the presence of LDN 27219 was able to inhibit 40.92 
± 4.53 % (n=3) of the transamidase activity in isolated rat mesenteric arteries, similarly to Z-DON 
(58.93 ± 7.84 %, n=4). On the other hand, DTT increased transglutaminase activity of the sample 
40.84 ± 7.82 % (n=4) (Figure 4B). Moreover, LDN 27219 induced concentration-dependent 
vasorelaxation of rat small mesenteric and human subcutaneous arteries mounted in isometric 









Figure 4. Effects of different TG2 inhibitors in the conformation in vitro and activity ex vivo of the 
enzyme. A. Study of recombinant human TG2 conformation using Native-PAGE. Top panel: 
Representative blots of the two visible bands, corresponding to the open and closed conformations, after 
electrophoresis of human TG2 in the presence of different effectors. Bottom: Average relative abundance 
of the bands presented as % of total intensity. Data are means ± SEM. *, P < 0.05 using paired two-tailed 
Student´s t-test, n=5 replicates in 4 gels B. Transglutaminase activity inhibition assay measured as the 
incorporation of BPA ex vivo. Top: Representative dot blot of BPA incorporation in small mesenteric 
arteries from a 12-14-week-old rat under different incubation conditions and Pan Actin expression as 
loading control. Bottom: Average transglutaminase (TGase) activity of the experiments shown in the top 
panel expressed as % of average activity in control conditions. Data are means ± SEM. *, P < 0.05 using 
one-way ANOVA with Dunnett post-test compared to control, n=3-4. (Modified from Manuscript I). 
The effect of conformational modulation of TG2 in endothelial function was investigated using 
wire myography. Incubation during 20 min with LDN 27219 increased the vasorelaxation induced 
by ACh CRCs in human subcutaneous arteries (pD2 Vehicle= 7.58 ± 0.06 vs. pD2 LDN= 8.09 ± 0.06. 
*, P < 0.05 using F-test) (Figure 5A) and rat mesenteric artery (not shown in this summary, see 
Manuscript I). In contrast, incubation with VA5 and Z-DON that are membrane-permeable 
inhibitors locking TG2 in its open conformation reduced ACh-induced vasorelaxation (pD2 Vehicle= 
7.53 ± 0.04; pD2VA5= 7.32 ± 0.03*; pD2Z-DON= 7.32 ± 0.05*. *, P < 0.05 using F-test compared to 
vehicle), while the non-permeable inhibitor Boc-DON failed to change it (pD2 Vehicle= 7.50 ± 0.05) 
(Figure 5B).  Additionally, the presence of VA5 or Z-DON prevented the potentiation of 
endothelium-dependent vasorelaxation (pD2 VA5= 7.32 ± 0.03 vs. pD2 VA5+LDN= 7.25 ± 0.06; pD2 Z-
DON= 7.32 ± 0.05 vs. pD2 Z-DON+LDN= 7.46 ± 0.03) (Figure 5C, D). 
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Figure 5. Effect of conformational modulation of TG2 on endothelium-dependent vasorelaxation ex 
vivo. A. Average responses to ACh CRCs in Phe-contracted human subcutaneous arteries incubated with 
either vehicle (DMSO) or reversible TG2 inhibitor LDN 27219, which promotes the closed conformation 
of the enzyme, n=7. B. Average responses to ACh CRCs in Phe-contracted rat mesenteric arteries incubated 
with either vehicle (DMSO) or irreversible and membrane permeable TG2 inhibitors VA5, Z-DON or the 
non-permeable inhibitor Boc-DON, which promote the open conformation of the enzyme, n=5-10. C. 
Average responses to ACh CRCs in Phe-contracted rat mesenteric arteries incubated with either vehicle 
(DMSO) or LDN 27219 both in presence of VA5, n=5-6. D. Average responses to ACh CRCs in Phe-
contracted human subcutaneous arteries incubated with either vehicle (DMSO) or LDN 27219 both in 
presence of Z-DON, n=5. Data are means ± SEM of % relaxation relative to maximum contraction. *, P < 
0.05 using two-way ANOVA compared to their respective controls. (Modified from Manuscript I). 
To investigate mechanisms involved in the potentiation of ACh-derived vasorelaxation by LDN 
27219, different endothelial-pathways were inhibited in rat mesenteric arteries. The presence of 
KCa3.1 and KCa2 blockers, TRAM-34 (10-6 mol/L) and UCL 1684 (10-6 mol/L) respectively, failed 
to prevent the potentiation by LDN 27219 (10-6 mol/L) (pD2 TRAM+UCL+Vehicle= 6.39 ± 0.07 vs. pD2 
TRAM+UCL+LDN= 6.90 ± 0.06 *, P < 0.05 using F-test) (Figure 6A). Contrarily, the inhibition of NOS 
or KCa1.1 channels by L-NOARG (10-4 mol/L) or IbTx (10-7 mol/L), respectively, abolished the 
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effect of LDN 27219 (pD2 L-NOARG+Vehicle= 6.71 ± 0.05 vs. pD2 L-NOARG+LDN= 6.70 ± 0.05; pD2 
IbTx+Vehicle= 6.73 ± 0.05 vs. pD2 IbTx+LDN= 6.70 ± 0.08) (Figure 6B, C). In arteries whose endothelium 
was removed, incubation with LDN 27219 also potentiated the vasorelaxation in response to SNP 
(pD2 Vehicle= 6.63 ± 0.07 vs. pD2 LDN= 7.36 ± 0.09 *, P < 0.05 using F-test) (Figure 6D).  
 
Figure 6. The mechanism underlying the potentiation of endothelium-dependent vasorelaxation by 
LDN 27219 ex vivo. A. Average responses to ACh CRCs in Phe-contracted rat mesenteric arteries 
incubated with either vehicle (DMSO) or reversible TG2 inhibitor LDN 27219, both in the presence of 
TRAM-34 (10-6 mol/L) and UCL 1684 (10-6 mol/L), n=5. B. Average responses to ACh CRCs in Phe-
contracted rat mesenteric arteries incubated with either vehicle (DMSO) or reversible TG2 inhibitor LDN 
27219, both in the presence of L-NOARG (10-4 mol/L), n=5. C. Average responses to ACh CRCs in Phe-
contracted rat mesenteric arteries incubated with either vehicle (DMSO) or reversible TG2 inhibitor LDN 
27219, both in the presence of IbTx (10-7 mol/L), n=6. D. Average responses to SNP CRCs in Phe-
contracted rat mesenteric arteries without endothelium, incubated with either vehicle (DMSO) or reversible 
TG2 inhibitor LDN 27219, n=6. Data are means ± SEM of % relaxation relative to maximum contraction. 
*, P < 0.05 using two-way ANOVA compared to their respective controls. (Modified from Manuscript I). 
In isolated VSMCs from rat mesenteric arteries, patch-clamp studies revealed that cells incubated 
with LDN 27219 (3x10-5 mol/L) presented higher potassium current amplitudes than under control 
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conditions, similarly to cells measured with high concentrations of intracellular Na2GTP (5x10-3 
mol/L) (Figure 7). Furthermore, in the presence of high intracellular Na2GTP, addition of LDN 
27219 to the extracellular medium failed to increase further potassium currents (not shown in this 
summary, see Manuscript I). Contrarily, incubation either with VA5 (5x10-5 mol/L) or IbTx (10-7 
mol/L) reduced potassium currents in isolated VSMCs (Figure 7) and prevented LDN 27219 
increases in potassium current (not shown in this summary, see Manuscript I).  
 
Figure 7. Effect of TG2 conformational modulation in potassium currents of freshly isolated VSMCs 
ex vivo. Top left: Picture of freshly isolated VSMCs from rat mesenteric artery and patch pipette during 
voltage-clamp recordings. Right: Averaged potassium current densities (pA/pF) of VSMCs in different 
conditions, n=4-7. Data are means ± SEM. *, P < 0.05 using two-way ANOVA compared to control 
conditions. (Modified from Manuscript I). 
The effects of LDN 27219 on endothelial function were studied in mesenteric arteries from rats of 
different ages. Incubation with LDN 27219 induced a more robust potentiation of endothelium-
dependent vasorelaxation in arteries from 35-40-week-old rats when compared to arteries from 
younger animals. The level of potentiation was calculated as the difference in the area under the 
curve (AUC) of ACh vasorelaxation between vehicle-incubated and LDN 27219-incubated 
arteries from the same rat (Figure 8A). This correlated with higher transamidase activity, measured 
as levels of incorporated BPA, in arteries from older animals (Figure 8B, C). Despite this, they did 
not present higher expression of TG2 (not shown in this summary, see Manuscript I). Additionally, 
in vivo infusion of LDN 27219 in anesthetized rats showed a dose-dependent blood lowering effect 
of LDN 27219 that was stronger in 35-40-week-old compared to 12-14-week-old rats. In contrast, 
infusion of vehicle (PEG-400) induced a dose-dependent increase in blood pressure and injection 
of VA5 failed to change it (Figure 8D). 
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Figure 8. Age-dependent blood pressure-lowering effects of TG2 modulation to its closed 
conformation ex vivo and in vivo. A. Averaged differences in AUC of ACh-induced relaxations between 
arteries incubated with vehicle and arteries incubated with LDN 27219 (10-6 mol/L) analyzed individually 
per rat. B. Representative dot blot of transamidase (TGase) activity measured as BPA incorporation in rat 
mesenteric arteries from the different age groups (upper panel) and amido-black staining of total protein 
corresponding to the blots in the upper panel (lower panel). C. Average transamidase activity, as % of total 
protein in small mesenteric arteries of each age group. Data are means ± SEM. *, P < 0.05 using one-way 
ANOVA with Bonferroni post-test. D. AUCs for the changes in blood pressure during 3 min infusion of 
either increasing doses of LDN 27219, increasing doses of the vehicle (PEG-400) or a single dose of VA5 
for the different age groups. n=5-8. Data are means ± SEM of AUC (mmHg•s). Positive AUCs indicate 
blood pressure lowering, and negative AUCs indicate increases in blood pressure. *, P < 0.05 using two-
way ANOVA with Bonferroni post-test compared to Vehicle. † P < 0.05 using two-way ANOVA with 
Bonferroni post-test compared to 12-14-week-old. (Modified from Manuscript I). 
57
6.2 Effect of LDN 27219 on small-artery endothelial dysfunction in diabetes 
The effect of acute TG2 conformational modulation on endothelial function was also studied in 
mesenteric arteries from male normoglycemic db/+ mice of different ages and diabetic db/db mice 
(for weights and blood glucose levels, see Manuscript II). From the 39-40-week-old db/+ mice 
group, 3 out of the 5 animals used for the study presented severe unilateral hydronephrosis. 
Vehicle-incubated arteries from db/+ animals presented a reduction in sensitivity to ACh with 
aging (pD2 16 weeks= 7.60 ± 0.08; pD2 24 weeks= 6.91 ± 0.08*; pD2 39 weeks= 6.49 ± 0.15*†. *, P < 0.05 
using F-test compared to 16-17-week-old mice. † P < 0.05 using F-test compared to 24-25-week-
old mice) and arteries from 39-40-week-old db/+ mice presented less maximal vasorelaxation to 
ACh (Emax 16 weeks= 83.67 ± 3.06; Emax 24 weeks= 87.25 ± 3.01; pD2 39 weeks= 24.62 ± 4.77*† in % 
of relaxation. *, P < 0.05 using F-test compared to 16-17-week-old mice. † P < 0.05 using F-test 
compared to 24-25-week-old mice). Arteries from 16-17-week-old diabetic db/db mice incubated 
with the vehicle also presented a reduced maximal relaxation to ACh compared to their db/+ 
counterparts (Emax db/db= 25.71 ± 9.45. *, P < 0.05 using F-test compared to 16-17-week-old db/+ 
mice). Incubation during 20 min with LDN 27219 (3x10-6 mol/L) failed to change the response to 
ACh in 16-week-old db/+ mice (pD2 LDN 27219= 7.73 ± 0.09) while it potentiated it in arteries from 
db/+ mice at 24-25 (pD2 LDN 27219= 7.31 ± 0.03. *, P < 0.05 using F-test compared to vehicle) and 
39-40 weeks of age (Emax LDN 27219= 59.28 ± 9.80 in % of relaxation. *, P < 0.05 using F-test 
compared to vehicle), as well as in arteries from 16-17-week-old db/db mice (Emax LDN 27219= 
59.23 ± 11.94 in % of relaxation. *, P < 0.05 using F-test compared to vehicle) (Figure 9A-D). 
The differences in AUC of ACh vasorelaxation between vehicle-incubated and LDN 27219-
incubated arteries increased with the age of the animals. In contrast, the potentiation in arteries 
from 16-17-week-old db/db animals was not significantly different than in age-paired db/+ despite 
a strong tendency (Figure 9E). The potentiation of SNP vasorelaxation by LDN 27219 increased 
with age in db/+ mice and in diabetic db/db animals compare with age-paired db/+ (Figure 9F). 
These results confirm the age-dependency of the LDN 27219 effect observed previously in rats 
and suggest that LDN 27219 may also improve endothelial function in diabetes. 
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Figure 9. Effect of LDN 27219 on age- and diabetes-related endothelial dysfunction in mice. Average 
responses to ACh CRCs in Phe-contracted mesenteric arteries from db/+ mice at 16-17 (n=8) (A), 24-25 
(n=6) (B) or 39-40 (n=5) (C) weeks of age or from 16-17-week-old diabetic db/db mice (n=8) (D) incubated 
with either vehicle (DMSO) or reversible TG2 inhibitor LDN 27219. Data are means ± SEM of % relaxation 
relative to maximum contraction. *, P < 0.05 using two-way ANOVA. E. Averaged differences in AUC of 
ACh-induced relaxations between vehicle-incubated and LDN 27219 (3x10-6 mol/L)-incubated arteries 
analyzed individually per mice. F. Averaged differences in AUC of SNP-induced relaxations between 
vehicle-incubated and LDN 27219 (3x10-6 mol/L)-incubated arteries analyzed individually per mice. *, P 
< 0.05 using one-way ANOVA with Bonferroni post-test. †, P < 0.05 using unpaired t-test. (Modified from 
Manuscript II).  
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Based on these observations, we explored the effect of long-term treatment with LDN 27219 on 
the onset of endothelial dysfunction in diabetic mice. At the moment of euthanasia before tissue 
collection, diabetic db/db mice at 10-11 weeks of age presented increased body weight and blood 
glucose levels compared to their age-paired db/+ counterparts. None of the treatments affected 
these parameters (for the development of body weight and blood sugar of the mice in the different 
treatment groups, see Manuscript II). By the end of the treatment, vehicle-treated diabetic db/db 
animals did not present elevated blood pressure compared to vehicle-treated normoglycemic db/+, 
and only db/db animals treated with AT1 receptor antagonist candesartan (3 mg/kg/24h) presented 
lower MAP, whereas treatment with LDN 27219 (8 mg/kg/24h) did not altered blood pressure 
(MAPdb/+ Vehicle= 94.36 ± 7.25; MAPdb/db Vehicle= 90.03 ± 3.33; MAPdb/db Candesartan= 73.55 ± 6.07*; 
MAPdb/db LDN 27219= 95.75 ± 3.39 in mmHg. *, P < 0.05 using t-test compared to db/db vehicle) 
(Figure 10).  
 
Figure 10. Development of MAP in the mice in the different treatment groups during long-term 
treatment study. Data are means ± SEM of MAP (mmHg), n= 5-6. *, P < 0.05 using t-test compared to 
vehicle in the third week of treatment. (Modified from Manuscript II). 
Despite the absence of difference in MAP, aortic rings from vehicle-treated db/db animals 
presented increased maximal vasoconstriction to NA when compared to vehicle treated db/+ mice. 
In db/db mice, treatment with candesartan reduced the maximal vasoconstriction to NA, while 
treatment with LDN 27219 failed to significantly change it (Emax db/+ vehicle= 142.10 ± 11.56; Emax 
db/db vehicle= 157.50 ± 5.15†; Emax db/db candesartan= 124.40 ± 11.97*; Emax db/db LDN 27219= 140.70 ± 
10.73 in % of KPSS contraction. *, P < 0.05 using F-test compared to db/db vehicle. †, P < 0.05 
using F-test compared to db/+ vehicle) (Figure 8A). Aortic rings from vehicle-treated db/db mice 
presented similar relaxation to ACh CRCs than rings from their db/+ counterparts, in db/db animals 
only treatment with candesartan slightly increased relaxation to ACh, although its change in 
potency (pD2) did not reach significance (pD2 db/+ vehicle = 7.57 ± 0.08; pD2 db/db vehicle = 7.34 ± 0.07; 
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pD2 db/db candesartan= 7.61 ± 0.21; pD2 db/db LDN 27219 = 7.37 ± 0.22) (Figure 11B). Endothelium-
independent vasorelaxation, measured by response to SNP CRCs did not change among any of the 
groups (pD2 db/+ vehicle = 7.96 ± 0.06; pD2 db/db vehicle = 7.92 ± 0.13; pD2 db/db candesartan= 8.07 ± 0.10; 
pD2 db/db LDN 27219 = 7.88 ± 0.17) (Figure 11C). 
 
Figure 11. Effect of long-term treatment with LDN 27219 in aortae from diabetic animals. A. Average 
contractions to NA CRCs in aortic rings from mice of the different treatment groups. Data are means ± 
SEM of % of KPSS contraction, n=6-12. B. Average vasorelaxations to ACh CRCs in Phe-contracted aortic 
rings from mice of the different treatment groups, n=5-12. C. Average vasorelaxations to SNP CRCs in 
Phe-contracted aortic rings from mice of the different treatment groups, n=8-12. Data are means ± SEM of 
% relaxation relative to maximum contraction. †, P < 0.05 using two-way ANOVA compared to db/+. *, P 
< 0.05 using two-way ANOVA compared to db/db vehicle. (Modified from Manuscript II). 
In contrast to aortae, small mesenteric arteries from vehicle-treated db/db mice presented slightly 
reduced contractile response to NA than mesenteric arteries from their db/+ counterparts. In db/db 
mice, treatment with candesartan slightly increased response to NA compared to vehicle, while 
treatment with LDN 27219 failed to change it. Despite these small differences, neither changes in 
pD2 nor maximal constriction to NA were significant (Emax db/+ vehicle= 133.90 ± 3.79; Emax db/db 
vehicle= 127.40 ± 7.41; Emax db/db candesartan= 141.20 ± 5.29; Emax db/db LDN 27219= 127.8 ± 7.143 in % 
of KPSS contraction) (Figure 12A). Arteries from vehicle-treated db/db mice showed reduced 
relaxation in response to ACh CRCs when compared with db/+ mice. Mesenteric arteries from 
db/db animals treated with candesartan showed a small improvement in vasorelaxation to ACh 
compared to arteries from vehicle-treated db/db, while arteries from mice treated with LDN 27219 
maintained their response to ACh better than candesartan-treated animals (Emax db/+ vehicle= 82.03 
± 4.65; Emax db/db vehicle= 23.08 ± 4.51†; Emax db/db candesartan= 37.85 ± 5.19*; Emax db/db LDN 27219= 
58.49 ± 4.28*# in % of relaxation relative to maximum contraction. *, P < 0.05 using F-test 
compared to db/db vehicle. †, P < 0.05 using F-test compared to db/+ vehicle. #, P < 0.05 using F-
test compared to db/db candesartan) (Figure 12B). On the other hand, the vasorelaxant response 
to SNP was not different in any of the treatment groups. (pD2 db/+ vehicle = 7.53 ± 0.07; pD2 db/db vehicle 
= 8.12 ± 0.60; pD2 db/db candesartan= 7.30± 0.10; pD2 db/db LDN 27219 = 8.50 ± 2.22) (Figure 12C). 
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Figure 12. Effect of long-term treatment with LDN 27219 in small mesenteric arteries from diabetic 
animals. A. Average contractions to NA CRCs in mesenteric arteries from mice of the different treatment 
groups. Data are means ± SEM of % of KPSS contraction. B. Average vasorelaxations to ACh CRCs in 
Phe-contracted mesenteric arteries from mice of the different treatment groups. C. Average vasorelaxations 
to SNP CRCs in Phe-contracted mesenteric arteries from mice of the different treatment groups. Data are 
means ± SEM of % relaxation relative to maximum contraction, n=10-11. †, P < 0.05 using two-way 
ANOVA compared to db/+. *, P < 0.05 using two-way ANOVA compared to db/db vehicle. #, P < 0.05 
using two-way ANOVA compared to db/db candesartan. (Modified from Manuscript II). 
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6.3 Characterization of calcium-activated potassium channels involved in the EDH 
response in rat intrarenal arteries 
Isolated RIAECs exhibited a characteristic cobblestone morphology, while the cells in clusters 
presented a more irregular shape, with visible projections connecting neighbor RIAECs (Figure 
13A, B). Concerning their passive electrophysiological properties, non-cultured isolated native 
RIAECs showed capacitances of 11.40 ± 0.295 pF (n=10) and resting membrane potentials of -
67.95 ± 3.53 mV (n=5) under gap-free recording conditions in the whole-cell configuration.  Under 
voltage-clamp conditions, application of a voltage-ramp (-100 to +120 mV. 600 msec., Vh= -50 
mV) on isolated RIAECs activated voltage-dependent outward potassium currents that showed 
outward rectification at the more positive membrane potentials (Figure 13C, D). 
Figure 13. Morphology of non-cultured, freshly isolated RIAECs and their potassium currents. 
Microphotographs of isolated RIAEC (A) and clusters (B) obtained after enzymatic digestion. Bar: 50 μm. 
C. Representative potassium current in isolated native RIAEC evoked by voltage-ramps under control 
conditions. D. Average I-V relationships for potassium currents from the experiments shown in C. Data are 
means ± SEM of current amplitude normalized to the maximal amplitude of the current (I/Imax).  n=12. 
(Modified from Manuscript III). 
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When ACh (10-5 mol/L) was added to the extracellular solution, a sustained outwardly directed 
current with an amplitude of 61.29 ± 12.88 pA could be observed at the baseline (Vh=-50 mV) 
(Figure 14A, B). Subsequent application of a voltage ramp (-100 to +120 mV. 600 msec) increased 
the amplitude and changed in the shape of the outward currents when compared to those induced 
by the voltage ramp under control conditions. This change of shape included inward rectification 
of the currents at the more negative potentials (Figure 14A, B). To identify the calcium-activated 
potassium channels involved in response to ACh in RIAECs, we repeated the ramps after the 
cumulatively addition of different blockers for these channels. In the presence of IbTx (10-7 
mol/L), a blocker of KCa1.1 channels, significant inhibition of the ACh-induced currents at the 
more positive membrane potentials could be observed without a change neither in the resting 
outward current nor in the inward current at the more negative potentials. Addition of TRAM-34 
(10-6 mol/L), a blocker of KCa3.1 channels, blocked the voltage-independent component of the 
outward currents, as well as the resting outward current and the inward current at more negative 
potentials. Finally, the blocker of KCa2 channels UCL 1684 (10-6 mol/L) significantly inhibited the 
remaining outward current (Figure 14C, D). 
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Figure 14. Contribution of different calcium-activated potassium channels to the ACh-induced 
currents in RIAECs. A. Microphotograph of isolated RIAEC under whole-cell configuration (top) and its 
baseline outward current at a holding potential of -50 mV before and during the addition of ACh to the 
extracellular solution (bottom). B. Average baseline outward currents of RIAECs at holding potential before 
and after the addition of ACh from the experiments shown in A. Data are means ± SEM. *, P < 0.05 using 
paired two-tailed Student´s t-test compared to control. C. Representative outward potassium currents 
evoked by voltage-ramps from -100 to +120 mV, 600 msec. Vh= -50 mV, in isolated RIAEC under control 
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conditions and after the addition of ACh to the extracellular solution. D. Averaged I-V relationships for 
potassium currents from the experiments shown in C. Data are means ± SEM of current amplitude 
normalized to the maximal amplitude of the current under control conditions (I/Imax). *, P < 0.05 using two-
way ANOVA compared to control, n=12. E. Representative potassium currents in the presence of ACh 
before and after the cumulative addition of IbTx, TRAM-34 and UCL 1684, blockers of KCa1.1, KCa3.1 and 
KCa2, respectively. F. Averaged I-V relationships for K+ currents from the experiments shown in E. Data 
are means ± SEM of current amplitude normalized to the maximal amplitude of the current after addition 
of ACh (I/Imax). *, P < 0.05 using two-way ANOVA compared to ACh. †, P < 0.05 using two-way ANOVA, 
n=6-12. (Modified from Manuscript III). 
The expression of KCa1.1, KCa3.1 and KCa2.3 in RIAECs was confirmed by immunohistochemistry 
of isolated cells (Figure 15) as well as in tissue slices of the kidney containing intrarenal arteries 
(data not shown in summary, see Manuscript III). Additionally, staining of VWF was carried out 
to confirm the endothelial identity of the cells and staining of the cell nuclei was performed using 
DAPI. 
 
Figure 15. Expression of calcium-activated potassium channels in freshly isolated RIAECs by 
immunofluorescence. Representative pictures of clusters of RIAECs expressing KCa1.1 (A), KCa3.1 (B) 
and KCa2.3 (C) (left column), VWF (central column) and nuclear staining with DAPI (right column). 
(Modified from Manuscript III). 
66
To examine the role of the different calcium-activated potassium channels in the EDH-type 
relaxation, isolated interlobar arteries were subjected to isometric tension measurements in the 
presence of L-NOARG (10-6 mol/L) and indomethacin (10-6 mol/L). Blockade of KCa1.1 by IbTx 
(10-7 mol/L) reduced the maximal EDH-type relaxation induced by ACh CRCs (Emax Vehicle= 
57.45 ± 3.46 vs. Emax IbTx= 33.40 ± 3.37 % of relaxation. *,P < 0.05 using F-test) (Figure 16A,B). 
To investigate the functional role of KCa1.1 channels in the endothelium of interlobar arteries, 
CRCs of the specific positive modulator of KCa1.1 channels NS11021 were performed in arteries 
with and without endothelium under NOS and COX inhibition. NS11021 presented less potent 
vasorelaxant effects in arteries without endothelium (PD2 w endo= 5.40 ± 0.04 vs. PD2 w/o endo= 5.02 
± 0.03. *, P < 0.05 using F-test) (Figure 16C,D) while this difference in potency was abolished in 




Figure 16. Role of endothelial KCa1.1 channels in ACh and NS11021-induced EDH relaxation of rat 
interlobar arteries. A. Representative traces showing vasorelaxation to ACh in Phe-contracted rat 
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interlobar arteries in the presence of either vehicle or IbTx, in conditions of NOS and COX inhibition by 
L-NOARG (10-6mol/L) and indomethacin (10-6mol/L), respectively. B. Averaged ACh CRCs from the 
experiments shown in A, n=6. C. Representative traces showing vasorelaxation induced by the KCa1.1 
channel opener NS11021 in Phe-contracted rat interlobar arteries with or without endothelium in conditions 
of NOS and COX inhibition. D. Averaged CRCs from the experiments shown in C, n = 8-9. E. 
Representative traces showing NS11021-induced vasorelaxation in rat interlobar arteries contracted with 
Phe, with or without endothelium in conditions of KCa1.1 channel blockade with IbTx and inhibition of 
NOS and COX. F. Averaged CRCs, from the experiments shown in E, n=6. Data are means ± SEM of % 
of relaxation relative to maximum Phe contraction. *, P<0.05 using two-way ANOVA compared to their 
respective controls. (Modified from Manuscript III). 
Blockade of KCa3.1 channels by TRAM-34 (10-6 mol/L) reduced the maximal vasorelaxation of 
interlobar arteries to ACh CRCs in conditions of NOS and COX inhibition (Emax Vehicle= 58.96 ± 
4.09 vs. Emax TRAM-34= 33.70 ± 3.16 % of relaxation. *, P < 0.05 using F-test) (Figure 17A, B). 
Further, combined blockade of KCa1.1 and KCa3.1 by TRAM-34 (10-6 mol/L) and IbTx (10-7 
mol/L) almost completely abolished relaxation to ACh in these arteries (Emax Vehicle= 57.80 ± 4.03 





Figure 17. Role of KCa3.1 channels in ACh-induced EDH relaxation of interlobar arteries. . A. 
Representative traces of ACh-induced vasorelaxation in Phe-contracted rat interlobar arteries in the 
presence of either vehicle, TRAM-34 alone or a combination of TRAM-34 plus IbTx, in conditions of NOS 
and COX inhibition. B. Averaged CRCs in rat interlobar arteries, from the experiments shown in A in the 
presence of either vehicle or TRAM-34 alone, n=6. C. Averaged CRCs from the experiments shown in A 
in presence of either vehicle or a combination of TRAM-34 plus IbTx, n=6. Data are means ± SEM of % 
of relaxation relative to maximum Phe contraction. *, P<0.05 using two-way ANOVA compared to vehicle. 
Incubation with UCL 1684 (10-6 mol/L), blocker of KCa2 channels, failed to change the EDH-
induced vasorelaxation in rat interlobar arteries (Emax Vehicle= 65.33 ± 4.31 vs. Emax UCL 1684= 
74.39 ± 4.58 % of relaxation) (Figure 18A, B). To confirm the presence of KCa2.3 channels in 
intrarenal arteries, CRCs of SKA-31, an opener of both KCa3.1 and KCa2 channels, were 
constructed in the presence of TRAM-34 (10-6 mol/L) alone or in combination with UCL 1684 
(10-6 mol/L). KCa2 blockade by UCL 1684 reduced the vasorelaxant potency of SKA-31 in the 
presence of TRAM-34 (PD2 TRAM-34= 4.93 ± 0.06 vs. PD2 TRAM-34 + UCL 1684= 4.59 ± 0.05. *, P < 
0.05 using F-test) (Figure 18C, D). 
70
 
Figure 18. Role of endothelial KCa2.3 channels in the EDH-type vasorelaxation of rat interlobar 
arteries. A. Representative ACh-induced vasorelaxation in Phe-contracted rat interlobar arteries in the 
presence of either vehicle or UCL 1684 in conditions of NOS and COX inhibition. B. Averaged CRCs from 
the experiments shown in A, n=6. C. Representative traces of vasorelaxation induced by the KCa3.1 and 
KCa2 channel opener SKA-31 in Phe-contracted rat interlobar arteries in the presence of either TRAM-34 
alone or a combination of TRAM-34 plus UCL 1684, in conditions of NOS and COX inhibition. D. 
Averaged CRCs from the experiments shown in C, n=5. Data are means ± SEM of % relaxation relative to 




7.1.1 Limitations of TG2 conformational shift and activity studies  
Native-PAGE studies in purified TG2 have demonstrated to be a useful approach to observe the 
conformational shift of the enzyme in response to different effectors (100,195), although the 
technique has important limitations. The incubation conditions and the presence of GTP and 
calcium are highly controlled in these experiments, being very different from the cellular context 
in which several effectors are present at the same time in different concentrations. This might 
explain why higher concentrations of LDN 27219, which is an allosteric inhibitor thought to be 
able to bind to different conformations of TG2 (24), are needed to observe an effect in 
conformation in the absence of other effectors- while lower concentrations of LDN 27219 show 
TG2-dependent effects in the arterial wall. To overcome these limitations, a mCerulean-TG2-
eYFP FRET biosensor has been developed, so that when transfected into cultured cells and 
measured with fluorescence lifetime imaging microscopy (FLIM) allows for the measurement of 
the TG2 construct conformation in living cells (19,123). Although this method allows 
quantification of the conformational change of TG2 in a cellular context, it is costly, and the extent 
to which the mCerulean-TG2-eYFP construct presents different behavior than the native TG2 
enzyme is currently unclear. 
Transglutaminase activity assays, both ex vivo and in vitro, are normally based on measuring the 
transglutaminase-dependent incorporation of biotinylated substrates to other proteins using 
streptavidin conjugated with a reporter molecule to detect the biotin group. One of the main 
limitations of this technique is that the measured reaction is common to all transglutaminases, 
although a certain level of specificity to measure TG2 activity can be obtained using different 
substrates. The selection of substrates for in vitro testing, however, can affect the inhibitory 
kinetics and potency of some allosteric inhibitors, as it has been shown for LDN 27219 (24). The 
main advantage of the in vitro test used in our experiments is that it uses a substrate (pepT26) that 
has demonstrated a strong preference for TG2 compared to TG1, TG3, and Factor XIIIa (201). 
Samples for in vitro transamidase activity assays have to be protein extracts, in which TG2 is not 
present in its cellular context, which is essential for the regulation of its activity as previously 
discussed (see Figure 3).  
Moreover, DTT is added in these assays to achieve maximal activation of transamidase activity in 
the sample at controlled calcium concentrations (202); this makes in vitro assays useful for 
inhibitor testing but does not inform of the transamidase activity of the sample in more 
physiological conditions. For these reasons, we used the BPA incorporation assay in arteries ex 
vivo to measure transglutaminase activity inhibition in a more physiological context, as well as to 
compare TG2 activation in samples from animals of different ages. This method is an accepted 
technique that has been widely used in different tissues and animal models (10,185). Although the 
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incorporation reaction in this assay takes place in a more physiological environment, with TG2 in 
a cellular and tissue contexts, it cannot be discarded that the stress caused to the arterial wall during 
tissue dissection might activate transglutaminase activity. Another limitation of this approach is 
the previously mentioned lack of specificity of BPA as a transglutaminase substrate (203). 
Therefore we cannot wholly discard that the activity of other transglutaminases may contribute to 
the signal we observe, even though we have only found the protein expression of TG2 in 
mesenteric arteries from Wistar Hannover rats (15). Additionally, some substrates, like 
biotinylated spermine, are poor probes for in situ measurements of TG2 transamidase activity in 
cells compared to BPA (204). These findings indicate that selection of substrates can also be a 
limitation when studying TG2 activity ex vivo, leading to over- or underrepresentation of its 
transamidase activity. 
7.1.2 Animal model limitations 
Although the use of small animals in cardiovascular research presents important limitations, 
particularly concerning cardiac function (205), murine models are well accepted for vascular 
research when studying regulation of vascular tone. Moreover, we validate our results with LDN 
27219 in small arteries of mice and rats using subcutaneous arteries from human donors. Sex 
differences are important and a topic of growing interest in cardiovascular studies. One of the 
limitations of the present study is that we only used male rats and mice. Although half of the donors 
of human subcutaneous arteries were female, the study did not have enough power to analyze the 
influence of sex in the response to LDN 27219. 
We study mice and rats of different ages to examine changes in endothelium-dependent and 
endothelium-independent vasorelaxation with aging. Although we did not use a model of 
accelerated aging, we were able to observe reduced relaxations in response to ACh and SNP in 
Wistar Hannover rats of 35-40 weeks of age, and in db/+ mice at 24-25 and 39-40 weeks of age 
compared to younger animals. These reductions in endothelium-dependent and independent 
vasorelaxation are consistent with the more aggravated changes observed by others as aging 
progress (1,28,49,55). It has to be noted that 3 out of 5 db/+ mice at 39-40 weeks of age used in 
our experiments presented severe unilateral hydronephrosis, despite not showing apparent 
symptoms of kidney disease. Although acquired hydronephrosis is not rare in laboratory mice 
during aging and usually the remaining kidney can compensate (206), we cannot exclude that, 
besides aging, other factors related to altered kidney function could play a role in the decrease of 
endothelium-dependent vasorelaxation in these mice. 
As a model for endothelial dysfunction in diabetes, we used the db/db model, which presents a 
mutation in the leptin receptor, making the homozygous mice obese and hyperglycemic. This 
model presents important cardiovascular differences when compared to diabetic human patients, 
for example, it presents unaltered or even reduced systemic blood pressure, as well as reduced 
heart rate and systolic contractility, not making it a good model for the macrovascular 
complications of diabetes (207). There are conflicting reports concerning the structural remodeling 
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taking place in the peripheral circulation of db/db mice, with some studies showing outward 
remodeling, increased blood flow, and unchanged collagen content (208); and others showing 
inward remodeling, increased stiffness and fibrotic markers (209). However, numerous studies 
have described endothelial dysfunction in conductance and resistance arteries from db/db mice as 
young as 6-8 weeks of age and progressing with aging (210–214). They are, therefore considered 
a valid model for endothelial dysfunction and microvascular complications in diabetes. 
7.1.3 Limitation of ex vivo vascular studies compared to in vivo results 
The translation of ex vivo vascular results to in vivo is ambiguous, several factors are lost in the 
process of isolation of arteries or cells for their study and play an essential role in the control of 
vascular tone, the influence of the central nervous system being one of the most important ones.  
It should also be noted that changes in vascular tone were studied in isometric conditions. Although 
isometric myographs are accepted methods to study small vessels, and have shown generally good 
translatability, the results they offer can present substantial differences compared to the 
physiological state of arteries. Another approach is to mount arteries in isobaric pressure 
myographs (215). For these reasons, we measured the effect of TG2 inhibitors in the blood pressure 
in vivo on anesthetized animals, where we were able to validate the blood pressure lowering effects 
and age-dependency of the promotion of the closed TG2 conformation by LDN 27219 (see Figure 
8). We cannot discard, however, that the intravenous anesthesia could be affecting the observed 
results. 
To avoid the changes in ion channel expression that can take place during cell culture, which may 
influence the interpretation and translation of patch-clamp results (216,217), we used non-cultured, 
freshly isolated VSMCs and RIAECs for our studies. In the experiments related to Manuscript III, 
we obtained RIAECs of 10-15 μm in diameter with a characteristic cobblestone appearance, which 
is consistent with the morphology reported by other groups studying non-cultured, freshly isolated 
endothelial cells from other vascular beds, such as in rat small pulmonary arteries (218) and aortae 
(219). We also report a value of Em of -67.96 ± 3.53 mV (n=5) for isolated RIAECs, which is 
more hyperpolarized than what has been published by other groups in endothelial cells of different 
vascular beds, which Em varied from -15 to -52.4 mV (218,220–223). This difference in Em may 
be explained by the free calcium concentration (10-6 mol/L) present in our intracellular solution to 
activate calcium-activated potassium channels, which most likely causes RIAECs 
hyperpolarization. 
7.1.4 Pharmacological limitations 
One of the most discussed limitations when using TG2 inhibitors to study the function of the 
enzyme is their selectivity. From the TG2 inhibitors that force the protein in its open conformation 
used in our study, Z-DON and Boc-DON show good selectivity for TG2, although they also 
inhibited TG1, TG3, and TG6 at working concentrations (189). At the same time, VA5 has not 
been directly tested. However, compounds of the VA5 family seem to possess high selectivity for 
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TG2, although they can inhibit Factor XIIIA (179,188). LDN 27219 has not been tested itself 
either, but some of its derivatives show similarly high selectivity for TG2 and TG3 (189). This is 
not surprising since LDN 27219 seems to bind at a GTP related site of the enzyme, and TG2 and 
TG3 have GTP binding activities. TG5 is another transglutaminase which has been shown to be 
modulated by GTP (104). Therefore, inhibition of TG5 by LDN 27219 cannot be discarded. As 
previously mentioned, in small mesenteric arteries from Wistar Hannover rats, only expression of 
TG1 and TG2 was found using PCR, although only TG2 protein was detected using western 
blotting (15). Moreover, the vascular effects of LDN 27219 both in isolated arteries and VSMCs 
were prevented by incubation with VA5 or Z-DON (See Figures 5 and 7), so it seems unlikely that 
the effects of LDN 27219 in our ex vivo experiments are due to off-target effects.  Equally unlikely 
seems to be that the blood pressure lowering effects of LDN 27219 in vivo are due to its action on 
other transglutaminases, since TG3 and TG5 seems mainly present in the epidermis (224) as well 
as in the ear and testes of the rat (15). However, other off-target effects cannot be completely ruled 
out neither in these experiments nor in long-term multiple-dose studies. 
As previously mentioned in the methods section, a single-dose pharmacokinetic study in C57BL/6 
mice showed the half-life of LDN 27219 to be approximate 5 h. The posology for the three-week 
treatment study on db/db mice was based on these data, although the pharmacokinetic study was 
carried out in lean mice. As drug distribution and metabolism are known to change during obesity 
(225), particularly for lipophilic substances such as LDN 27219, it is highly likely that its half-life 
is substantially different in db/db mice. For several lipophilic drugs, it has been described how 
adipocytes can accumulate the substance and become slowly emptying reservoirs (226), this would 
increase the volume of distribution of the drug, leading to longer half-life but lower maximal 
plasma concentrations. However, this did not seem to affect the effect of LDN 27219 effect on 
endothelial function. 
Despite the animals in the long-term study did not present any behavioral change, neither reduced 
weight nor any macroscopic alterations, and initial tests have shown low cytotoxicity for LDN 
27219 derivatives (189), very little is known about the chronic toxicity of LDN 27219. Therefore, 
toxic effects of the three-week treatment cannot be discarded. 
7.2 Main findings 
The abundant expression of TG2 in the vasculature has led to different hypotheses concerning its 
role in vascular biology. Despite the first events where TG2 was shown to play a role are related 
to long-term remodeling processes such as increment of ECM stiffness, arterial inward remodeling 
and angiogenesis, its role in the short-term regulation of vascular tone has long been suspected. 
However, the exact mechanisms and the relevance of TG2 different conformational states have 
not been characterized to date. 
Our findings link for the first time the closed conformation of TG2 with vasorelaxant and 
endothelium-dependent vasorelaxation potentiating effects, and suggest that increasing amounts 
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of TG2 in its open conformation during aging and diabetes could play a role in the decreased 
VSMC sensitivity to NO by reduced KCa1.1 channel gating. 
Moreover, we characterize the calcium-activated potassium channels that are involved in the 
endothelium-dependent vasorelaxation of small intrarenal arteries from rats, showing expression 
of KCa1.1 channels in the endothelium and their controversial role in the EDH response. 
7.2.1 Vascular effects of the pharmacological modulation of TG2 to its closed conformation in 
rats throughout the aging  
The main findings of this study are that the closed conformation of TG2 has a vasorelaxant effect. 
Our results indicate that LDN 27219 by binding to TG2 promotes the closed conformation, leading 
to vasorelaxation both ex vivo in resistance arteries and to lowering of MAP in vivo. Incubation 
with LDN 27219 also induced potentiation of endothelium-dependent vasorelaxation by increasing 
VSMC sensitivity to NO through the opening of KCa1.1 channels. Contrarily, inhibitors that lock 
the open conformation of TG2 have neither direct effect on vascular wall tension nor blood 
pressure lowering effects in vivo, and they slightly reduce endothelium-dependent vasorelaxation 
and KCa1.1 channel opening. Moreover, we find an increased potentiation of endothelium-
dependent vasorelaxation and decrease in blood pressure by LDN 27219 in older compared to 
younger rats and mice. These results suggest that an increased amount of TG2 in the open 
conformation may play a role in age-related endothelial dysfunction and that the modulation of 
TG2 towards closed conformation may be a suitable strategy to restore age-dependent changes in 
endothelial function. 
As previously mentioned, LDN 27219 is a potent, slow-binding, reversible inhibitor that has been 
reported to dock at a GTP binding-related site of TG2 (24), and has been suggested to stabilize the 
closed conformation by in silico docking simulation (25). Native-PAGE studies have been 
previously used to study the conformational shift of TG2 (100,195), therefore our results provide 
direct evidence that LDN 27219 promotes the closed conformation of TG2. Moreover, the present 
results show an apparent endothelium-dependent vasorelaxation with LDN 27219 that involves 
the NO pathway (see Manuscript I). The vasorelaxation by LDN 27219 in human subcutaneous 
arteries suggests for the first time, to the best of our knowledge, that TG2 plays a vital role in the 
regulation of vascular tone in human arteries. Surprisingly, the more potent TG2 inhibitor Z-DON 
failed to change the tension of U46619-contracted small mesenteric arteries. This is despite it 
inhibits transglutaminase activity in arteries ex vivo. However, Z-DON has been shown to bind 
irreversibly to the active site of TG2 and seems to lock the enzyme in its open conformation, as 
suggested by its complex with TG2 in crystallization studies (22) and our conformation shift 
studies. These results indicate that the effect of TG2 in vascular tone is independent of its 
transamidase function and seem to be more related to its conformational state. 
Previous patch-clamp studies have reported that, in the presence of GTP, TG2 was able to directly 
open KCa1.1 channels in VSMCs (128). Moreover, in a recent study, it has been shown that 
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endothelium-intact aortic rings from TG2 knockout mice are more sensitive to Phe-induced 
contraction than aortic rings from wild type mice, this difference being abolished in arteries 
without endothelium. The effect was also reversed by the addition of external TG2 independently 
of its transglutaminase activity (151). These findings support a potential role of TG2 in 
vasorelaxation and are in agreement with our current results in both human and rat arteries. We 
observed a potentiation of ACh-induced vasorelaxation after incubation with LDN 27219, which 
stabilizes the close conformation of TG2. In contrast, the cell-permeable irreversible inhibitors 
VA5 and Z-DON, which lock TG2 in the open conformation of TG2, had the opposite effect, 
reducing ACh-induced and SNP-induced vasorelaxations. Meanwhile, the non-permeable cell 
inhibitor Boc-DON failed to change ACh-induced vasorelaxation significantly. These results 
suggested a link between the closed conformation of intracellular TG2 and increased endothelium-
dependent vasorelaxation, which is independent of the transamidase activity of the enzyme.  
KCa3.1 and KCa2.3 channels are mainly expressed in the endothelium of rat small mesenteric 
arteries (227), and we observed that the effect of LDN 27219 on ACh-induced vasorelaxation was 
independent of these channels. In contrast, the inhibition of NOS by L-NOARG abolished the 
effect of LDN 27219 on ACh relaxation. In agreement with previously mentioned studies (128), 
we observed that the blockade of KCa1.1 channels by IbTx prevented the effect of LDN 27219 on 
endothelium-dependent relaxation. Taken together, these observations and the results on 
endothelium-denuded arteries showing that LDN 27219 incubation also increased SNP-induced 
vasorelaxation indicate that the effect of LDN 27219 is mainly at the vascular smooth muscle level 
and through KCa1.1 channel activation. Moreover, we found involvement of KCa1.1 channels and 
showed that the closed conformation of TG2 was responsible of channel opening using patch 
clamp recordings in isolated VSMCs. We showed that cells incubated with LDN 27219 presented 
similarly high potassium conductances to VSMCs measured with GTP in the intracellular solution. 
Additionally, LDN 27219 was not able to further increase potassium conductances in cells 
measured with intracellular GTP, suggesting a common mechanism of action. In contrast, arteries 
incubated with IbTx and VA5, presented smaller potassium conductances (see Figure 7) that were 
not sensitive to LDN 27219. These findings provide evidence that LDN 27219 through modulation 
of TG2 to the open conformation leads to opening of KCa1.1 channels in the vascular VSMCs, 
while inhibitors blocking TG2 in the open conformation has the opposite effect. 
Although, in myograph-mounted arteries, blockade of KCa1.1 channels by IbTx abolished the 
effect of LDN 27219 on ACh-induced vasorelaxation, in our patch-clamp recordings, we observed 
a minor involvement of Kv7 channels in the LDN 27219-induced currents in VSMCs. This is 
consistent with previous results from our group that link the vasorelaxant effect of cystamine with 
Kv7 channel opening (15) and therefore, we cannot exclude their involvement in the vascular 
effects of LDN 27219. 
Previous studies have shown that with aging, TG2 S-nitrosylation decreases leading to increased 
externalization of TG2 and over-activation of its transamidase activity, resulting in increased 
vascular stiffness in arteries from both rats and humans without changing TG2 protein expression 
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(9,10,151).  This may be explained by a decrease in NO bioavailability with aging, as we also 
suggest since arteries from 35-40-week-old rats showed a decreased ACh- and SNP-induced 
vasorelaxation compared to younger rats. Accordingly, we found increased transamidase activity, 
without increases in TG2 expression; together with an increased potentiation of ACh-induced 
vasorelaxation by LDN 27219 in arteries from old animals (see Figure 8). These results suggest 
that an increased amount of TG2 in the open conformation due to decreased NO-bioavailability 
may play a role in early age-dependent changes in endothelial function, and that this can be 
alleviated by the modulation of TG2 to its closed conformation 
Several more specific and active-site directed TG2 inhibitors, that supposedly lock the enzyme in 
its open conformation, have shown no effect on MAP nor heart rate when administered in vivo in 
mice (184,185,228). This is consistent with our results concerning VA5 infusion, which failed to 
change MAP in anesthetized rats. Contrarily, intravenous infusion of LDN 27219 dose-
dependently decreased MAP in rats from all age groups, and in agreement with the potentiating 
effect ex vivo, this effect was bigger in the 35-40 weeks old rats than in the 12-14 weeks old rats. 
These findings support that the conformation of TG2 rather than the transamidase activity plays a 
role in the regulation of blood pressure and suggest a role for TG2 in early age-dependent changes 
of vascular function.  
In conclusion, our study suggests that LDN 27219 is able to promote the closed conformation of 
TG2, and by this mechanism to open KCa1.1 channels in VSMCs leading to potentiation of 
endothelium-dependent vasorelaxation and lowering blood pressure as well. Moreover, these 
effects seem to increase with aging, suggesting that modulation of TG2 conformation could be a 
potential strategy to treat age-related changes in endothelial function. 
7.2.2 In vivo treatment with a TG2 modulator for prevention of small artery endothelial 
dysfunction in diabetic mice 
In the db/db model of diabetic and obese mice, we investigated the effect of acute treatment with 
LDN 27219 in diabetes-induced endothelial dysfunction. Additionally, we evaluated the effects of 
long-term LDN 27219 treatment to prevent endothelial dysfunction in db/db mice, compared with 
long-term treatment with an AT1 receptor antagonist (candesartan). Consistently with our previous 
results in rats, we observed age-dependent potentiation of ACh- and SNP-induced small artery 
vasorelaxation by LDN 27219 in normoglycemic db/+ mice of different ages. Additionally, we 
found a similar increase in LDN 27219-potentiation of endothelium-dependent and endothelium-
independent vasorelaxation in arteries from diabetic db/db animals compared to their age-paired 
normoglycemic counterparts. Finally, we found that three-week treatment with IP injections of 
LDN 27219 was able to prevent endothelial dysfunction in db/db animals more effectively than 
treatment with candesartan, being this effect specific for small arteries. 
As previously mentioned, reduced NO bioavailability during aging has been linked with increased 
TG2 externalization and activity in the vasculature (9,10,151), and we showed that in rats, this was 
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correlated with increased potentiation of ACh and SNP vasorelaxation by acute incubation with 
LDN 27219 in small arteries. Obesity and diabetes have been also linked with decreased NO 
synthesis, and therefore endothelial dysfunction in both humans and rodents (2).  In this study, we 
found reduced sensitivity to ACh and SNP with aging and the same age-dependent effect of LDN 
27219 in the potentiation of these responses in db/+ mice, as we previously described in rats. 
Additionally, we found decreased ACh- and SNP-induced vasorelaxation in arteries from diabetic 
mice, consistently with what has been observed by others (211,214), and an increased potentiation 
of those vasorelaxations by acute incubation with LDN 27219 compared to arteries from their 
normoglycemic counterparts. This suggests that similarly to aging, reduced NO bioavailability in 
diabetes and obesity could also lead to increases in the open conformation of TG2 in the 
vasculature. The increase in the open conformation could play a role in decreasing KCa1.1 channel 
activation and reducing relaxation to NO, being these alleviated by acute treatment with LDN 
27219, which promotes the closed conformation of TG2.  
Most interestingly, we observed a considerable variation of the data in the potentiation of ACh by 
LDN 27219 in arteries from diabetic animals (see Figure 9E), showing that in half of the arteries, 
LDN 27219 caused nearly no potentiation. In contrast, in the others, it presented a significant 
effect, resulting in a bimodal distribution of the data. Considering the poor basal endothelium-
dependent vasorelaxation of these arteries, this could suggest that for LDN 27219 to exert a 
potentiating effect, a minimum level of NO production is needed. This idea seems to be supported 
by the change towards normality in the data distribution when the direct NO donor SNP was used 
(see Figure 9F). 
The role of TG2 in glucose intolerance and insulin secretion is controversial, and conflicting results 
have been presented (141–143). During our three-week treatment study with LDN 27219 and 
candesartan in 7-8-week old mice, we observed increased weight and blood glucose in db/db 
compared to db/+ mice as previously reported, and none of the treatments caused a significant 
change in these parameters. Even though we did not explore glucose tolerance specifically, our 
results seem to indicate that TG2 inhibition was not sufficient to alter glucose metabolism at a 
systemic level.  
Diabetic db/db mice have been previously reported to present similar or even reduced MAP when 
compared to their heterozygous littermates (207,208). Accordingly, we found no difference in 
MAP measured in the conscious animals between vehicle-treated db/db mice and vehicle-treated 
db/+ mice, and only treatment with candesartan reduced MAP significantly in db/db mice. We 
showed previously that LDN 27219 lowered MAP in anesthetized rats, which suggests that 
conscious and normotensive db/db mice might be able to compensate for the blood pressure-
lowering effect of LDN 27219 during long-term administration. Another possible explanation for 
this might be the difference in pharmacokinetics between lean and obese animals, which could 
translate to reduced plasma concentrations of LDN 27219 in db/db animals as discussed in the 
Pharmacological limitations section. 
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Several studies in conductance and resistance arteries from diabetic mice and patients  have shown 
that AT1 receptor inhibitors, which are used in the clinic to treat cardiovascular complications in 
diabetes, reduce sensitivity to vasoconstrictors and improve endothelium-dependent 
vasorelaxation (229,230). Consistently with these results, we found that long-term treatment with 
candesartan was able to reduce vasoconstriction to NA in aortae from db/db mice, which presented 
increased aortic sensitivity to this vasoconstrictor compared with their db/+ littermates. 
Candesartan also increased ACh-induced vasorelaxation in aortae from db/db mice and prevented 
endothelial dysfunction in resistance arteries of these animals. Surprisingly, we found no 
statistically significant endothelial dysfunction in aortae from db/db animals despite a marked 
tendency in this direction. These result differ from the previous literature finding endothelial 
dysfunction in aortae from db/db mice of approximately this age (210), and could be explained by 
the reduced glycemia of the mice used in our experiments. 
Previous studies have also demonstrated the role of TG2 transamidase activity in endothelial cell 
apoptosis (12,14) and increased endothelial leakage in diabetes (13), and have shown that 
pharmacological inhibition or genetic silencing of TG2 were able to prevent these processes. 
However, the effects of TG2 inhibition in the preservation of endothelium-dependent 
vasorelaxation have not been previously explored. We observed that treatment with LDN 27219 
prevented endothelial dysfunction in small mesenteric arteries more effectively than candesartan, 
although it had no significant effect in aortae. Surprisingly, the vasorelaxation to SNP was 
unaltered by long-term treatment with LDN 27219 and unaffected in db/db animals. These results 
suggest that preservation of the endothelium-dependent vasorelaxation by long-term treatment 
with LDN 27219 acts by a different mechanism than the opening of KCa1.1 channels described in 
rats during acute incubation of isolated arteries. This mechanism might be related with the 
previously mentioned decrease in endothelial cell death induced by TG2 inhibitors (12–14). 
In conclusion, our long-term results suggest a specific effect in the prevention of endothelial 
dysfunction by LDN 27219 in resistance arteries. This could be explained by the reduced harm in 
the endothelium of large arteries from these animals, but might also be evidence of the less 
important role of TG2 in the remodeling of large arteries, which has been shown in other 
pathophysiological states such as hypertension (150). 
7.2.3 Calcium-activated potassium channels in the intrarenal EDH response in rats 
With the perspective of using TG2 modulators in kidney diseases that could benefit from additional 
vasoprotection, we examined RIAECs and interlobar arteries to characterize the potassium 
channels involved in preglomerular endothelium-dependent vasorelaxation. The main findings of 
this study are that KCa1.1, KCa3.1, and KCa2.3 channels are expressed in the endothelium of 
intrarenal arteries. However only KCa1.1 and KCa3.1 channels played a role in EDH-type relaxation 
on renal interlobar arteries ex vivo under isometric conditions. 
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While the presence of KCa3.1 and KCa2.3 channels in endothelial cells of intrarenal arteries has 
been extensively reported by others (231–235), the expression of KCa1.1 currents has been found 
only in the endothelium of larger porcine renal arteries by inside-out patch-clamp experiments 
(42). In smaller intrarenal arteries, immunofluorescence experiments detected KCa1.1 channel 
protein in endothelial cells from mouse preglomerular arterioles (43), but its functional role 
remains unclear. In isolated RIAECs, we observed ACh-activated potassium currents that were 
blocked by the consecutive addition of blockers of KCa1.1, KCa3.1 and KCa2 channels (Figure 14). 
Iberiotoxin-sensitive currents were mainly present at the more depolarized potentials and were 
voltage-dependent, while TRAM-34- and UCL 1684-sensitive currents were voltage-independent. 
In addition, TRAM-34-sensitive currents presented an inward rectification at more negative 
voltages that has been previously described as characteristic of KCa3.1 channels (236,237). Our 
results suggest that KCa1.1, KCa3.1 and KCa2.3 channels are functionally expressed in the 
endothelium of RIAECs and participate in ACh-induced hyperpolarization of endothelial cells. 
The expression of the proteins of these channels in the endothelium was confirmed by 
immunohistochemistry both in isolated RIAECs and in renal tissue slices containing intrarenal 
arteries. 
Several animal models and preparations ex vivo as well as in vivo has been used to investigate the 
role of the EDH in intrarenal vasodilation. However, the role of the different calcium-activated 
potassium channels, particularly of KCa1.1 channels, remains controversial. Hence, IbTx decreased 
the relaxation induced by EDH in rat small renal arteries under isometric conditions and NOS 
inhibition, although the location of these channels was not addressed in the study (238). However, 
10-3 mol/L tetraethylammonium (TEA) failed to change the EDH-type response in arteries from 
rat hydronephrotic kidneys under isobaric conditions, casting a doubt about the role of KCa1.1 
channels at least in a pathological state (82). Moreover, several studies have shown the inhibitory 
effect of charybdotoxin (ChTx), which inhibits both KCa1.1 and KCa3.1 channels- on EDH-induced 
vasorelaxation of isolated preglomerular arteries from different species including humans 
(231,235,239–242), which could also indicate a role for KCa1.1 channels. In vivo experiments 
addressing the role of KCa1.1 in the renal circulation have also shown contradicting results. While 
the infusion of IbTx in rats neither reduced the renal blood flow under resting conditions nor 
changed the renal response to vasoconstrictors, a reduction of renal blood flow was observed after 
infusion of 10-3 mol/L of TEA under similar experimental conditions in the same study (243) as 
well as in others (43). As TEA at that concentration is considered to be relatively specific for 
KCa1.1 channels, these results seem to contradict the lack of effect of IbTx. However, this 
discrepancy might be explained by the short pre-treatment time (4-5 min) with IbTx in Magnusson 
et al. (243), which could be insufficient to achieve maximum blockade of KCa1.1 channels 
considering the slow-binding kinetics of the peptide (244,245) that usually requires much longer 
incubation times even in ex vivo experiments. On the other hand, TEA has fast-binding kinetics 
(244,246) that could achieve KCa1.1 channel blockade in the same incubation period. However, 
the involvement of other potassium channels in the TEA-induced reduction of renal blood flow 
cannot be ruled out.  
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Most importantly, experiments in these studies cannot discriminate between KCa1.1 channels 
expressed in the endothelium or in VSMCs, informing only of the overall contribution of these 
channels in renal circulation. In our study, we observe that KCa1.1 channels blockade with IbTx 
was able to reduce the EDH-induced vasorelaxation on rat interlobar arteries mounted in isometric 
myographs, under conditions of NOS and COX inhibition. Moreover, we showed that the 
vasorelaxation induced by the selective KCa1.1 channel opener NS11021 was larger in arteries with 
intact endothelium compared to those without endothelium, and that this difference was abolished 
after incubation with IbTx (see Figure 16). These result demonstrated the functional expression of 
KCa1.1 channels in the endothelium of interlobar arteries, which was also confirmed by 
immunohistochemistry. However, H2O2 has been shown to induce vasorelaxation in human 
coronary arterioles indirectly activating KCa1.1 channels in VSMCs (247), and in previous work 
we shown that H2O2 acts as an hyperpolarizing factor mediating intrarenal artery relaxation to ACh 
under NOS and COX inhibition (248). Therefore, we cannot exclude that the opening of KCa1.1 
channels by H2O2 in VSMC may contribute to the EDH-induced vasorelaxation of intrarenal 
arteries. 
The role of KCa3.1 and KCa2.3 channels in the renovascular EDH response has been studied mainly 
in combined blockade with other channels. The unspecific calcium-activated potassium channel 
blocker ChTx either alone (82,239–241) or in combination with the KCa2 blocker apamin 
(231,235,242) has been shown to reduce EDH-induced vasorelaxation in intrarenal arteries. These 
result support the importance of calcium-activated potassium channels in the intrarenal EDH 
response, but do not allow discrimination between channel subtypes. The more specific blocker of  
KCa3.1 channels, TRAM-34 has been used recently in combination with apamin, reducing the 
vasorelaxation induced by EDH in myograph-mounted rat and mice renal interlobar arteries under 
isometric conditions (232,249). Still, the individual contribution of the KCa3.1 and KCa2 channels 
was not assessed in these studies. In small renal arteries from rats and pigs under isometric 
conditions, ChTx plus apamin induced an additional reduction of the EDH-mediated 
vasorelaxation compared to ChTx alone (240,250), although inhibition with apamin alone failed 
to change the EDH response (250), suggesting a minor role for KCa2.3 channels only detectable 
when KCa1.1 and KCa3.1 were blocked. This is consistent with in vivo experiments where infusion 
of apamin alone did not change renal blood flow by itself under resting conditions, requiring a 
combined inhibition of several potassium channels to observe an effect (43). This is consistent 
with our results, where inhibition of KCa2 channels with UCL 1684 alone did not change EDH 
vasorelaxation despite these channels being functionally expressed in the endothelium as 
demonstrated by the patch-clamp studies and by relaxation to SKA-31. 
Another potential reason why we did not observe an effect of KCa2 channel inhibition is related to 
its specific functions and subcellular location. KCa2.3 channels are expressed in endothelial cells 
near homocellular gap junctions and in the caveolae (251), which could indicate that the primary 
role for these channels is in the vasodilation associated with mechanosensation or other processes 
related to the caveolae, including NO release, that cannot be observed under our isometric 
82
experimental conditions and NOS inhibition (252–254). Although the opening of both KCa3.1 and 
KCa2.3 channel has been linked to NO release (200,255), experiments using KCa2.3 and KCa3.1 
channel knock-out mice showed that genetic deletion of KCa2.3 reduced shear stress-induced 
dilator responses and ACh-induced vasodilation with intact NO synthesis in small arteries under 
isobaric conditions, but failed to change it under NOS and COX inhibition. Contrarily, genetic 
deletion of KCa3.1 significantly reduced EDH-type response under NOS and COX inhibition (256), 
supporting a differential role of these channels. 
Results in vivo addressing the role of KCa3.1 and KCa2.3 in renal EDH-type relaxation seem to 
support our results suggesting a major role of both KCa1.1 and KCa3.1 channels, since inhibition 
with ChTx plus apamin significantly inhibited the ACh-induced increase of renal blood flow under 
NOS and COX inhibition in streptozotocin-induced diabetic Wistar rats (257), while infusion of 
the more specific KCa3.1 blocker TRAM-34 plus apamin failed to significantly change it in 
Sprague-Dawley rats in a similar setting, although there was a tendency in that direction (232).  
In summary, we show in this study that KCa1.1, KCa3.1 and KCa2.3 channels are functionally 
expressed in the freshly isolated RIAECs and mediate endothelial cell hyperpolarization. However, 
only KCa1.1 and KCa3.1 seem to play a significant role in the EDH-induced vasorelaxation of these 
arteries in isometric conditions, suggesting that KCa2.3 channels might be important for other 
processes that cannot be observed in our experimental conditions, such as NO release or shear 
stress-induced vasodilation. The results of this study elucidated the role of KCa1.1 channels in the 
endothelium of the preglomerular circulation, and suggest that positive modulation of these 














The present Ph.D. project was based on the hypothesis that TG2 modulation can improve 
endothelium-dependent vasorelaxation through the opening of potassium channels and, therefore, 
be an effective strategy for the prevention of endothelial dysfunction in aging and diabetes; 
conditions with increased vascular levels of TG2 in the open conformation. Furthermore, we aimed 
to characterize the potassium channels involved in the EDH response in the intrarenal circulation. 
The main findings of our project were: 
1- The reversible TG2 inhibitor LDN 27219 stabilizes the closed conformation of TG2 and 
inhibits its transamidase activity in resistance arteries.  
2- Promotion of the closed conformation of TG2 by LDN 27219 in arteries ex vivo results in 
a direct vasorelaxant effect and potentiates endothelium-dependent vasorelaxation by 
increasing the sensitivity of VSMCs to NO, through the opening of KCa1.1 channels. 
3- The potentiation of endothelium-dependent vasorelaxation by LDN 27219 increases with 
aging. This correlates with increased transamidase activity levels in the vasculature of 
aging subjects, which could indicate higher amounts of TG2 in the open conformation.  
4- In vivo, infusion of LDN 27219 dose-dependently lowers MAP, increasing this effect with 
the age of the animal.  
5- TG2 inhibitors that lock the enzyme in its opening conformation, reduce endothelium-
dependent vasorelaxation and opening of potassium channels, and failed to change MAP 
in vivo.  
6- The potentiation of endothelium-dependent vasorelaxation by LDN 27219 also increases 
in arteries from diabetic mice compared with those from normoglycemic control mice.  
7- Long-term treatment with LDN 27219 administered IP prevents small artery endothelial 
dysfunction in pre-diabetic animals more effectively than oral candesartan, without 
affecting blood pressure or SNP-induced vasorelaxation.  
8- In the preglomerular renal circulation KCa1.1, KCa3.1 and KCa2.3 channels are functionally 
expressed in the endothelium of rat intrarenal arteries and they are activated upon 
muscarinic stimulation with ACh. 
9- KCa1.1 and KCa3.1 play a major role in EDH-derived vasorelaxation of intrarenal arteries, 
whereas blockade of KCa2 channels failed to change ACh-induced vasorelaxation.  
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In summary, we find that modulation of TG2 to its closed conformation is a promising new strategy 
to counteract changes in endothelial function of small vessels resulting from aging and diabetes, 
in which increased amounts of TG2 in the open conformation could play a role in the reduced 
vascular sensitivity to NO by decreasing KCa1.1 opening. Additionally, KCa1.1 channels are a 
potential new target to improve endothelium-dependent vasorelaxation in the preglomerular 
circulation. 
 
Figure 19. Proposed model for the role of TG2 conformation in vascular dysfunction during aging 
and diabetes.  
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Figure 20. Scheme describing the suggested involvement of KCa1.1 and KCa3.1 in the EDH (e.g. 

















We have shown that pharmacological modulation of TG2 to its closed conformation inhibits 
transamidase activity and offers additional vasoprotection compared to other mechanisms of TG2 
inhibition. Moreover, we outline the possibility of using TG2 inhibitors that stabilize the closed 
conformation in fibrotic kidney diseases. Other TG2 inhibitors lacking a vasoprotective effects 
have demonstrated efficacy in fibrotic kidney diseases. An additional benefit of inhibitors 
stabilizing the closed conformation are expected due to their effect improving endothelium-
dependent vasorelaxation through KCa1.1 channel modulation. This could be particularly 
interesting considering the strong dependence of the preglomerular endothelial function on KCa1.1 
channels. Considering this potential synergy between the antifibrotic effect of transglutaminase 
activity inhibition and the vasoprotection resulting from the closed conformation, it would be 
interesting to explore the long-term application of TG2 inhibitors stabilizing the closed 
conformation for fibrotic diseases, e.g. CKD and pulmonary hypertension. 
Although the conformation of TG2 has been shown to be of great importance in several 
pathophysiological processes, and its modulation has demonstrated to be a promising therapeutic 
strategy, very little is known about the value of TG2 as a biomarker especially in cardiovascular 
diseases. The use of irreversible TG2 inhibitors as positron emission tomography (PET) tracers 
has been recently proposed as a potential tool to study TG2 conformation in vivo, particularly in 
cancer (258,259). However, these irreversible inhibitors are known to force the enzyme into the 
open conformation and, therefore, cannot inform of the natural conformational state of the enzyme 
in vivo, although they might be useful for the detection of extracellular TG2. Our work suggest 
that a negative feedback loop might exist between NO and the open conformation of TG2. Thus, 
it has been previously shown that reduced NO bioavailability in the vascular system leads to 
increased externalization and activation of TG2 in its open conformation (9,10,151). On the other 
hand, we show that increased amounts of TG2 in its open conformation might lead to lower KCa1.1 
channel opening in the VSMC with the consequent loss of NO-dependent vasorelaxation, even 
before endothelial dysfunction becomes apparent. This idea implies that the amount of TG2 in the 
open conformation in the resistance vasculature will increase with aging and diabetes and could 
be correlated with increased risk of microvascular complications. To address this hypothesis, it 
would be interesting to combine the use of PET tracers to study externalization of TG2 in vivo 
with the examination of vasoreactivity in resistance arteries ex vivo in diabetic mice/patients. For 
the moment, we plan to carry out extensive studies in resistance arteries from human patients in 
order explore the relationship between the diabetic state, aging, elevated transamidase activity, 
vascular function and sensitivity to TG2 inhibitors. 
With this thesis, we elucidated the role of the different conformation of TG2 in the regulation of 
vascular tone. However, a lot of work is yet to be done to understand the complex role of TG2 in 
the cardiovascular system. Its elusive and varied externalization mechanisms (120) and its 
emerging role in inflammation and autophagy (18) seem a promising development for  the field of 
TG2 research, which hopefully will continue to be fruitful and exciting in the upcoming years. 
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Particularly relevant for our findings in this thesis is the very recent association between the 
transamidase activity of TG2 and O-GlcNAcylation of proteins, which suggests an important role 
of TG2 in glucose metabolism at the cellular level (144). This fits well with recent reports on the 
importance of TG2 activation in the sustained damage on the endothelium of diabetic animals even 
after successful glycemic normalization (14), and makes the effect of TG2 modulators on post-
translational modification of proteins in diabetes an interesting direction for future research. 
Finally, at the moment of publication of this thesis, two TG2-targeted therapies are in clinical 
trials, suggesting that years of basic research on this enzyme might soon translate into a benefit for 
the patients. Considering the translational potential of the present work, which has led to a patent 
application, we plan to continue the development of acylhydrazide inhibitors to promote the closed 
conformation of TG2, studying their potential toxicity, target selectivity and developing scalable 
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ABSTRACT 
Tissue transglutaminase 2 (TG2) is an enzyme which in the open conformation state exerts 
transamidase activity, leading to protein cross-binding and development of fibrosis. In the 
closed conformation state, TG2 seems important for transmembrane signaling. The unspecific 
transglutaminase inhibitor cystamine causes vasodilation. However, the role of TG2 
conformation in vascular function is unknown. We investigated the vascular effects of several 
TG2 inhibitors, by measurements of relaxation in isolated rat and human small arteries, 
patch-clamp studies on vascular smooth muscle cells and blood pressure measurements 
during intravenous infusion in anesthetized rats. LDN 27219 promoted the closed TG2 
conformation and inhibited transamidase activity  in small arteries. In contrast to inhibitors 
promoting the open conformation of TG2 (Z-DON, VA5), LDN 27219 concentration-
dependently relaxed rat and human small arteries. LDN 27219 potentiated acetylcholine-
induced relaxation by increasing sensitivity to nitric oxide through opening of smooth muscle 
large-conductance calcium-activated potassium channels; these effects were abolished by 
membrane permeable TG2 inhibitors promoting the open conformation. In isolated arteries 
from older rats, transamidase activity was increased and LDN 27219 improved acetylcholine-
induced relaxation more than in younger rats. Infusion of LDN 27219 decreased blood 
pressure more effectively in 35-week than 12-week-old rats. In summary, pharmacological 
modulation of TG2 to the closed conformation leads to age-dependent blood pressure 
lowering and potentiation of endothelium-dependent vasorelaxation by opening potassium 
channels. Our findings suggest that promotion of the closed conformation of TG2 is a 
potential strategy to treat age-related endothelial dysfunction and to lower blood pressure.  












Transamidase activity and externalization of  tissue transglutaminase (TG2) are involved in 
structural changes in the vasculature such as cardiovascular stiffness in aging,1–3 vascular 
remodeling in response to reduced blood flow,4,5 and endothelial dysfunction in diabetes.6,7 
Moreover, recent studies by our group and others suggest that TG2 plays a role in the 
regulation of vascular tone.8,9 
TG2 is a member of the transglutaminase family of enzymes (TG1-7 and Factor XIII) and it 
is highly expressed in both endothelial and smooth muscle cells throughout the vascular 
tree.10 TG2 has several functions depending on its cellular location, conformation and 
microenvironment (redox state, availability of Ca2+ and nucleotides).11,12 In the Ca2+-bound 
open conformation TG2 has transamidase activity, leading to covalent crosslinking of 
structural proteins while in the closed conformation TG2 has GTP-binding activity 
functioning as a G protein (Ghα).13 As these two activities are mutually exclusive and despite 
TG2 is in dynamic equilibrium, transamidase activity is thought to be mainly present in 
extracellular TG2 and during local intracellular Ca2+ increments. In contrast, intracellular 
TG2 in the closed/GTP-bound enzymatic state, constitutively exerts transmembrane signaling 
by linking several G protein coupled receptors with signaling cascades.  
There has been an interest to develop new TG2 irreversible inhibitors that modulate the 
enzyme into its open conformation, such as Z-DON14 or VA5,15 inhibiting at the same time 
the transamidase and GTP binding activities.16 On the other hand, there are some reversible 
TG2 inhibitors like LDN 27219, which is a potent, slow-binding, inhibitor that has been 
reported to dock at a GTP binding-related site of TG2.17  Additionally, in silico docking 
simulations of LDN 27219 binding to TG2 have suggested that it might stabilize the closed 
conformation of the enzyme.18 Although we found vasorelaxant effects of some TG2 
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inhibitors,8 it is unclear whether the conformation of the TG2 protein plays a role in the 
regulation of the vascular tone, particularly in vascular aging. 
We hypothesized that pharmacological modulation promoting the closed conformation of 
TG2 would lead to vasorelaxation by opening of potassium channels, and hence restore the 
age-related changes in endothelial function and blood pressure (BP). This study for the first 
time links the closed conformation of TG2 with vasodilatory effects ex vivo and in vivo and 
with an increased sensitivity to nitric oxide (NO) in the vascular smooth muscle through the 
opening of large-conductance calcium-activated potassium channels (BKCa). These effects 
increase with age and correlate to transamidase activity in small arteries, suggesting that 
conformational modulation of TG2 is a potential strategy to restore endothelial function 
during aging. 
METHODS 
For a more detailed description of the methods and composition of used solutions, see Data 
Supplement. 
Animals and tissue preparation:  
Male Wistar Hannover rats at 6-7, 12-14 and 35-40 weeks of age were used. For ex vivo 
studies, animals were randomly selected and euthanized by decapitation and exsanguination. 
The mesenteric bed was immediately removed and mesenteric resistance arteries (internal 
lumen diameters 200-300 µm) were isolated. Animal protocols and care were approved by 
the Danish Animal Experiments Inspectorate (permission 2014-15-2934-0159 and 2019-15-
0201-00009) and followed Aarhus University institutional guidelines and the NIH 
guidelines.19  
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Human subcutaneous resistance arteries were obtained from fat biopsies of the gluteal region 
from both male and female patients (30-70 years of age) with or without essential 
hypertension (for details, see Table S1), and isolated for ex vivo studies. The study using 
human tissue was approved by the Regional Ethics Committee, Central Denmark 
(permission: 1-10-72-120-17) and conducted in accordance with the principles of the 
Helsinki Declaration II for medical research and Aarhus University institutional guidelines. 
All participants gave informed consent prior to participation. 
Native-PAGE 
To study the effect of different TG2 inhibitors on enzyme conformation, purified and 
functional human TG2 produced in insect cells was obtained from Zedira (Darmstadt, 
Germany) and native gel electrophoresis experiments were performed as previously 
described.20,21  
Transamidase activity assay in intact arteries 
A dot blot assay was used to determine 5-biotin(amido)pentylamine (BPA) incorporation in 
structural proteins as a measure of transamidase activity ex vivo as previously described.1 
Freshly isolated mesenteric resistance arteries were incubated in a BPA solution for 4h, 
washed and homogenized. Incorporated BPA was quantified by chemiluminescence using 
HRP-streptavidin. 
Isometric tension studies 
Resistance arteries from rats and human donnors were mounted in microvascular myographs 
for isometric tension recordings (Danish Myotechnology, Aarhus, Denmark).8  Changes in 
tension were recorded in response to different TG2 inhibitors and their effect on 
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endothelium-dependent vasorelaxation was studied. In a subset of arteries, the endothelium 
was removed by rubbing the lumen with a human scalp hair. 
Whole-cell voltage-clamp studies 
Freshly isolated smooth muscle cells (SMCs) from rat mesenteric artery were used for patch-
clamp recordings within 5 h after the isolation procedure as previously described.8 Current-
voltage relations were determined using voltage ramps. 
 In vivo mean arterial pressure (MAP) and heart rate (HR) measurements 
Male Wistar rats at 12-14 and 35-40 weeks of age were anesthetized with s-ketamine and 
pentobarbital. Changes in MAP and electrocardiographic signal were studied using solid-state 
catheterization of the carotid artery and ECG needles.22  
Statistical analysis 
Data are expressed as means ± SEM, where “n” is the number of animals studied in each 
group or the number of replicates in the case of native-PAGE studies. Normality of the data 
was verified examining their quantile-quantile (Q-Q) plots against the normal distribution. 
Native-PAGE results were analyzed by paired two-tailed Student´s t-test. Concentration–
response curves were analyzed by two-way ANOVA followed by Bonferroni post-test for 
multiple comparisons. One-way ANOVA was used for multiple testing, followed by the 
appropiate multiple comparison post-test, when there was only one independent variable of 
interest. Values of P<0.05 were considered significant. All analyses were performed using 




Conformational state is important for the effect of TG inhibition on vascular tone 
We investigated the effect of LDN 27219 on TG2 conformation using native gel 
electrophoresis. In accordance with previous in silico simulations,18 incubation of isolated 
human TG2 with LDN 27219 increased the relative abundance of the closed conformation of 
the enzyme compared to vehicle in vitro. Meanwhile, GTP completely forced the enzyme 
into its closed conformation and Z-DON in the presence of calcium forced TG2 into its open 
conformation (Figure 1A). We also studied the capacity of these inhibitors to reduce 
transamidase activity in rat small mesenteric arteries ex vivo using the BPA incorporation 
assay. We observed that incubation with LDN 27219 and Z-DON inhibited transamidase 
activity in a similar way, while 1,4-dithiothreitol (DTT) increased transamidase activity as 
previously reported (Figure 1B). 2,5 
In isolated rat mesenteric resistance arteries contracted with the thromboxane analogue 
U46619, LDN-27219 induced concentration-dependent relaxations, which were significantly 
reduced in arteries without endothelium and in the presence of the NO synthase (NOS) 
inhibitor Nω-Nitro-L-arginine (L-NOARG), indicating that LDN 27219 vasorelaxation is 
NO-dependent. Contrarily, Z-DON failed to change vessel wall tension (Figure 1C). LDN 
27219 also induced relaxation in U46619-contracted human subcutaneous resistance arteries 
(Figure 1D).  
Pharmacologically induced closed conformation of TG2 potentiates endothelium-
dependent relaxation by increasing SMC sensitivity to NO 
Incubation with LDN 27219 for 20 min increased the response to acetylcholine (ACh) in 
phenylephrine (Phe)-contracted subcutaneous arteries from human biopsies (Figure 2A-C). 
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This effect was also observed in arteries from 12-14-week-old rats (Figure 2D). Contrarily, 
incubation with VA5 and Z-DON that are irreversible and membrane-permeable TG2 
inhibitors and lock the enzyme in its open conformation, caused a slight inhibition of ACh-
induced relaxation in rat mesenteric arteries, while a non-permeable TG2 inhibitor Boc-DON 
failed to change relaxation (Figure 2E and Figure S1A). LDN 27219 potentiation of ACh-
induced vasorelaxation was abolished by the presence of the irreversible membrane-
permeable TG2 inhibitors (Figure 2F and Figure S1B). Additionally, in vitro transamidase 
activity assays showed that VA5 inhibited transamidase activity more potently than LDN 
27219 (Figure S1C). These results indicate that LDN 27219-induced vasorelaxation is mainly 
due to its capacity to induce the closed conformation of TG2 and not directly related with 
transamidase activity inhibition.  
The potentiating effect of LDN 27219 on endothelium-dependent vasorelaxation was still 
observed in the presence of IKCa and SKCa channel blockers TRAM-34 and UCL 1684 
(Figure 3A), while it was abolished after incubation with L-NOARG (Figure 3B), suggesting 
that, at the level of the endothelium, it was independent of endothelial potassium channels 
and related to the NO pathway.  
At the level of SMCs, LDN 27219 potentiation of ACh-induced vasorelaxation was still 
present, although apparently reduced, in the presence of the guanylate cyclase inhibitor ODQ 
(Figure S2), while it was abolished after incubation with the BKCa channel blocker 
iberiotoxin (Figure 3C). Additionally, we found that incubation with LDN 27219 was able to 
hyperpolarize and increase the ACh-induced hyperpolarization in the smooth muscle layer of 
myograph-mounted arteries in the presence of TRAM-34 and UCL 1684, being these effects 
abolished by the addition of iberiotoxin (Figure S3). These findings suggested that the effect 
of LDN 27219 takes place mainly at the SMC level by opening BKCa channels and therefore 
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increasing its sensitivity to NO. We confirmed this hypothesis by studying the effect of LDN 
27219 incubation on arteries without endothelium, where LDN 27219 also potentiated 
relaxations induced by the NO donor sodium nitroprusside (SNP) (Figure 3D). Contrarily, 
incubation with VA5 and Z-DON reduced SNP-induced vasorelaxation (Figure S4). 
Modulation towards TG2 closed conformation induces BKCa channel opening in SMCs.  
To further understand the role of potassium channels and TG2 conformational changes in the 
effect of LDN 27219, voltage-clamp studies were performed on SMCs freshly isolated from 
rat small mesenteric arteries. LDN 27219 markedly enhanced outward potassium currents 
reaching its maximum effect at 12 min (Figure 4A). In agreement with our previous results, 
this effect was reduced in SMCs that had been incubated with iberiotoxin. Moreover, a small 
part of the remaining LDN 27219-elicited potassium current under BKCa channel blockage 
was sensitive to the Kv7 channel blocker, XE991 (Figure 4B). Thus, in addition to a major 
role of BKCa channels, these results suggest a minor role for Kv7 channels in LDN 27219 
vasorelaxation. 
We also tested how the conformational modulation of TG2 affected LDN 27219-elicited 
increases in potassium currents of isolated SMCs. Induction of the TG2 open conformation 
with VA5, reduced the current density of SMCs compared to control conditions (Figure S5) 
and completely inhibited the enhancement of potassium currents by LDN 27219 (Figure 4C). 
GTP, GDP and ATP have been shown to dock TG2 and inducing its closed conformation. 
SMCs exposed to Na2GTP in the intracellular solution, showed higher current densities than 
SMCs under control conditions (Figure S5). This was similar to the potassium current 
recorded from SMCs stimulated with LDN 27219, and addition of LDN 27219 did not cause 
further enhancement of these currents (Figure 4D). Taken together, these results suggest that 
LDN 27219 mimics the effect of GTP by promoting the closed conformation of TG2 and 
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opens BKCa channels, while the open conformation of TG2 slightly decrease the activation of 
BKCa channels.  
Pharmacological induction of TG2 closed conformation leads to ex vivo and in vivo age-
dependent BP-lowering effects. 
Previous studies suggest the involvement of TG2 in age-related cardiovascular complications. 
1,3 To study the effect of age on the potentiation of endothelial function by LDN 27219, we 
used small mesenteric arteries from 6-7 and 35-40-week-old rats. Arteries from 6-7-week-old 
rats presented similar responses to ACh and SNP compared to the 12-14-week-old rats. 
Contrarily, the arteries from rats at 35-40 weeks of age, showed slightly reduced endothelial 
function and less response to SNP (Table S2). Incubation with LDN 27219 for 20 min 
produced a potentiation of the response to ACh only in arteries from older animals (Figure 
5A-B). The response to SNP in arteries without endothelium was potentiated by incubation 
with LDN 27219 in both age groups (Fig 5C-D). The differences on area under the curve 
(AUC) of the responses to ACh and to SNP between vehicle-incubated and LDN 27219-
incubated arteries were bigger in rats at 35-40 weeks of age compared to younger rats (Figure 
5E and Figure S6). Neither the expressions of TG2, BKCa alpha nor beta subunits were 
increased in arteries from older rats in comparison with younger rats (Figure S7), but arteries 
from 35-40-week-old rats presented increased transamidase activity (Figure 5F), suggesting a 
larger amount of functional TG2 in the open conformation in arteries from older animals. 
In vivo intravenous administration of LDN 27219 in anesthetized rats at 12-14 and 35-40 
weeks of age induced dose-dependent decreases in MAP that was maintained throughout the 
3 min of infusion. This was followed by a transient raise over the baseline immediately after 
the end of drug administration (Figure 6A) without having any effect neither on HR 
compared to the vehicle (Figure S8) nor on electrocardiographic parameters (Table S3). 
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Infusion of the corresponding vehicle (polyethylene glycol 400) slightly increased MAP at 
the highest dose (Figure 6A) although it reduced HR (Figure S8). Rats at 35-40 weeks of age 
showed a tendency to higher basal MAP compared with 12-14-week-old rats (111.40 ± 5.55 
vs. 97.20 ± 4.02 in mmHg, n=11-15. p=0.065 using unpaired t-test) as well as to lower HR 
(348.7 ± 9.88 vs. 374.7 ± 10.93 in beats per min, n=11-15. p=0.093 using unpaired t-test). 
There were not differences in the measured ECG parameters between both age groups. 
Responses to increasing doses of LDN 27219 had significantly larger AUCs in 35-40-week-
old rats compared to 12-14-week-old rats (Figure 6C). This indicates greater effects on BP in 
older rats, being consistent with ex vivo measurements. Infusion of a single dose of VA5 
failed to change MAP (Figure 6B-C). 
DISCUSSION 
There are three major findings of the present investigation. First, we provide direct evidence 
that LDN 27219 promotes the closed conformation of TG2 using native-PAGE studies. 
Secondly, our findings suggest that LDN 27219 by promoting the closed conformation leads 
to vasodilation and improves endothelium-dependent relaxation in rat and human resistance 
arteries which is in contrast to the effect of the inhibitors that lock TG2 open, VA515 and Z-
DON,14 hence suggesting the effect of vascular tone is independent of TG2 transamidase 
activity. This points to a mechanism where the closed conformation of TG2 in the smooth 
muscle layer couples to opening of BKCa channels. Thirdly, we provide evidence that 
promoting the closed conformation of TG2 leads to improved endothelium-dependent 
relaxation of resistance arteries and blood pressure lowering in an age-dependent manner.   
Recent studies have shown that only endothelium-intact aortic rings from TG2 knockout mice 
are more sensitive to Phe-induced contraction compared to arotic rings from wild type mice, 
being this difference absent in arteries without endothelium. The difference in sensitivity to 
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Phe endothelium-intact aortic rings from TG2 knockout mice was  reversed by the addition of 
external TG2 independently of its transamidase activity.9 These results might be explained by 
patch-clamp studies reporting that, in the presence of GTP, TG2 is able directly to open BKCa 
channels in vascular SMCs,23 which would lead to hyperpolarization and vasodilation. Our 
findings in human and rat arteries provide a mechanistic explanation for these findings. We 
observed a potentiation of ACh-induced vasorelaxation after incubation with LDN 27219, 
which stabilizes the close conformation of TG2. In contrast, the cell permeable irreversible 
inhibitors VA5 and Z-DON, which lock TG2 in the open conformation of TG2,14,15 had the 
opposite effect, reducing ACh-induced and SNP-induced vasorelaxations. Meanwhile, the 
non-permeable cell inhibitor Boc-DON failed to significantly change ACh-induced 
vasorelaxation. These results suggest a link between the closed conformation of intracellular 
TG2 and increased endothelium-dependent vasorelaxation, which is independent of the 
transamidase activity of the enzyme.  
There are several lines of evidence supporting that LDN 27219 affects vascular tone by a 
specific action on TG2 conformation. First, LDN 27219 induces the TG2 closed 
conformation similarly to GTP in the native-PAGE studies. Second, previous findings have 
shown that GTP-bound TG2 opens BKCa channels,23 and addition of LDN 27219 in the 
presence of intracellular GTP, failed to further increase potassium conductance in isolated 
SMCs suggesting a common mechanism of action for LDN 27219 and GTP. Third, we 
observed that SMCs incubated with VA5, an irreversible TG2 inhibitor that locks the enzyme 
in its open conformation,15 presented smaller potassium currents than under control 
conditions that were insensitive to LDN 27219. Therefore, our findings show that LDN 
27219 by promoting the closed conformation of TG2 leads to activation of BKCa channels 
and increased sensitivity to endothelium-derived NO. 
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TG2 plays an important role in several age-related alterations in the cardiovascular system.1,3 
In large arteries, the decrease in NO bioavailability related to aging has been associated with 
an increased externalization of TG2 and over-activation of its transamidase activity leading to 
increased vascular stiffness in both rats and humans.1,9,24 However, no significant changes in 
TG2 expression in aging arteries were found.1 This can be explained by S-nitrosation and 
redox status of TG2 that regulates TG2 activation and trafficking.1,5,24 In agreement, we 
found increased transamidase activity without a significant TG2 expression increase in 
arteries from 35-40-week-old rats, which presented reduced ACh- and SNP-induced 
vasorelaxations compared to younger rats, suggesting decreased NO-bioavailability and 
sensitivity. Accordingly, these arteries from older rats showed an increased potentiation of 
ACh-derived vasorelaxation by LDN 27219. These results suggest that an increased amount 
of TG2 in the open conformation due to reduced NO-bioavailability may play a role in early 
age-dependent changes in endothelial function. This could however be alleviated by the 
modulation of TG2 to its closed conformation.  
Contrarily to cystamine, several active-site directed TG2 inhibitors have shown no effect on 
BP nor HR when administered in vivo in mice.25,26 In the present study, intravenous infusion 
of LDN 27219 caused a dose-dependent decrease in MAP in anesthetized rats. Analysis of 
LDN 27219 pharmacokinetics in male C57BL/6 mice showed that the half-life of the 
compound in blood is approximately 5 h (data not shown). This suggests that the rapid 
reversal of the effect of LDN 27219 on MAP is due to compensatory sympathetic 
vasoconstriction rather than degradation or excretion of the compound. In agreement with the 
potentiating effect ex vivo, the AUC of the decrease in MAP caused by LDN 27219 was 
larger in the 35-40-week-old than in the 12-14-week-old rats, These findings support a role of 
TG2 in early age-dependent changes of vascular function, and that TG2 conformation plays 
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an important role for regulation of BP independently of its transamidase activity, since VA5 
failed to change BP. 
Limitations  
In addition to TG2, TG1 and TG4 have been found in rat aorta and vena cava.27 In rat small 
mesenteric arteries, we only detected a marked expression of TG2 and a weak band for TG1 
in RT-PCR studies but no TG1 protein was detected by immunoblotting.8 Although little is 
known about the selectivity of LDN 27219 against other transglutaminases, analysis of other 
hydrazide inhibitors from the same family showed a high selectivity for TG2 and TG3.28 TG3 
is mainly located in the epidermis29 as well as in the ear and testes of the rat.8 Considering 
that observed ex vivo effects of LDN 27219 on arteries and isolated SMCs were completely 
inhibited by other selective TG2 inhibitors, it seems unlikely that the inhibition of other 
transglutaminases or off-target mechanisms contribute to the BP lowering in vivo induced by 
LDN 27219. 
PERSPECTIVES 
In conclusion, our study suggests that LDN 27219 is able to modify the dynamic equilibrium 
of TG2 towards the closed conformation, leading to direct relaxation and potentiation of NO-
dependent vasorelaxation by positive modulation of the BKCa channels in SMCs. These 
effects are present in rats and human resistance arteries and seem to increase with animal 
aging. Besides the role of TG2 in the development of vascular stiffness,1,2,9 elevated amounts 
of TG2 in its open conformation might also participate in age-related endothelial dysfunction. 





We thank laboratory technician Heidi Schou Knudsen for performing the immunoblotting for 
TG2 and BKCa channel alpha and beta subunits. We thank Ms. Diana Feiteira for her 
technical assistance.  
SOURCES OF FUNDING 
U. Simonsen was supported by grants from the Danish Heart Foundation (16-R107-A6681-
22967), the NovoNordisk Foundation (NNF130C0007739; NNF190C0055688), and the 
Danish Research Council (DFF-6110-00622B). N.H. Buus was supported by Aarhus 




1.  Santhanam L, Tuday EC, Webb AK, Dowzicky P, Kim JH, Oh YJ, Sikka G, Kuo M, 
Halushka MK, MacGregor AM, et al. Decreased S-nitrosylation of tissue 
transglutaminase contributes to age-related increases in vascular stiffness. Circ Res. 
2010;107:117-125. doi:10.1161/CIRCRESAHA.109.215228 
2.  Jung SM, Jandu S, Steppan J, Belkin A, An SS, Pak A, Choi EY, Nyhan D, Butlin M, 
Viegas K, Avolio A, Berkowitz DE, Santhanam L. Increased tissue transglutaminase 
activity contributes to central vascular stiffness in eNOS knockout mice. Am J Physiol 
Heart Circ Physiol. 2013;305:H803-10. doi:10.1152/ajpheart.00103.2013 
3.  Oh YJ, Pau VC, Steppan J, Sikka G, Bead VR, Nyhan D, Levine BD, Berkowitz DE, 
126
Santhanam L. Role of tissue transglutaminase in age-associated ventricular stiffness. 
Amino Acids. 2016;49:695-704. doi:10.1007/s00726-016-2295-z 
4.  Bakker ENTP, Pistea A, Spaan JAE, Rolf T, De Vries CJ, Van Rooijen N, Candi E, 
Vanbavel E. Flow-dependent remodeling of small arteries in mice deficient for tissue-
type transglutaminase: Possible compensation by macrophage-derived factor XIII. 
Circ Res. 2006;99:86-92. doi:10.1161/01.RES.0000229657.83816.a7 
5.  van den Akker J, VanBavel E, van Geel R, Matlung HL, Guvenc Tuna B, Janssen 
GMC, van Veelen PA, Boelens WC, de Mey JGR, Bakker ENTP. The redox state of 
transglutaminase 2 controls arterial remodeling. PLoS One. 2011;6:e23067. 
doi:10.1371/journal.pone.0023067 
6.  Lee Y-J, Jung S-H, Kim S-HS-Y, Kim M-S, Lee S, Hwang J, Kim S-HS-Y, Kim Y-M, 
Ha K-S. Essential Role of Transglutaminase 2 in Vascular Endothelial Growth Factor–
Induced Vascular Leakage in the Retina of Diabetic Mice. Diabetes. 2016;65:2414-
2428. http://diabetes.diabetesjournals.org/content/65/8/2414.abstract. 
7.  Lee J-Y, Lee Y-J, Jeon H-Y, Han E-T, Park WS, Hong S-H, Kim Y-M, Ha K-S. The 
vicious cycle between transglutaminase 2 and reactive oxygen species in 
hyperglycemic memory–induced endothelial dysfunction. FASEB J. 2019;33:12655-
12667. doi:10.1096/fj.201901358rr 
8.  Engholm M, Pinilla E, Mogensen S, Matchkov V, Hedegaard ER, Chen H, Mulvany 
MJ, Simonsen U. Involvement of transglutaminase 2 and voltage-gated potassium 
channels in cystamine vasodilatation in rat mesenteric small arteries. Br J Pharmacol. 
2016;173:839-855. doi:10.1111/bph.13393 
9.  Steppan J, Bergman Y, Viegas K, Armstrong D, Tan S, Wang H, Melucci S, Hori D, 
Park SY, Barreto SF, et al. Tissue transglutaminase modulates vascular stiffness and 
127
function through crosslinking-dependent and crosslinking-independent functions. J Am 
Heart Assoc. 2017;6:e004161. doi:10.1161/JAHA.116.004161 
10.  Sane DC, Kontos JL, Greenberg CS. Roles of transglutaminases in cardiac and 
vascular diseases. Front Biosci. 2007;12:2530-2545. doi:2253 [pii] 
11.  Eckert RL, Kaartinen MT, Nurminskaya M, Belkin AM, Colak G, Johnson GVW, 
Mehta K. Transglutaminase regulation of cell function. Physiol Rev. 2014;94:383-417. 
doi:10.1152/physrev.00019.2013 
12.  Han BG, Cho JW, Cho YD, Jeong KC, Kim SY, Lee B Il. Crystal structure of human 
transglutaminase 2 in complex with adenosine triphosphate. Int J Biol Macromol. 
2010;47:190-195. doi:10.1016/j.ijbiomac.2010.04.023 
13.  Nurminskaya M V., Belkin AM. Cellular Functions of Tissue Transglutaminase. Int 
Rev Cell Mol Biol. 2012;294:1-97. doi:10.1016/B978-0-12-394305-7.00001-X 
14.  Lindemann I, Heine A, Klebe G. Transglutaminase 2 in complex with a novel 
inhibitor. PDB ID 3S3J.:10.2210/pdb3S3J/pdb. 
15.  Mironov GG, Clouthier CM, Akbar A, Keillor JW, Berezovski M V. Simultaneous 
analysis of enzyme structure and activity by kinetic capillary electrophoresis-MS. Nat 
Chem Biol. 2016;12:918-922. doi:10.1038/nchembio.2170 
16.  Keillor JW, Apperley KYP, Akbar A. Inhibitors of tissue transglutaminase. Trends 
Pharmacol Sci. 2015;36:32-40. doi:10.1016/j.tips.2014.10.014 
17.  Case A, Stein RL. Kinetic analysis of the interaction of tissue transglutaminase with a 
nonpeptidic slow-binding inhibitor. Biochemistry. 2007;46:1106-1115. 
doi:10.1021/bi061787u 
18.  Fisher O. Subcloning, Enzymatic Characterization, and in silico Docking of 
Transglutaminase 2. 2009. http://hdl.handle.net/10192/23253. 
128
19.  National Research Council (US) Committee for the Update of the Guide for the Care 
and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 
8th ed. (National Academies Press, ed.). Washington, DC; 2011. doi:10.17226/12910 
20.  Pinkas DM, Strop P, Brunger AT, Khosla C. Transglutaminase 2 undergoes a large 
conformational change upon activation. PLoS Biol. 2007;5:2788-2796. 
doi:10.1371/journal.pbio.0050327 
21.  Iversen R, Mysling S, Hnida K, Jørgensen TJD, Sollid LM. Activity-regulating 
structural changes and autoantibody epitopes in transglutaminase 2 assessed by 
hydrogen/deuterium exchange. Proc Natl Acad Sci U S A. 2014;111:17146-17151. 
doi:10.1073/pnas.1407457111/-/DCSupplemental 
22.  Corydon KK, Matchkov V, Fais R, Abramochkin D, Hedegaard ER, Comerma-
Steffensen S, Simonsen U. Effect of ischemic preconditioning and a Kv7 channel 
blocker on cardiac ischemia-reperfusion injury in rats. Eur J Pharmacol. 2020;866. 
doi:10.1016/j.ejphar.2019.172820 
23.  Lee MY, Chung S, Bang HW, Baek KJ, Uhm D. Modulation of large conductance 
Ca2+-activated K+ channel by Galphah (transglutaminase II) in the vascular smooth 
muscle cell. Pflugers Arch. 1997;433:671-673. doi:10.1007/s004240050330 
24.  Jandu SK, Webb AK, Pak A, Sevinc B, Nyhan D, Belkin AM, Flavahan NA, 
Berkowitz DE, Santhanam L. Nitric oxide regulates tissue transglutaminase 
localization and function in the vasculature. Amino Acids. 2013;44:261-269. 
doi:10.1007/s00726-011-1090-0 
25.  Wang Z, Stuckey DJ, Murdoch CE, Camelliti P, Lip GYH, Griffin M. Cardiac fibrosis 
can be attenuated by blocking the activity of transglutaminase 2 using a selective 
small-molecule inhibitor. Cell Death Dis. 2018;9:613. doi:10.1038/s41419-018-0573-2 
129
26.  Shinde A V., Su Y, Palanski BA, Fujikura K, Garcia MJ, Frangogiannis NG. 
Pharmacologic inhibition of the enzymatic effects of tissue transglutaminase reduces 
cardiac fibrosis and attenuates cardiomyocyte hypertrophy following pressure 
overload. J Mol Cell Cardiol. 2018;117:36-48. doi:10.1016/j.yjmcc.2018.02.016 
27.  Johnson KB, Petersen-Jones H, Thompson JM, Hitomi K, Itoh M, Bakker ENTP, 
Johnson GVW, Cola G, Watts SW. Vena cava and aortic smooth muscle cells express 
transglutaminases 1 and 4 in addition to transglutaminase 2. Am J Physiol - Hear Circ 
Physiol. 2012;302:1355-1366. doi:10.1152/ajpheart.00918.2011 
28.  Schaertl S, Prime M, Wityak J, Dominguez C, Munoz-Sanjuan I, Pacifici RE, 
Courtney S, Scheel A, Macdonald D. A profiling platform for the characterization of 
transglutaminase 2 (TG2) inhibitors. J Biomol Screen. 2010;15:478-487. 
doi:10.1177/1087057110366035 
29.  Aeschlimann D, Koeller MK, Allen-Hoffmann BL, Mosher DF. Isolation of a cDNA 
encoding a novel member of the transglutaminase gene family from human 
keratinocytes. Detection and identification of transglutaminase gene products based on 
reverse transcription-polymerase chain reaction with degenerate primers. J Biol Chem. 
1998;273:3452-3460. doi:10.1074/jbc.273.6.3452 
NOVELTY AND SIGNIFICANCE 
What is new? 
• Promotion of the closed conformation of transglutaminase 2 (TG2) in the vasculature 
by the reversible inhibitor LDN 27219 is linked with: a direct vasorelaxant effect, an 
increased nitric oxide sensitivity in the vascular smooth muscle caused by opening of 
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potassium channels, which potentiates endothelium-derived vasorelaxation, as well as 
a blood pressure lowering effect during intravenous infusion. 
• Contrarily, TG2 inhibitors locking the open conformation fail to change vascular tone, 
reduce endothelium-dependent vasorelaxation and do not lower blood pressure. 
• Arteries from older animals have more TG2 in its open conformation, which 
translates in stronger vasoprotective effects of pharmacological induction of the TG2 
closed conformation with aging. 
What is relevant? 
• The open conformation of TG2 presents transamidase activity, which is profibrotic 
and linked to age-related vascular alterations. 
• TG2 inhibitors promoting the closed conformation might offer extensive vascular 
protection by inhibition of transamidase activity, improvement of endothelial function 
and lowering of blood pressure. 
Summary 
In isolated small arteries from rats and humans, promotion of the closed conformation of 
transglutaminase 2 (TG2) by LDN 27219 resulted in direct vasorelaxation and increased 
endothelium-dependent vasorelaxation by opening of smooth muscle potassium channels. 
Infusion of LDN 27219 in anesthesized rats induced concentration-dependent blood pressure 
lowering. Both the in vitro and in vivo effects increased with the age of the animal, and 






Figure 1. Effects of pharmacological modulation of tissue transglutaminase (TG2) 
conformation on vessel tension ex vivo. A. Native-PAGE conformational study of 
recombinant human TG2. Top panel: representative blots from the same gel after 
electrophoresis of purified TG2 treated with different effectors. Bottom: average relative 
abundance (presented as % of total intensity) of the two visible bands, corresponding to the 
open and to the closed conformation of the enzyme. Data are means ± SEM. *, P<0.05 using 
paired two-tailed Student´s t-test, n=5 replicates in 4 gels. B. Transglutaminase inhibition in 
mesenteric arteries by LDN 27219 and Z-DON. Top panel: Representative dot blot of 5-
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biotin(amido)pentylamine (BPA) incorporation, as a measure of transamidase (TGase) 
activity in 12-14-week-old rat mesenteric arteries incubated under different conditions and 
pan-actin expression as loading control. Bottom: Average transamidase activity, as % 
normalized to control conditions. n=3-4. Data are means ± SEM. *, P<0.05 using one-way 
ANOVA with Dunnett post-test compared to control. C. Isometric tension studies of U46619-
contracted small mesenteric arteries from male rats at 12-14 weeks of age: average 
concentration-response curves for LDN 27219 in the presence or absence of nitric oxide 
synthase inhibitor Nω-Nitro-L-arginine (L-NOARG) (10-4 mol/L), and Z-DON. n=6-9. D. 
Averaged concentration-response curves for LDN 27219 in U46619-contracted subcutaneous 
arteries from human patients. n=8. Data are means ± SEM of % relaxation relative to 
maximum contraction. *, P<0.05 using two-way ANOVA with Bonferroni post-test 












Figure 2. Effects of pharmacological modulation of tissue transglutaminase (TG2) 
conformation on endothelium-dependent vasorelaxation ex vivo. A-B. Original traces 
showing acetylcholine (ACh)-induced vasorelaxation in phenylephrine (Phe)-contracted 
human subcutaneous arteries after treatment with reversible TG2 inhibitor LDN 27219 (3x10-
6 mol/L) or vehicle during 20 min. C. Averaged concentration-response curves from the 
experiments shown in A-B, n=7. D. Averaged ACh concentration-response curves after 
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incubation with LDN 27219 (10-6 mol/L) or vehicle in Phe-contracted small mesenteric 
arteries from male rats at 12-14 weeks of age, n=6. E. Averaged ACh concentration-response 
curves after incubation with cell-permeable irreversible inhibitor VA5 (10-5 mol/L), which 
locks the open conformation of the enzyme, LDN 27219 (10-6 mol/L) on the same set of 
experiments (positive control) or vehicle in Phe-contracted small mesenteric arteries from 
male rats n=4-10. F. Averaged ACh concentration-response curves after incubation with 
LDN 27219 (10-6 mol/L) or vehicle, both in presence of VA5 (10-5 mol/L) in Phe-contracted 
small mesenteric arteries from male rats. Data are means ± SEM of % relaxation relative to 
maximum contraction. *, P<0.05 using two-way ANOVA with Bonferroni post-test 













Figure 3. Mechanisms behind the potentiation of endothelium-derived vasorelaxation 
by LDN 27219. A-D. Averaged concentration-response curves for acetylcholine (ACh) in 
phenylephrine (Phe)-contracted small mesenteric arteries from male rats at 12-14 weeks of 
age, after 20 min incubation with either vehicle or LDN 27219 (10-6 mol/L) in the presence 
of: A. TRAM-34 and UCL 1684, inhibitors of intermediate and small-conductance calcium-
activated potassium channels (IKCa and SKCa), respectively, n=5. B. Nitric oxide synthase 
inhibitor Nω-Nitro-L-arginine (L-NOARG), n=5. C. Large-conductance calcium-activated 
potassium channel (BKCa) blocker iberiotoxin, n=6. D. Averaged concentration-response 
curves for nitric oxide donor sodium nitroprusside (SNP) in Phe-contracted rat small 
mesenteric arteries without endothelium, after incubation with either vehicle or LDN 27219, 
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n=6. Data are means ± SEM of % relaxation relative to maximum contraction. *, P<0.05 



















Figure 4. Effect of LDN 27219 on potassium currents in freshly isolated smooth mucle 
cells (SMCs). Left: representative potassium currents in SMCs isolated from 12-14-week-old 
rat small mesenteric artery evoked by voltage-ramps between -100 and +160 mV. Right: 
averaged I-V relations for potassium currents from the experiments shown in the left. Effect 
of 12 min incubation with LDN 27219 in: A. Control conditions, n=7. B. Presence of large-
conductance calcium-activated potassium channel (BKCa) blocker iberiotoxin before and after 
the addition of Kv7 channel blocker XE991, n=5.  C. Presence of TG2 irreversible inhibitor 
VA5, which locks the enzyme in its open conformation, n=6. D. Presence of GTP in the 
intracellular pipette solution (GTPi), n=5. Data are means ± SEM of current amplitude 
normalized to maximal amplitude of the current under control condition (I/Imax). *, P<0.05 












Figure 5. Age-dependence effect on endothelial function of pharmacological modulation 
of tissue transglutaminase (TG2) to its closed conformation by LDN 27219. Averaged 
concentration-response curves for acetylcholine (ACh) in phenylephrine (Phe)-contracted 
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myograph-mounted small mesenteric arteries, treated with either LDN 27219 or vehicle for 
20 min, from male rats at: A. 6-7 weeks of age, n=6. B. 35-40 weeks of age, n=7. Averaged 
concentration-response curves for nitric oxide donor sodium nitroprusside (SNP) in Phe-
contracted small mesenteric arteries without endothelium, treated with either LDN 27219 or 
vehicle for 20 min, from male rats at: C. 6-7 weeks of age, n=5. D. 35-40 weeks of age, n=7. 
Data are means ± SEM of % relaxation relative to maximum contraction. *, P < 0.05 using 
two-way ANOVA with Bonferroni post-test compared to vehicle. E. Averaged differences in 
area under the curve (AUC) of the response to ACh between vehicle-incubated and LDN 
27219-incubated (10-6 mol/L) arteries analysed individually per rat. F. Top panel: 
Representative dot blot of 5-biotin(amido)pentylamine (BPA) incorporation, as a measure of 
transamidase (TGase) activity in rat mesenteric arteries from the different age groups and 
their corresponding total protein amido-black staining. Bottom: Average TGase activity, as % 
of total protein in small mesenteric arteries of each age group. Data are means ± SEM. *, 










Figure 6. Age-dependent effect on mean arterial pressure (MAP) of pharmacological 
modulation of tissue transglutaminase (TG2) conformation by LDN 27219 in vivo. A. 
Representative MAP measurements of two anesthetized rats at 12 weeks of age infused with 
three doses of either LDN 27219 (top) or vehicle (PEG-400 = polyethylene glycol 400) 
(bottom) during 3 min. B. Representative MAP measurement of an anesthetized 12-week-old 
rat during the 3 min infusion of a single dose of VA5. C. Averaged area under the curves 
(AUCs) for the experiments presented in A and B for the different age groups. n=5-8. Data 
are means ± SEM of AUC (mmHg•s). Negative AUCs indicate contraction. *, P<0.05 using 
two-way ANOVA with Bonferroni post-test compared to Vehicle. † P<0.05 using two-way 
ANOVA with Bonferroni post-test compared to 12-14-week-old.  
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Animals and tissue preparation:  
Male Wistar rats at 6-7, 12-14 and 35-40 weeks of age, weighing 200-250, 300-400 and 600-700 
g, respectively, were obtained from Taconic Denmark ApS (Rye, Denmark) and housed in the 
animal facility of Aarhus University in cages (Universal Euro III type Long) with standard wood 
bedding and space for two rats. There was a 12 h cycle of light and dark, and rats were maintained 
on standard chow and water ad libitum. Human subcutaneous arteries were obtained from fat 
biopsies of the gluteal region from both male and female Caucasian patients (30-70 years of age) 
with or without essential hypertension. A list of patient characteristics can be seen in Table S1. 
For ‘ex vivo’ studies, animals were randomly selected and euthanized by decapitation and 
exsanguination following the NIH guidelines for the care and use of laboratory animals.1 The 
mesenteric bed was immediately extracted and placed in 4ºC physiological saline solution (PSS, 
pH= 7.4) of the following composition (mmol/L): 119 NaCl, 4.7 KCl, 1.18 KH2PO4, 1.17 MgSO4, 
1.5 CaCl2, 24.9 NaHCO3, 0.026 EDTA and 5.5 glucose. Mesenteric second-order branches 
(internal diameters of 200-300 μm) were isolated. Human subcutaneous arteries (internal 
diameters of 300-400 μm) were dissected from the biopsies under the same conditions as 
mentioned above for the rat mesenteric arteries. For ‘in vivo’ experiments animals were fasted 8 h 
before anesthesia with 35 mg/kg of S-ketamine and 50 mg/kg of pentobarbital sodium 
administered intraperitoneally. Animal protocols and care were approved by the Danish Animal 
Experiments Inspectorate (permission 2014-15-2934-0159) and followed the NIH guidelines. The 
study using human arterial tissue was approved by the Regional Ethics Committee, Central 
Denmark (permission 1-10-72-120-17) and conducted in accordance with the principles of the 
Helsinki Declaration II for medical research. All participants gave informed consent prior to 
participation. 
Native-PAGE 
Purified and functional human TG2 protein produced in insect cells was obtained from Zedira 
(Darmstadt, Germany) and native gel electrophoresis experiments were performed using a method 
similar to those previously described.2,3 Briefly, TG2 (2.5x10-6 mol/L) was incubated for 30 min 
at room temperature in buffer (75 mmol/L imidazole, 0.5 mmol/L EDTA, 5 mmol/L DTT [pH 
7.2], 10% DMSO) with or without GTPNa2 (10-3 mol/L) or LDN 27219 (10-3 mol/L ) before adding 
Native Sample Buffer for Protein Gels (Bio-Rad) or in preincubation buffer with Z-DON (2x10-4 
mol/L) 30 min prior addition of CaCl2 (5x10-3 mol/L) for 20 min. Native sample buffer was added 
(dilution 1:2), and 1.5 μg of protein was loaded onto a 4–20% Criterion™ TGX Stain-Free™ gel 
(Bio-Rad) using Tris-glycine (Bio-Rad) as the running buffer. For 75 min, 125 V was applied at 4 
ºC. The bands were visualized using stain-free technology by exposing the gels to UV light and 
capturing the image using a PXi 4 Touch image analysis system (Syngene). Band intensity analysis 
was carried out using GeneTools 4 software (Syngene) and results were expressed as relative 
abundance of the two observable bands, corresponding to the open and the closed conformation of 
TG2, in each lane. 
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Isometric tension studies 
Small mesenteric arteries and human subcutaneous arteries (approximately 2 mm length) were 
mounted in microvascular myographs (Danish Myotechnology, Aarhus, Denmark) using two 40 
μm wires and stretched to their optimal diameter for isometric tension recordings, which 
corresponded to 0.9 times the estimated internal diameter at 100 mmHg of transmural pressure.4 
PSS solution in the myograph bath was heated to 37ºC and continuously bubbled with 5% CO2,-
75% N2-20% O2 to maintain pH (7.4). The vessel viability was tested at the beginning of each 
experiment by measuring the vasoconstrictor responses to a solution with a high K+ concentration 
(KPSS), equivalent to PSS except that NaCl was exchanged for KCl on an equimolar basis, giving 
a final concentration of 123.7 mmol/L K+ and the presence of endothelium was confirmed by 
addition of acetylcholine (ACh) (10-5 mol/L) after pre-constriction with noradrenaline (5·10-6 
mol/L), arteries with less than 75% of relaxation were discarded. 
Mesenteric arteries from rats were pre-contracted with the thromboxane analogue, U46619 (4x10-
7 mol/L) and concentration-response curves for TG2 specific inhibitors, LDN 27219 (10-8-10-5 
mol/L) and Z-DON (10-10-3x10-5 mol/L) were constructed. To study the role of the endothelial 
pathways in relaxation, concentration-response curves for LDN 27219 were constructed in the 
presence of an eNOS inhibitor, Nω-Nitro-L-arginine (L-NOARG) (10-4 mol/L), and in arteries 
whose endothelium had been removed mechanically by rubbing the lumen repeatedly with a 
human scalp hair. Successful endothelial removal was examined by absence of relaxation to ACh 
(10-5 mol/L). Human subcutaneous arteries were contracted with U46619 (3x10-8 mol/L) and 
concentration-response curves for LDN 27219 (10-8-10-4 mol/L) were constructed. 
To investigate the effect of TG2 conformational modulation in endothelial function, arteries from 
animals of different ages were contracted with Phenylephrine (Phe) (10-5 mol/L). Afterwards, ACh 
concentration-response curves were constructed after 25 min incubation with LDN 27219 (10-6 
mol/L)  together with 1 h incubation of the irreversible TG2 inhibitors: Z-DON (4x10-5 mol/L), 
Boc-DON (10-5 mol/L) or VA5 (10-5 mol/L) which had shown to lock the enzyme in its open 
conformation,24 or with vehicle (DMSO). Differences in incubation time account for the different 
membrane permeability of the compounds. Human subcutaneous arteries were contracted with Phe 
(3x10-6 mol/L) and ACh concentration-response curves were constructed after 25 min incubation 
with LDN 27219 (3x10-6 mol/L) or with vehicle. 
To investigate the endothelial pathways involved in potentiation of endothelium-dependent 
vasodilation in arteries from rats, concentration-response curves for ACh were constructed in the 
absence and the presence of LDN 27219 plus blockers of small and intermediate conductance 
calcium-activated potassium channels (SKCa and IKCa) UCL 1684 (10-6 mol/L) and TRAM-34 (10-
6 mol/L), respectively, L-NOARG (10-4 mol/L), large conductance calcium-activated potassium 
channel (BKCa) blocker iberiotoxin (10-7 mol/L), or the guanylate cyclase inhibitor ODQ (3·10-6 
mol/L). 
To assess if effects observed were mainly at the smooth muscle cell level, concentration-response 
curves for the NO donor sodium nitroprusside (SNP) (10-8-10-5 mol/L) were also constructed in 
presence and absence of LDN 27219 in rat arteries whose endothelium had been removed by 
rubbing the lumen with a human scalp hair. 
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Relaxations were expressed as percentage relative to the contraction level and differences in Area 
Under the Curve (AUC) for ACh and SNP responses between vehicle-incubated arteries and LDN 
27219-incubated arteries were calculated for each age group using Graphpad Prism 7.2 (GraphPad 
Software, San Diego, California, USA). 
‘Ex vivo’ transamidase activity assay 
To measure transamidase activity ‘ex vivo’, a dot blot assay based on the incorporation of the 
tranglustaminase substrate 5-(biotinamido)pentylamine (BPA) to structural proteins was used as 
previously described.5 Small mesenteric arteries from rats of the different age groups were 
dissected and immediately incubated in PSS containing BPA (10-4 mol/L) and an increased 
concentration of Ca2+ (2.5x10-3 mol/L) at 37oC for 4 h. During incubation, PSS was continuously 
bubbled with 5% CO2,-75% N2-20% O2 to maintain pH (7.4). Then, unreacted BPA was washed 
by rinsing the arteries with PBS before tissue homogenization and protein extraction in RIPA lysis 
buffer (0.5 mmol/L tris/HCL pH 7.4, 10 mmol/L EDTA, 1.5 mmol/L NaCl, 2.5 % deoxycholic 
acid, 10 % NP-40) with Halt Protease and Phosphatase Inhibitor Cocktail (ThermoFisher 
Scientifics, Massachusetts, USA). The amount of extracted protein was quantified by a modified 
Lowry method and 10 μg of total proteins were loaded onto a nitrocellulose membrane using the 
BioRad Dot Blot apparatus (Bio-Dot® Apparatus). The membrane was blocked in 5% BSA for 2 
h and then incubated with HRP-conjugated streptavidin (Amersham Bioscience; dilution 1:10,000 
in 0.5% BSA) for 2 h to detect BPA incorporation. The membrane was then washed in TBS-T, 
removed from the dot blot apparatus and developed using an ECL-Plus kit (General Electric (GE) 
Health care, Copenhagen, Denmark). The images were captured by a luminescence camera using 
a PXi 4 Touch image analysis system (Syngene). After development, membranes were rinsed in 
water and stained with amido black (0.1% (w/v) in 10% acetic acid) for total protein staining. Blots 
were quantified using GeneTools 4 software (Syngene) and normalized to the total protein. For 
each sample results are the average intensity expressed as % of total protein of two replicates.  
Additionally, small mesenteric arteries from rats at 12-14 weeks of age were used for the inhibition 
assay ‘ex vivo’. Arteries were incubated in PSS containing BPA and Ca2+ as previously described 
but in presence of either vehicle, LDN 27219 (10-6 mol/L), Z-DON (4·10-5 mol/L) or dithiothreitol 
(DTT) (10-3 mol/L), which has been demonstrated to increase TG2 transamidase activity. Two 
replicates for each treatment and animal were added in one blot, the average activity under control 
conditions was set to 100% and the results are expressed as % of transamidase activity normalized 
to control conditions and presented in Figure 1. 
‘In vitro’ transamidase activity inhibition assay 
To measure transamidase activity ‘in vitro’ an assay based on the incorporation of a biotinylated 
preferred TG2 substrate (Biotin-pepT26) as amine-acceptor into a spermine coated strip as amine-
donnor was used. Liver samples from young (6-7-week-old) and old rats (35-40-week-old) snap 
frozen with liquid nitrogen until the assay was performed. The samples were thawed and 
homogenized in RIPA lysis buffer (0.5 mmol/L tris/HCL pH 7.4, 10 mmol/L EDTA, 1.5 mmol/L 
NaCl, 2.5 % deoxycholic acid, 10 % NP-40) with Halt Protease and Phosphatase Inhibitor Cocktail 
(ThermoFisher Scientifics, Massachusetts, USA). Livers were left 30 min on ice before sonicating 
for 45 seconds and then centrifuged at 13000 rpm for 10 min at 4 ºC. The supernatant was 
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collected, and the protein concentration was measured by a modified Lowry method. Samples were 
prepared to achieve a concentration of 8 µg/µL using the diluent buffer of the Specific Tissue 
Transglutaminase Colometric Microassay Kit TG2-CovtTest (Zedira, Darmstadt, Germany). 
Then, 25 µL of sample were incubated with 25 µl of different concentrations of the inhibitors LDN 
27219 (10-7 – 10-4 mol/L) or VA-5 (10-7 – 10-5 mol/L), or the vehicle for 20 min on ice. The assay 
was performed following the manufacturer’s protocol.  
In short, microtiter strips coated with spermine were washed and 50 µL of study sample or 50 µL 
of standard were added along with 10 µL of diluent buffer and 50 µL of ice-cold assay-mixture 
(Biotin-pepT26 / CaCl2, 20% DTT). The plate was then incubated for 30 min at 37 ºC, and after 
pertinent washes with wash buffer and 0.1 mol/L NaOH, incubated again with horseradish 
peroxidase streptavidin (1:2000 dilution in wash buffer) for 15 min at 37 ºC. Later, HRP substrate 
was added for 5 min at room temperature and subsequently, the reaction was stopped with a 
blocking reagent. The final optical density was read at 450 nm and data was quantitatively 
evaluated with the standard curve. Duplicates from each sample or standard were performed, and 
the average value was calculated in all the study samples. Results are presented as % of 
transamidase activity under control conditions. 
Resting membrane potential measurements 
Small mesenteric arteries were mounted and normalized in a myograph as described above. KCl-
filled glass microelectrodes (40-100 MΩ of resistance) were used to obtain intracellular recordings 
of resting membrane potential, placing an Ag/AgCl electrode in the myograph bath as reference 
electrode. Input resistance was assessed by observing the change in potential caused by applying 
current pulses of 1 nA; the electrode resistance was compensated using the amplifier (Intro-710, 
WPI) before penetrating inside the smooth muscle cell. PSS solution in the myograph bath was 
heated to 37ºC and light bubbling with 95% O2 - 5% CO2 was maintained through the protocol. 
The effect of 25 min incubation with LDN 27219 (10-6 mol/L) on resting membrane potential and 
on ACh (10-8-10-5 mol/L) induced hyperpolarization was studied in the absence and the presence 
of iberiotoxin (10-7 mol/L). To minimize the effect of endothelial potassium channels the protocol 
was repeated in the presence of TRAM-34 (10-6 mol/L) and UCL 1684 (10-6 mol/L). Resting 
membrane potential was expressed in absolute values (mV). 
Experimental procedure for electrophysiological studies 
Cell isolation 
For isolation of SMCs, rat mesenteric arteries were dissected, opened longitudinally and stored in 
ice-cold dissociation solution containing (mmol/L): 119 NaCl, 4.7 KCl, 1.18 KH2PO4, 1.17 
MgSO4, 24.9 NaHCO3, 0.027 EDTA, and 11 glucose, pH= 7.4. Arteries were then equilibrated 
during 10 min in a dissociation solution with BSA (1 mg/mL) at 37ºC and then exposed to the 
same solution supplemented with papain (0.5 mg/mL; Worthington Biochemical Corp., 
Lakewood, NJ, USA) and DTT (1 mg/mL) at 37ºC for 8 min. Arteries were then washed in ice-
cold dissociation solution and moved to dissociation solution containing BSA (1 mg/mL) and 
collagenase (0.7 mg/mL type F and 0.4 mg/mL type H; Sigma.) at 37°C for 3 min. After washing 
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in ice-cold dissociation solution, isolated SMCs were obtained by gentle trituration of the digested 
arteries with a fire polished glass pipette into the SMC extracellular solution (for composition, see 
below). 
After the digestion protocol, SMCs were seeded in micro-dishes (ibidi GmbH, Martinsried, 
Germany) and used for patch clamp recordings 15 min after the isolation protocol and within the 
next 5 hs. 
Whole cell voltage clamp studies 
Extracellular patch-clamp solution for SMCs contained the following (mmol/L): 130 NaCl, 5 KCl, 
1.2 MgCl2, 1.5 CaCl2, 10 glucose and 10 HEPES (adjusted to pH 7.3 with NaOH). The patch 
pipette (intracellular) solution for SMCs contained the following (mmol/L): 130 KCl, 1.2 MgCl2, 
0.1 EGTA and 10 HEPES (adjusted to pH 7.2 with KOH). To study the effect of intracellular GTP 
in LDN 27219 activity over potassium currents, patch pipette solution with 5 mmol/L Na2GTP 
was used in some experiments. 
Membrane currents were recorded under the whole-cell configuration of the patch-clamp 
technique using an Axon Multiclamp 700A amplifier (Axon instruments, Molecular Devices, CA, 
USA). Patch pipettes were made of borosilicate glass capillaries (World Precision Instruments, 
FL, USA) fabricated using a dual-stage puller PP-830 (Narishige, Tokyo, Japan) and had 
resistances of 4-7 MΩ. Current recordings were digitized on line at 10 kHz and low pass filtered 
at 2 kHz using a Digidata 1440 A (Axon Instruments), to acquire and store data pClamp 10 
software was used. Current-voltage relations were determined using 600 ms voltage ramps from -
100 to 160 mV and a holding potential (Vh) of -65 mV for SMCs.4 
In SMCs amplitudes of K+-outward currents were measured under control conditions and 12 min 
after the addition of LDN 27219 (3x10-5 mol/L) to the extracellular solution by a perfusion system. 
To address which potassium channels were involved in LDN 27219 effect, the protocol was 
repeated in presence of iberiotoxin (10-7 mol/L), and Kv7 blocker XE991 (10-5 mol/L) was added. 
To study how conformational modulation of TG2 affected LDN 27219 activity over potassium 
channels, the initial protocol was repeated after 1 h incubation with VA5 (5x10-5 mol/L) or with 
GTP present in the intracellular solution.  
Immunoblotting for TG2 and BKCa channels 
Small mesenteric arteries from rats of different ages were snap frozen with liquid nitrogen and 
kept at -80°C, until homogenization. The tissues were homogenized and centrifuged in a lysis 
buffer (20 mmol/L tris/HCL, 5 mmol/L EGTA, 150 mmol/L NaCl, 20 mmol/L glycorophosphate, 
10 mmol/L NaF, 1 % triton X-1000, 0.1 % tween-20, pH 7.5) with Halt Protease and Phosphatase 
Inhibitor Cocktail (ThermoFisher Scientifics, Massachusetts, USA). The amount of protein 
extracted was quantified by a modified Lowry method and samples were diluted in Laemmli 
Sample Buffer (Bio-rad) containing DTT to a final concentration of 1 g/L of total protein. After 
boiling (99°C for 5 min), the samples were left to refrigerate and 10 μg of protein was loaded onto 
4–20% Criterion™ TGX Stain-Free™ gels (Bio-Rad), using XT MOPS (Bio-Rad) as the running 
buffer.  
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The samples were subjected to electrophoresis for 1 h at 125 V, before being transferred to a 
polyvinylidene fluoride (PVDF) membrane by applying 100 V for 1 h at 4°C using Tris-glycine 
(Bio-Rad) (20% ethanol) as the transfer buffer. After the transfer, total protein was visualized using 
stain-free technology by exposing the membranes to UV light and the images were captured using 
a PXi 4 Touch image analysis system (Syngene). The membranes were washed twice for 15 min 
in PBS-T (150 mmol/L NaCl, 50 mmol/L NaH2PO4, 0.05 % (v/v) Tween® 20) and TBS-T (10 
mmol/L tris base,100 mmol/L NaCl, 1 mmol/L EDTA, 0.1 % (w/v) Tween® 20) for 1 h and then 
blocked in 0.3% I-block™ (Applied Biosystems) for 2–4 h before being incubated overnight at 
4°C with the primary antibody. Anti-Transglutaminase 2 antibody (ab421, Abcam) at a dilution of 
1:200, anti-BKCa alpha antibody (APC-107, Alomone labs) at a dilution of 1:100, and anti-BKCa 
beta 1 antibody (ab3587, Abcam) at a dilution of 1:250 were used as primary antibodies in TBS-
T with 0.3 % I-block™ (Applied Biosystems). The membrane was then washed in TBS-T and 
incubated for 2 h in the secondary antibody, Goat anti-Rabbit IgG (G-21234, Invitrogen). The 
membrane was developed using an ECL-Plus kit (General Electric (GE) Health care, Copenhagen, 
Denmark) and the images were captured by a luminescence camera using a PXi 4 Touch image 
analysis system (Syngene). Blots were quantified using GeneTools 4 software (Syngene) and 
normalized to the total protein intensity in their lane. 
‘In vivo’ mean arterial pressure (MAP) and heart rate (HR) measurements 
Male Wistar rats at 12-14 and 35-40 weeks of age were used for the ‘in vivo’ experiments. Group 
sizes were calculated with an expected effect size f of 1, desired power of 95% and an alfa of 0.05 
and age-paired animals were randomly assigned to treatment or vehicle group. 
Rats were anesthetized with intraperitoneal injections of s-ketamine (35 mg/kg) and pentobarbital 
(50 mg/kg) and placed in a heated blanket to maintain body temperature at 37ºC. ECG needles 
were installed in the Einthoven configuration for electrocardiographic recordings of the standard 
lead II derivation, which were obtained by an animal bio-amplifier (AD Instruments), and a solid 
state catheter (model no. SPR-1000 Millar Inc, Houston, USA) was introduced into the carotid 
artery to measure MAP. MAP and electrocardiographic data was continuously recorded on a 
computerized data acquisition system (PowerLab, ADInstruments) and ECG signals were low-
pass filtered by using the standard filter file for ECG recordings. The ADInstruments software 
automatically obtained the different electrocardiographical values. Adequate depth of anesthesia 
was checked periodically by absence of the toe pinch withdrawal effect and 1/3 of the initial dose 
of anesthetics was administered intraperitoneally when needed (usually each 90 min).   
The rats were infused through a catheter in the jugular vein for 3 min with either three doses of 
LDN 27219 (0,1; 1 and 2 mg/kg) or the corresponding doses of vehicle (PEG-400), using a syringe 
infusion pump (Hardvard Apparatus Model 55-2219) and leaving a rest period of 10 min between 
the doses. To study the effect of TG2 inhibitors that lock the open conformation of the enzyme, 
the animals in the vehicle group were infused with a single dose of VA5 (1 mg/kg) for 3 min at 
the end of the protocol. MAP and HR values before, during and two min after the infusion were 
expressed as means ± SEM. AUCs for changes in MAP during the infusion were also calculated 




For the conformational shift assay using native polyacrylamide gel electrophoresis (native-PAGE) 
purified and functional human TG2 protein produced in insect cells was obtained from Zedira 
(Darmstadt, Germany). 
The following drugs were used: ACh, Na2GTP (guanosine 5′-triphosphate sodium salt), 
Indomethacin, Nω-Nitro-L-arginine (L-NOARG), ODQ (1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-
1-one), Phenylephrine, sodium nitroprusside (SNP), U46619 (9α- epoxymethanoprostaglandin 
F2α) and XE991 (10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone dihydrochloride) from 
Sigma (St. Louis, MO, USA). Iberiotoxin, LDN 27219, TRAM-34 and UCL 1684 were obtained 
from Tocris Bioscience (Bristol, UK). Boc-DON and Z-DON were obtained from Zedira 
(Darmstadt, Germany). VA5 was from ChemShuttle (Hayward, CA, USA). Unless otherwise 
stated all substances were dissolved in distilled water. For ‘ex vivo’ experiments U46619 was 
dissolved in ethanol and Boc-DON, LDN 27219, ODQ, TRAM-34, UCL 1684, XE991 and Z-
DON were dissolved in DMSO and stored at -20ºC. Further dilution of the above mentioned 
compounds were made in distilled water. The DMSO concentration in the bath were kept below 
0.01% and did not affect vessel contractility. For ‘in vivo’ experiments, LDN 27219 and VA5 were 
dissolved in PEG-400. 
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Hypertension Female 43 4
Hypertension Female 67 3
Hypertension Female 47 2
Healthy Control Male 62 none
Healthy Control Male 43 none
Healthy Control Male 39 none
Healthy Control Male 33 none
Healthy Control Female 35 none
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Table S2: Level of contraction induced by different vasoconstrictors and Emax and pD2  














Control 12 3.06 ± 0.30 LDN 27219 89.35 ± 3.58 5.99 ± 0.07
w/o endothelium 6 2.53 ± 0.28 LDN 27219 49.59 ± 10.76 * 4.97 ± 0.12 *
L-NOARG (10-4 mol/L) 7 2.99 ± 0.30 LDN 27219 83.87 ± 10.79 5.48 ± 0.07 *
Control 9 2.14 ± 0.17 Z-DON 13.48 ± 4.92 * ND
Figure 1F Control 8
U46619          
(3x10-8 mol/L)
4.19 ± 0.44 LDN 27219 94.52 ± 1.73 5.14 ± 0.09
Vehicle 7 4.42 ± 0.47 91.75 ± 6.68 7.58 ± 0.06
LDN 27219 (3x10-6 mol/L) 7 3.97 ± 0.48 96.02 ± 1.58 8.09 ± 0.06 *
Vehicle 6 3.20 ± 0.38 94.97 ± 1.28 6.90 ± 0.03
LDN 27219 (10-6 mol/L) 6 3.74 ± 0.30 97.44 ± 0.93 7.18 ± 0.03 *
Vehicle 10 3.54 ± 0.12 96.61 ± 0.72 7.53 ± 0.04
VA5 (10-6 mol/L) 6 3.37 ± 0.18 96.33 ± 0.60 7.32 ± 0.03 *
LDN 27219 (10-6 mol/L) 4 3.35 ± 0.36 96.27 ± 0.68 7.86 ± 0.05 *
VA5 (10-6 mol/L) + Vehicle 6 3.37 ± 0.18 96.33 ± 0.60 7.32 ± 0.03 
VA5 (10-6 mol/L) + LDN 27219 (10-6 mol/L) 5 2.88 ± 0.24 91.37 ± 3.10 7.24 ± 0.06
TRAM-34 (10-6 mol/L) + UCL 1684 (10-6 mol/L) + 
Vehicle
5 2.49 ± 0.56 80.29 ± 6.97 6.39 ± 0.07
TRAM-34 (10-6 mol/L) + UCL 1684 (10-6 mol/L) + 
LDN 27219 (10-6 mol/L)
5 2.35 ± 0.59 88.81 ± 3.73 6.90 ± 0.06*
L-NOARG (10-4 mol/L) + Vehicle 5 3.37 ± 0.23 94.88 ± 1.25 6.71 ± 0.05
L-NOARG (10-4 mol/L) + LDN 27219 (10-6 mol/L) 5 4.47 ± 0.22 * 93.97 ± 1.63 6.70 ± 0.05
Ibtx (10-7 mol/L) + Vehicle 6 4.15 ± 0.28 98.94 ±1.38 6.71 ±  0.05
Ibtx (10-7 mol/L) + LDN 27219 (10-6 mol/L) 6 4.23 ± 0.29 95.12 ± 0.89 6.68 ± 0.08
Vehicle - w/o endo 6 3.72 ± 0.47 84.37 ± 5.36 6.63 ±0.07
LDN 27219 (10-6 mol/L) - w/o endo 6 3.23 ± 0.35 90.33 ± 4.96 7.36 ± 0.09 *
Vehicle 6 2.77 ± 0.23 94.01 ± 1.77 6.86 ± 0.04
LDN 27219 (10-6 mol/L) 6 2.78 ± 0.16 95.78 ± 0.5 6.96 ± 0.04
Vehicle 7 3.36 ± 0.34 88.66 ± 4.81 6.76 ± 0.06 †
LDN 27219 (10-6 mol/L) 7 3.77 ± 0.33 94.87 ± 2.04 7.30 ± 0.04 *
Vehicle - w/o endo 5 2.54 ± 0.44 86.28 ± 5.47 6.48 ± 0.08
LDN 27219 (10-6 mol/L) - w/o endo 5 2.53 ± 0.50 90.47 ± 2.60 7.01 ± 0.07 *
Vehicle - w/o endo 7 4.17 ± 0.26 53.43 ± 4.43 † 5.43 ± 0.09 †
LDN 27219 (10-6 mol/L) - w/o endo 7 4.47 ± 0.37 71.87 ± 5.27 * 6.60 ± 0.09 * 
Figure 1E
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Figure 3D
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Values are means ± SEM and are calculated from the data in figures indicated in the left column. n: number of animals used. *, P < 0.05 
compared to control/vehicle conditions using paired two-tailed Student´s t-test , except in the pD2 values where an F-test was used. †, P < 0.05 
compared to vehicle conditions in 12 - 14 weeks old animals using paired two-tailed Student´s t-test , except in the pD2 values where an F-test 
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Table S3: ECG parameters of rats from the different age groups before, during and two 











































































































































































































Values are means ± SEM. n: number of animals used. The rate-corrected QT interval (QTc) was calculated using the 
standard Bazett’s formula (QTc= QT·√RR-1)




0,1 mg/kg 1 mg/kg 2 mg/kg




SUPPLEMENTAL FIGURES    
 
Figure S1. Effect of incubation with TG2 inhibitors that lock the enzyme open on ACh 
response. A. Averaged concentration-response curves for ACh of myograph-mounted small 
mesenteric arteries from male rats at 12-14 weeks of age, treated with either cell-permeable 
irreversible TG2 inhibitor Z-DON, cell non-permeable irreversible inhibitor Boc-DON or vehicle. 
Data are means ± SEM of % relaxation relative to maximum contraction. *, P > 0.05 using two-
way ANOVA compared to vehicle, n = 5 - 10. B. Effect of incubation with LDN 27219 on ACh 
response in the presence of Z-DON: Averaged concentration-response curves for ACh of 
myograph-mounted small mesenteric arteries from male rats at 12-14 weeks of age, treated either 
with LDN 27219 or vehicle, in the presence of Z-DON. Data are means ± SEM of % relaxation 
relative to maximum contraction, n = 5. C. Transamidase activity inhibition assays ‘in vitro’: 
Averaged concentration-response curves for LDN-27219 or VA5 ‘in vitro’. Data are means ± SEM 
of % transglutaminase activity relative to control conditions. pD2 LDN 27219= 4.41±0.32; pD2 VA5= 
6.28±0.24 †, P< 0.05 using F test, n = 4 – 8. 
154
 
Figure S2. Effect of incubation with LDN 27219 on ACh response in the presence of ODQ. 
Averaged concentration-response curves for ACh of myograph-mounted small mesenteric arteries 
from male rats at 12-14 weeks of age, treated either with LDN 27219 (10-6 mol/L) or vehicle, in 
the presence of ODQ (3x10-6 mol/L). Data are means ± SEM of % relaxation relative to maximum 































Figure S3. Effect of LDN 27219 on SMC resting membrane potential in rat small mesenteric 
arteries. Resting membrane potential (Em) recordings of SMCs in the vascular wall of myograph-
mounted mesenteric arteries from male rats at 12-14 weeks of age. Recordings were performed 
during addition of increasing doses of ACh in the absence or in the presence of LDN 27219 and/or 
BKCa channel blocker iberiotoxin. A. Averaged Em values of intact arteries, n = 5. B. Averaged 
Em values of arteries in the presence of IKCa channel blocker TRAM-34 and SKCa channel UCL 
1684, n = 6. C. Representative trace of Em recordings in the presence of TRAM-34 and UCL 1684. 
Data are means ± SEM of Em (mV). *, P < 0.05 using two-way ANOVA with Bonferroni post-




Figure S4. Effect of incubation with TG2 openers on SNP response in endothelium-denuded 
arteries. Averaged concentration-response curves for SNP in myograph-mounted small 
mesenteric arteries without endothelium from male rats at 12-14 weeks of age, treated either with 
different cell-permeable irreversible TG2 inhibitors that lock the open conformation of the enzyme 
or vehicle. Data are means ± SEM of % relaxation relative to maximum contraction. *, P < 0.05 
using two-way ANOVA with Bonferroni post-test compared to vehicle. †, P < 0.05 using two-way 





























Figure S5. K+ outward currents expressed as a current density (pA/pF) for SMCs in the 
presence of different activators/blockers. Averaged current density (pA/pF) of SMCs exposed 
to different treatments. Data are means ± SEM of current density (pA/pF). *, P < 0.05 using two-





Figure S6. Area under the curve (AUC) difference between vehicle-incubated and LDN 
27219-incubated arteries in response to SNP in the different age groups. Averaged differences 
in AUC of the responses to NO donor SNP of arteries incubated with vehicle and arteries incubated 
with LDN 27219 in each age group. Data are means ± SEM. *, P < 0.05 using one-way ANOVA 
with Bonferroni post-test.  
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Figure S7. Protein expression of TG2, BKCa alpha and beta 1 subunit in different age groups. 
A. Representative immunoblot of TG2, located at 82 kDa, in rat mesenteric arteries from the 
different age groups (upper panel). Stain-free total protein of the lanes corresponding to the blots 
in the upper panel (lower panel). B. Average TG2 protein expression, as % of total protein in small 
mesenteric arteries of each age group. C. Representative immunoblot of BK-alpha, located at 100 
kDa, in rat mesenteric arteries from the different age groups from the same membrane (upper 
panel). Stain-free total protein of the lanes corresponding to the blots in the upper panel (lower 
panel). D. Averaged BK-alpha protein expression, as % of total protein in small mesenteric arteries 
of each age group. E. Representative immunoblot of BK-beta 1, located at 110 kDa, in rat 
mesenteric arteries from the different age groups from the same membrane (upper panel). Stain-
free total protein of the lanes corresponding to the blots in the upper panel (lower panel). F. 
Averaged BK-beta 1 protein expression, as % of total protein in small mesenteric arteries of each 
age group. Data are means ± SEM. *, P < 0.05 using one-way ANOVA with Bonferroni post-test. 
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Figure S8. Effects on heart rate (HR) before, during and after infusion of LDN-27219, PEG-
400 and VA5. A. Averaged HR values measured before (Bef.), during (Dur.) and 2 min after (Aft.) 
intra-jugular infusion of 3 doses of LDN 27219 to 12-14-week-old rats. n = 6. B. Averaged HR 
values measured before (Bef.), during (Dur.) and 2 min after (Aft.) intra-jugular infusion of 3 doses 
of LDN 27219 to 35-40-week-old rats, n = 7. C. Averaged HR values measured before (Bef.), 
during (Dur.) and 2 min after (Aft.) intra-jugular infusion of 3 doses of vehicle (PEG-400) to 12-
14-week-old rats, n = 5. D. Averaged HR values measured before (Bef.), during (Dur.) and 2 min 
after (Aft.) intra-jugular infusion of 3 doses of vehicle (PEG-400) to 35-40-week-old rats, n = 8. 
E. Averaged HR values measured before (Bef.), during (Dur.) and 2 min after (Aft.) intra-jugular 
infusion of a single dose of VA5 to 12-14 and 35-40-week-old rats. Data are means ± SEM. *, P 
< 0.05 using paired two-tailed Student´s t-test compared to before infusion (Bef.). 
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12. APPENDIX 2: MANUSCRIPT II
Acute and chronic treatment with the transglutaminase 2 inhibitor LDN 27219 restores 
endothelium-dependent vasorelaxation in resistance arteries from diabetic db/db mice. 
Estéfano Pinilla and Ulf Simonsen.  
In submission for publication. 
162
13. APPENDIX 3: MANUSCRIPT III
Endothelial large- and intermediate-conductance Ca2+ -activated K+ channels mediate rat 
intrarenal artery endothelium derived hyperpolarization response. 
Estéfano Pinilla, Ana Sánchez, María P Martínez, Mercedes Muñoz, Albino García-Sacristán, Ralf 
Köhler, Dolores Prieto, and Luis Rivera. 
Submitted for publication. 
192
14. APPENDIX 4: PATENT APPLICATION
Tissue Transglutaminase Modulators for Medicinal Use.   
Estéfano Pinilla and Ulf Simonsen.  
International PCT patent application number WO2020030648A1. 13 Feb. 2020. 
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